[{"title01":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","title02":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","journal":"Leukemia","issue":"2025 November 21. doi: 10.1038\/s41375-025-02813-1. Online ahead of print","author":"Wang X, Yao H, Chen J, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41272183"},{"title01":"Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP.","title02":"Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP.","journal":"Blood advances","issue":"2025 November 25; 9(22):5902-5912. doi: 10.1182\/bloodadvances.2025017902","author":"Alyamany R, Houghton DE, Sridharan M, Pruthi RK, Shah S, Godby RC, Wolanskyj-Spinner A, Go RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875595"},{"title01":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","title02":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","journal":"Blood","issue":"2025 November 27; 146(22):2656-2669. doi: 10.1182\/blood.2025028504","author":"Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones D, Hall S, Cruz JC, Verneris MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906917"},{"title01":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","title02":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","journal":"Blood","issue":"2025 November 27; 146(22):2670-2680. doi: 10.1182\/blood.2025029987","author":"Beer SA, Cairns DA, Pawlyn C, Holroyd A, Ferris E, Cook G, Drayson M, Boyd K, Proszek P, Davies FE, de Tute R, Jenner M, Morgan GJ, Owen R, Hubank M, Houlston R, Jackson G, Kaiser MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834881"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3600-3609. doi: 10.1200\/JCO-25-01238","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288237. Online ahead of print","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","title02":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","journal":"Br J Haematol","issue":"2025 November 28. doi: 10.1111\/bjh.70267. Online ahead of print","author":"He Y, Hu J, Zhai J, Wang L, Cheng X, Wang J, Dong F, Zhao X, Zhang F, Ema H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41315050"},{"title01":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","title02":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017908. Online ahead of print","author":"Schroder J, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","title02":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016812. Online ahead of print","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin N, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo LD, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","title02":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025018340. Online ahead of print","author":"Artz AS, Logan BR, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston L, Walston JD, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE Jr, Imus P, Hogan WJ, Nadiminti KV, Bhatt VR, Olin RL, Maakaron JE, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease.","title02":"Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease.","journal":"Blood advances","issue":"2025 November 25; 9(22):5811-5813. doi: 10.1182\/bloodadvances.2025017353","author":"Mejias-Figueroa JA, Saraf SL, Takemoto CM, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811819"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025017217. Online ahead of print","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy VJ, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","title02":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","journal":"Blood advances","issue":"2025 November 25; 9(22):5920-5934. doi: 10.1182\/bloodadvances.2025016970","author":"Meng X, Melsen JE, van der Holst R, de Mooij B, Vloemans S, van Eggermond M, Berghuis D, Lankester AC, de Kivit S, Pike-Overzet K, Langerak AW, Staal FJT, Ott de Bruin LM, Cante-Barrett K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829114"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","title02":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","journal":"Blood","issue":"2025 November 27; 146(22):2656-2669. doi: 10.1182\/blood.2025028504","author":"Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones D, Hall S, Cruz JC, Verneris MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906917"},{"title01":"A prime editing strategy to rewrite the gamma-globin promoters and reactivate fetal hemoglobin for sickle cell disease.","title02":"A prime editing strategy to rewrite the gamma-globin promoters and reactivate fetal hemoglobin for sickle cell disease.","journal":"Blood","issue":"2025 November 27; 146(22):2641-2655. doi: 10.1182\/blood.2024028166","author":"Chalumeau A, Bou Dames M, Fontana L, Amistadi S, Antoniou P, Loganathan P, Mombled M, Corre G, Peterka M, Amendola M, Giovannangeli C, Maresca M, Miccio A, Brusson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857666"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Belzutifan for Advanced Pheochromocytoma or Paraganglioma.","title02":"Belzutifan for Advanced Pheochromocytoma or Paraganglioma.","journal":"N Engl J Med","issue":"2025 November 20; 393(20):2012-2022. doi: 10.1056\/NEJMoa2504964","author":"Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124218"},{"title01":"Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.","title02":"Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.","journal":"N Engl J Med","issue":"2025 November 27; 393(21):2131-2141. doi: 10.1056\/NEJMoa2504411","author":"Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gomez Del Olmo V, Hodges PG, Torres-Iglesias R, Berte R, Saint-Mezard P, Lazar H, Benedict N, Barker D, Bernasconi C, Picard D, Buscarini E, Mager HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41297007"},{"title01":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","title02":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","journal":"Lancet","issue":"2025 November 29; 406(10519):2551-2563. doi: 10.1016\/S0140-6736(25)02097-5","author":"Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41218619"},{"title01":"Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.","title02":"Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.","journal":"Blood advances","issue":"2025 November 25; 9(22):5732-5735. doi: 10.1182\/bloodadvances.2024014855","author":"Lee JW, Jang JH, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y, Nagafuji K, Usuki K, Gau JP, Morita Y, Tang JL, Chang H, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758947"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025017217. Online ahead of print","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy VJ, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017433. Online ahead of print","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2024015776. Online ahead of print","author":"Liu QW, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288526. Online ahead of print","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.","title02":"Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.","journal":"Br J Haematol","issue":"2025 November 30. doi: 10.1111\/bjh.70266. Online ahead of print","author":"Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Diez-Campelo M, de Paz R, Santillana GS, Thepot S, Kazmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41320720"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","title02":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","journal":"Blood","issue":"2025 November 27; 146(22):2681-2695. doi: 10.1182\/blood.2024027692","author":"Cheng WY, Yi X, Wang ZY, Li JF, Zhang JY, Zhang RH, Zhang QQ, Weng XQ, Huang T, Zhu YM, Wang C, Yin W, Zhang JN, Wu HY, Li JM, Zhu HM, Chen L, Wang WF, Dai YT, Gao CX, Liu X, Wang S, Wang SY, Jiao B, Chen Z, Fang H, Yin T, Shen Y, Chen SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829168"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","title02":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288681. Online ahead of print","author":"Barosi G, Rosti V, Campanelli R, Massa M, Abba C, Carolei A, Catarsi P, Inzoli A, Pergola L, Barbui T, Tatarelli C, Finazzi MC, Condorelli A, Salmoiraghi S, Rambaldi A, Gianatti A, De Stefano V, Galli A, Gandossini M, Bardelli M, Gale RP, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262049"},{"title01":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","title02":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.289078. Online ahead of print","author":"Faldu P, Abdelaziz R, Yousuf M, Pardanani A, Patnaik M, Tefferi A, Gangat N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307118"},{"title01":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia.","title02":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288404. Online ahead of print","author":"Reeves BN, Song J, Leier A, Smith A, Kim SJ, Chen SL, Tashi T, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307126"},{"title01":"Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells.","title02":"Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells.","journal":"Blood advances","issue":"2025 November 25; 9(22):5915-5919. doi: 10.1182\/bloodadvances.2025017242","author":"Bywater MJ, Haldar R, Janardhanan Y, Cooper E, Cooper L, Chan SHN, Hayes N, Ling V, Straube J, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864222"},{"title01":"Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.","title02":"Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.","journal":"Blood","issue":"2025 November 27; 146(22):2629-2640. doi: 10.1182\/blood.2025029909","author":"Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920572"},{"title01":"A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.","title02":"A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2561-2573. doi: 10.1182\/blood.2025028649","author":"Xu PP, Zhu Y, Shi ZY, Wang L, Cheng S, Qian Y, Zhao Y, He Y, Yi HM, Ou-Yang BS, Jiang XF, Li B, Song Q, Mu RJ, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829156"},{"title01":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","title02":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","journal":"Leukemia","issue":"2025 November 18. doi: 10.1038\/s41375-025-02802-4. Online ahead of print","author":"Pertesi M, Demangel D, Niroula A, Perrial E, Mahecha Escobar ML, Vallee M, Liacos C, Samur MK, Sperling AS, Munshi NC, Kastritis E, Dimopoulos MA, McKay JD, Mellqvist UH, Hansson M, Dumontet C, Nilsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254116"},{"title01":"Return to employment outcomes in patients with multiple myeloma.","title02":"Return to employment outcomes in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70257. Online ahead of print","author":"Lilli NL, Pequin M, Dulondel L, Blin N, Gastinne T, Tessoulin B, Dubruille V, Antier C, Roquelaure Y, Moreau P, Porro B, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250906"},{"title01":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.","title02":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.","journal":"Blood advances","issue":"2025 November 25; 9(22):5708-5719. doi: 10.1182\/bloodadvances.2025016949","author":"Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763276"},{"title01":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.","title02":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.","journal":"Blood advances","issue":"2025 November 25; 9(22):5814-5827. doi: 10.1182\/bloodadvances.2025017214","author":"Spencer A, Gavriatopoulou M, Coriu D, Lysen A, Gutierrez NC, Escalante F, Eugenia Fantl DB, Hajek R, Seguro F, Kaur G, Bittencourt R, Kinda SB, Chu MP, Safah H, Martinez-Lopez J, de Queiroz Crusoe E, Cordeiro de Farias DL, Offidani M, Askari E, Sevindik OG, Maisnar V, Teng CL, Hughes O, Taylor R, Lehn K, Feng D, Thiebaut-Millot R, Li X, Murray L, Jung P, Rossi EL, Kongpachith S, Nichol A, Ross JA, Hader C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829119"},{"title01":"Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.","title02":"Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.","journal":"Blood advances","issue":"2025 November 25; 9(22):5828-5836. doi: 10.1182\/bloodadvances.2025017394","author":"Smits F, Groen K, Levin MD, Stege CAM, van Kampen R, van der Spek E, Nijhof I, Bilgin YM, Thielen N, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, de Heer K, Vekemans MC, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845265"},{"title01":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1.","title02":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1.","journal":"Blood advances","issue":"2025 November 25; 9(22):5752-5762. doi: 10.1182\/bloodadvances.2025016613","author":"Schinke C, Rodriguez-Otero P, van de Donk NWCJ, Lipe B, Lavi N, Rasche L, Parekh S, Van Oekelen O, Vishwamitra D, Skerget S, Cortes-Selva D, Verona R, Hilder B, Masterson T, Campagna M, Khedkar S, Renaud T, Tolbert J, Kane C, Gray KS, Saber I, Heuck C, Chari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864183"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288237. Online ahead of print","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","title02":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","journal":"Br J Haematol","issue":"2025 November 28. doi: 10.1111\/bjh.70267. Online ahead of print","author":"He Y, Hu J, Zhai J, Wang L, Cheng X, Wang J, Dong F, Zhao X, Zhang F, Ema H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41315050"},{"title01":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","title02":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70230. Online ahead of print","author":"Elfeky R, Broderick V, Ewins AM, Rivers E, Roberts W, Slatter M, Guest J, Hill A, Samrin L, Mclelland V, Holden V, Gardiner B, Sealy L, Waller L, Betteridge C, Tholouli E, Lee J, Broome H, Blundell Jones J, Prescott N, Hudson N, Hurrell R, Rao K, Gibson B, James B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41246914"},{"title01":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","title02":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70259. Online ahead of print","author":"Zhu X, Fu H, Liu J, Xu Z, Sun Y, Lv M, Mo X, Cheng Y, Xu L, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250797"},{"title01":"Return to employment outcomes in patients with multiple myeloma.","title02":"Return to employment outcomes in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70257. Online ahead of print","author":"Lilli NL, Pequin M, Dulondel L, Blin N, Gastinne T, Tessoulin B, Dubruille V, Antier C, Roquelaure Y, Moreau P, Porro B, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250906"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","title02":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","journal":"Blood advances","issue":"2025 November 25; 9(22):5920-5934. doi: 10.1182\/bloodadvances.2025016970","author":"Meng X, Melsen JE, van der Holst R, de Mooij B, Vloemans S, van Eggermond M, Berghuis D, Lankester AC, de Kivit S, Pike-Overzet K, Langerak AW, Staal FJT, Ott de Bruin LM, Cante-Barrett K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829114"},{"title01":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","title02":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016648. Online ahead of print","author":"Farhadfar N, El Jurdi N, Baker K, Ghosh S, Bat-Erdene M MPH, Chen H, Sahu R, Weiss R, Mi J, Desatnik G, Williams LR, Tkaczyk ER, Lee SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191519"},{"title01":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.","title02":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.","journal":"Blood advances","issue":"2025 November 25; 9(22):5763-5773. doi: 10.1182\/bloodadvances.2025017116","author":"Akahoshi Y, Portelli J, Katsivelos N, Louloudis IE, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Hexner EO, Kitko CL, Kraus S, Merli P, Olson TS, Pasic I, Qayed M, Reshef R, Schechter T, Marx J, Ullrich E, Vasova I, Weber D, Wolfl M, Zeiser R, Baez J, Eng G, Gleich S, Kowalyk S, Morales G, Spyrou N, Young R, DeFilipp Z, Hogan WJ, Nakamura R, Levine JE, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815797"},{"title01":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","title02":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025018340. Online ahead of print","author":"Artz AS, Logan BR, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston L, Walston JD, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE Jr, Imus P, Hogan WJ, Nadiminti KV, Bhatt VR, Olin RL, Maakaron JE, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","title02":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016812. Online ahead of print","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin N, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo LD, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Old but gold: ILC-induced T-cell senescence prevents GVHD.","title02":"Old but gold: ILC-induced T-cell senescence prevents GVHD.","journal":"Blood","issue":"2025 November 27; 146(22):2620-2621. doi: 10.1182\/blood.2025030805","author":"Chen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307933"},{"title01":"Death receptor 3 gives life to Tregs in GVHD.","title02":"Death receptor 3 gives life to Tregs in GVHD.","journal":"Blood","issue":"2025 November 27; 146(22):2626-2627. doi: 10.1182\/blood.2025030671","author":"Shaikh H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307935"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","title02":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70230. Online ahead of print","author":"Elfeky R, Broderick V, Ewins AM, Rivers E, Roberts W, Slatter M, Guest J, Hill A, Samrin L, Mclelland V, Holden V, Gardiner B, Sealy L, Waller L, Betteridge C, Tholouli E, Lee J, Broome H, Blundell Jones J, Prescott N, Hudson N, Hurrell R, Rao K, Gibson B, James B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41246914"},{"title01":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","title02":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70259. Online ahead of print","author":"Zhu X, Fu H, Liu J, Xu Z, Sun Y, Lv M, Mo X, Cheng Y, Xu L, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250797"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017433. Online ahead of print","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2024015776. Online ahead of print","author":"Liu QW, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2025 November 20. doi: 10.1038\/s41375-025-02808-y. Online ahead of print","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41266881"},{"title01":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","title02":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 18; JCO2500507. doi: 10.1200\/JCO-25-00507. Online ahead of print","author":"Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41252666"},{"title01":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma.","title02":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3573-3577. doi: 10.1200\/JCO-25-00668","author":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100801"},{"title01":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 20; JCO2502667. doi: 10.1200\/JCO-25-02667. Online ahead of print","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264903"},{"title01":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","title02":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288045. Online ahead of print","author":"Kiener TA, Schweighofer-Zwink G, Rendl G, Kern JM, Baskova L, Neureiter D, Melchardt T, Raderer M, Greil R, Pirich C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307123"},{"title01":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","title02":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288946. Online ahead of print","author":"Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307133"},{"title01":"Combinatorial targeting of MYC\/BCL2-associated vulnerabilities in high-grade B-cell lymphoma.","title02":"Combinatorial targeting of MYC\/BCL2-associated vulnerabilities in high-grade B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70249. Online ahead of print","author":"Donati G, Nicoli P, Miele F, Podini P, Dina G, Quattrini A, Amati B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41255023"},{"title01":"Repurposing pacritinib to target MYD88-mutated Waldenstrom macroglobulinaemia.","title02":"Repurposing pacritinib to target MYD88-mutated Waldenstrom macroglobulinaemia.","journal":"Br J Haematol","issue":"2025 November 19. doi: 10.1111\/bjh.70254. Online ahead of print","author":"Liu S, Kofides A, Liu X, Hatcher JM, Sun H, Tsakmaklis N, Guijosa A, Guerrera ML, Pizzarella D, Peachey AL, Patterson CJ, Hunter ZR, Meid K, Castillo JJ, Sarosiek SR, Treon SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41255253"},{"title01":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2025017165. Online ahead of print","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed\/Refractory Mantle Cell Lymphoma.","title02":"Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed\/Refractory Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025017160. Online ahead of print","author":"Phillips TJ, Di M, Miller T, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269777"},{"title01":"Han JX, Koh MJ, Boussi L, et al. Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583-602.","title02":"Han JX, Koh MJ, Boussi L, et al. Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583-602.","journal":"Blood advances","issue":"2025 November 25; 9(22):5936. doi: 10.1182\/bloodadvances.2025018400","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288992"},{"title01":"MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.","title02":"MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017760. Online ahead of print","author":"Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang JZ, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami GG, Chen-Kiang S, Elemento O, Maddocks KJ, Leonard JP, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289154"},{"title01":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","title02":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","journal":"Blood advances","issue":"2025 November 25; 9(22):5880-5887. doi: 10.1182\/bloodadvances.2025016424","author":"Mauvieux L, Herbrecht R, Eischen A, Galoisy AC, Rolland D, Gervais C, Mayeur-Rousse C, Hueber-Bonnot S, Nicolae A, Fornecker LM, Goetsch T, Severac F, Bizoi R, Fabacher T, Miguet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41236721"},{"title01":"An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.","title02":"An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.","journal":"Blood advances","issue":"2025 November 25; 9(22):5837-5852. doi: 10.1182\/bloodadvances.2025016375","author":"Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson S, Butte AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902085"},{"title01":"Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.","title02":"Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.","journal":"Blood advances","issue":"2025 November 25; 9(22):5792-5801. doi: 10.1182\/bloodadvances.2025016930","author":"Atallah-Yunes SA, Khurana A, Habermann TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811832"},{"title01":"Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.","title02":"Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.","journal":"Blood advances","issue":"2025 November 25; 9(22):5720-5731. doi: 10.1182\/bloodadvances.2025016685","author":"Ramaswami R, Lurain K, Polizzotto MN, Widell A, Ekwede I, Tassi E, Rupert A, Marshall VA, Roth MJ, Filie AC, Pittaluga S, Jaffe ES, Wang HW, Whitby D, Uldrick TS, Yarchoan R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763275"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Big cells, bigger BTK resistance in mantle cell lymphoma.","title02":"Big cells, bigger BTK resistance in mantle cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2500-2501. doi: 10.1182\/blood.2025029937","author":"Taylor J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264326"},{"title01":"Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.","title02":"Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.","journal":"Blood","issue":"2025 November 25. doi: 10.1182\/blood.2025031423. Online ahead of print","author":"Hosoya H, Bastidas Torres AN, Fernandez-Pol S, Gubatan JM, Najidh S, Duran GE, Dong F, Ehlinger Z, Lohman C, Wright C 3rd, Sahaf B, Mackall CL, Miklos DB, Sidana S, Kurtz DM, Khodadoust MS, Mikkilineni L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288531"},{"title01":"Old problems, new tools: ZR2 in older patients with DLBCL.","title02":"Old problems, new tools: ZR2 in older patients with DLBCL.","journal":"Blood","issue":"2025 November 20; 146(21):2501-2502. doi: 10.1182\/blood.2025030855","author":"de Jonge AV, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264332"},{"title01":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.","title02":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2544-2560. doi: 10.1182\/blood.2024026919","author":"Wang W, Cai Q, Liu Y, Nie L, Lee HH, Yan F, Fei Y, Yao Y, Li Y, Tan L, Lorenzi PL, Wang YN, Yao J, Chen Z, McIntosh JM, Yu CT, Jain P, Jiang VC, Vargas J, Li X, Zhang T, Li S, Santos D, Thirumurthi S, Seeley EH, Simon LM, Flowers C, Ok CY, Wang M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700581"},{"title01":"Dreaming of a Better Future: Drug Development in Myeloma.","title02":"Dreaming of a Better Future: Drug Development in Myeloma.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2024015740. Online ahead of print","author":"Lonial S, Parikh R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269780"},{"title01":"A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.","title02":"A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.","journal":"Blood","issue":"2025 November 20; 146(21):2517-2530. doi: 10.1182\/blood.2025028587","author":"Bruins WSC, Smits F, Duetz C, Groen K, Korst CLBM, de Jonge AV, Verkleij CPM, Rentenaar R, Cosovic M, Eken M, Twickler I, Homan-Weert PM, Sonneveld P, Moreau P, Claesen J, van de Donk NWCJ, Zweegman S, Mutis T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829164"},{"title01":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","title02":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","journal":"Blood","issue":"2025 November 27; 146(22):2670-2680. doi: 10.1182\/blood.2025029987","author":"Beer SA, Cairns DA, Pawlyn C, Holroyd A, Ferris E, Cook G, Drayson M, Boyd K, Proszek P, Davies FE, de Tute R, Jenner M, Morgan GJ, Owen R, Hubank M, Houlston R, Jackson G, Kaiser MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834881"},{"title01":"Isatuximab for relapsed and\/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).","title02":"Isatuximab for relapsed and\/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).","journal":"Blood","issue":"2025 November 20; 146(21):2507-2516. doi: 10.1182\/blood.2024027962","author":"Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott EC, Hoering A, Durie BGM, Orlowski RZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40925099"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2025 November 24. doi: 10.1182\/blood.2025031426. Online ahead of print","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3600-3609. doi: 10.1200\/JCO-25-01238","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","title02":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288739. Online ahead of print","author":"Takano H, Takagi S, Kato K, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Yamamoto H, Asano-Mori Y, Yamamoto G, Wake A, Taniguchi S, Uchida N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262038"},{"title01":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","title02":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288752. Online ahead of print","author":"Wei Q, Pemmaraju N, Wang SA, Hu S, DiNardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros JL, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262054"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","title02":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288221. Online ahead of print","author":"Jaiswal AK, Scherer GM, Thaxton ML, Sorrentino JP, Yuen C, Mehta MM, Sharma G, Lin TL, Tran TM, Cohen A, Ritter AJ, Kotecha RS, Sanford JR, Damoiseaux RD, Garg NK, Rao DS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307127"},{"title01":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","title02":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288377. Online ahead of print","author":"Shu M, Ding W, Wang L, Wang Z, Wang L, Zhu M, Liu D, Shen H, Wang Y, Dou X, Ma X, Zhang Y, Xu Y, Wang Y, Xue S, Fu J, Qiu H, Tang X, Han Y, Huang J, Wu D, Dai H, Wen L, Chen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307138"},{"title01":"A comparative analysis between real-time polymerase chain reaction and next-generation sequencing for the simultaneous detection of key fusions in acute myeloid leukaemia.","title02":"A comparative analysis between real-time polymerase chain reaction and next-generation sequencing for the simultaneous detection of key fusions in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70250. Online ahead of print","author":"Vieira AF, Erazo FAH, Lamas AMR, de Sousa CF, Souza GLB, Costa YA, da Silva Lira N, Pitaluga EM, da Silva SDB, de Sousa Misael NC, Bastos FQ, de Carvalho Pereira G, Xavier FD, Velasco LFR, Furtado FM, Barra GB, de Souza Andrade M, Amato AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41243548"},{"title01":"Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.","title02":"Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.","journal":"Br J Haematol","issue":"2025 November 25. doi: 10.1111\/bjh.70264. Online ahead of print","author":"Kynning MK, Westerberg E, Forsell L, Creignou M, Berggren DM, Tesi B, Bernard E, Papaemmanuil E, Nannya Y, Franco LC, Valentini D, Lindberg EH, Ogawa S, Ejerblad E, Ungerstedt J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41287892"},{"title01":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","title02":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025017083. Online ahead of print","author":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V MD, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J MD, Ting SB, Hou JZ Hematology Oncology, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti AK, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes WL, Chyla B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269778"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.","title02":"TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.","journal":"Blood advances","issue":"2025 November 25; 9(22):5888-5901. doi: 10.1182\/bloodadvances.2025017018","author":"Lawler ME, Romer-Seibert JS, Bowman MS, Mitra R, Eischen CM, Bowman RL, Meyer SE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40833891"},{"title01":"Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.","title02":"Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.","journal":"Blood advances","issue":"2025 November 25; 9(22):5937-5944. doi: 10.1182\/bloodadvances.2024015611","author":"MacPhee L, Rouhi A, Vu LP, Kuchenbauer F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845247"},{"title01":"Role of race and ethnicity in survival among children\/young adults with relapsed ALL: a Children&#8217;s Oncology Group report.","title02":"Role of race and ethnicity in survival among children\/young adults with relapsed ALL: a Children&#8217;s Oncology Group report.","journal":"Blood advances","issue":"2025 November 25; 9(22):5738-5751. doi: 10.1182\/bloodadvances.2025016670","author":"Ligon JA, Ji L, Dang A, Xu X, Rheingold SR, Bhojwani D, Devidas M, Kairalla JA, Shago M, Heerema NA, Carroll AJ, Borowitz M, Wood BL, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Loh ML, Gupta S, Winestone LE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815811"},{"title01":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","title02":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025018090. Online ahead of print","author":"Aquilanti EA, Kageler L, Bozinov V, Meyerson ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259746"},{"title01":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","title02":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","journal":"Blood advances","issue":"2025 November 25; 9(22):5880-5887. doi: 10.1182\/bloodadvances.2025016424","author":"Mauvieux L, Herbrecht R, Eischen A, Galoisy AC, Rolland D, Gervais C, Mayeur-Rousse C, Hueber-Bonnot S, Nicolae A, Fornecker LM, Goetsch T, Severac F, Bizoi R, Fabacher T, Miguet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41236721"},{"title01":"An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.","title02":"An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.","journal":"Blood advances","issue":"2025 November 25; 9(22):5802-5810. doi: 10.1182\/bloodadvances.2025016978","author":"Mason EJ, Crain AM, Scheurer ME, Lupo PJ, Rabin KR, Taylor OA, Roberts M, Woodhouse JP, Chavana A, Ludwig K, Klesse L, Heym K, Griffin T, Erana R, Bernini JC, Gramatges MM, Yi JS, Pruitt SL, Bernhardt MB, Zhu H, Mittelman SD, Huynh V, Orgel E, Schraw JM, Brown AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829116"},{"title01":"Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.","title02":"Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 November 25; 9(22):5861-5869. doi: 10.1182\/bloodadvances.2025017044","author":"Hoppmann AL, Hurley DM, Cramer S, Brown MJ, Ghosal R, Alberg AJ, Bhatia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845260"},{"title01":"Proteomics: the key to understanding AML hematopoietic aging.","title02":"Proteomics: the key to understanding AML hematopoietic aging.","journal":"Blood","issue":"2025 November 27; 146(22):2623-2624. doi: 10.1182\/blood.2025030883","author":"Gosline SJC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307939"},{"title01":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","title02":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","journal":"Blood","issue":"2025 November 27; 146(22):2681-2695. doi: 10.1182\/blood.2024027692","author":"Cheng WY, Yi X, Wang ZY, Li JF, Zhang JY, Zhang RH, Zhang QQ, Weng XQ, Huang T, Zhu YM, Wang C, Yin W, Zhang JN, Wu HY, Li JM, Zhu HM, Chen L, Wang WF, Dai YT, Gao CX, Liu X, Wang S, Wang SY, Jiao B, Chen Z, Fang H, Yin T, Shen Y, Chen SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829168"},{"title01":"Confirmation by conformation: rescue of mutant p53 in AML.","title02":"Confirmation by conformation: rescue of mutant p53 in AML.","journal":"Blood","issue":"2025 November 20; 146(21):2503-2504. doi: 10.1182\/blood.2025030273","author":"Lane DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264333"},{"title01":"NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.","title02":"NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.","journal":"Blood","issue":"2025 November 20; 146(21):2612. doi: 10.1182\/blood.2025030468","author":"Parisi X, Loghavi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264323"},{"title01":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.","title02":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2589-2596. doi: 10.1182\/blood.2025029132","author":"O'Brien C, Nursimulu N, Tyagi A, Culp-Hill R, Arruda A, Murphy T, Minden MD, Kent A, Stevens B, Pollyea DA, Hope K, Kumar S, Reisz JA, D'Alessandro A, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857673"},{"title01":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.","title02":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.","journal":"Blood","issue":"2025 November 20; 146(21):2608-2611. doi: 10.1182\/blood.2025029391","author":"Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth M, Sasaki K, Tewari P, Issa GC, Farhat A, Connors J, Sheikh I, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla K, Petropoulos D, Daver N, Kadia T, Cuglievan B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971491"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.","title02":"Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288615. Online ahead of print","author":"Lin KS, Yan M, Ganesan N, Chang T, Dogan A, Epstein-Peterson Z, Eren OC, Ghione P, Iyengar V, Johnson W, Ksanznak K, Moskowitz A, Sordi B, Horwitz S, Xiao W, Stuver R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307131"},{"title01":"Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.","title02":"Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2024.286813. Online ahead of print","author":"Joffe E, Uppal M, Zheng S, Bantilan KS, Batlevi C, Epstein-Peterson Z, Ghione P, Hamlin P, Matasar M, Moskowitz A, Noy A, Palomba ML, Keudell GV, Falchi L, Yahalom J, Segodin V, Kotlov N, Egorov E, Degryse S, Bagaev A, Fowler N, Arcila M, Dogan A, Salles G, Kumar A, Zelenetz AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307120"},{"title01":"A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.","title02":"A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70237. Online ahead of print","author":"Hess G, Eyre TA, Jen MH, Zhang J, Goebel B, Abhyankar S, Dreyling M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251068"},{"title01":"Mosunetuzumab is effective and well tolerated in older patients with relapsed\/refractory follicular lymphoma: Subgroup analysis of a phase I\/II study.","title02":"Mosunetuzumab is effective and well tolerated in older patients with relapsed\/refractory follicular lymphoma: Subgroup analysis of a phase I\/II study.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70212. Online ahead of print","author":"Thiruvengadam SK, Popplewell LL, Herrera AF, Mei M, Nikolaenko L, Zuo X, Yin S, Zhou M, Mun Y, Wu M, Wei MC, Budde LE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254806"},{"title01":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","title02":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","journal":"Leukemia","issue":"2025 November 18. doi: 10.1038\/s41375-025-02796-z. Online ahead of print","author":"Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254114"},{"title01":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","title02":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November 17. doi: 10.1038\/s41375-025-02803-3. Online ahead of print","author":"Sui P, Li Y, Hong J, Delma CR, Chen S, Wang J, Zhang P, Han S, Noor A, Yang H, Pang Y, Luan Y, Xu M, Lee J, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41249566"},{"title01":"Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.","title02":"Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.","journal":"Lancet","issue":"2025 November 29; 406(10519):2533-2535. doi: 10.1016\/S0140-6736(25)01732-5","author":"Sembill S, Marx M, Eikelberg I, Hofs M, Fuhrmann T, Karow A, Imschweiler T, Niehues T, Wotschofsky Z, Krumbholz M, Reinhardt D, Suttorp M, Woelfle J, Metzler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41274296"},{"title01":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2025 November 20; JCO2501666. doi: 10.1200\/JCO-25-01666. Online ahead of print","author":"Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264888"},{"title01":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2025 November 20; JCO2502252. doi: 10.1200\/JCO-25-02252. Online ahead of print","author":"Marvin-Peek J, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264889"},{"title01":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2025 November 21; JCO2501695. doi: 10.1200\/JCO-25-01695. Online ahead of print","author":"Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270246"},{"title01":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2025 November 21; JCO2502231. doi: 10.1200\/JCO-25-02231. Online ahead of print","author":"Sharman JP, Liu B, Wang DY, Leow CC, Barr PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270260"},{"title01":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","title02":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288255. Online ahead of print","author":"Shah B, Francis R, Pei J, Neumann-Domer R, Mackrides N, Testa JR, Nejati R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262051"},{"title01":"Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","title02":"Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288397. Online ahead of print","author":"Oszer A, Pawlik B, Cwilichowska-Puslecka N, Marschollek P, Richert-Przygonska M, Mielcarek-Siedziuk M, Crawford JC, Mazurek M, Koladiya A, Kalwak K, Styczynski J, Janczar S, Poreba M, Velasquez MP, Davis KL, Mlynarski W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262045"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288526. Online ahead of print","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication.","title02":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288362. Online ahead of print","author":"Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Kayser S, Schliemann C, Kaufmann M, Kieser M, Platzbecker U, Muller-Tidow C, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262039"},{"title01":"Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.","title02":"Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.","journal":"Br J Haematol","issue":"2025 November 25. doi: 10.1111\/bjh.70265. Online ahead of print","author":"Xu S, Yang B, Liu X, Xu Z, Weng P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41292110"},{"title01":"Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.","title02":"Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.","journal":"Br J Haematol","issue":"2025 November 30. doi: 10.1111\/bjh.70271. Online ahead of print","author":"Wang LY, Gao HT, Fu Q, Jiang Q, Jiang H, Wang Y, Xu LP, Zhang XH, Huang XJ, Tang FF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41320982"},{"title01":"Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.","title02":"Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70252. Online ahead of print","author":"Yao CY, Hsu CL, Yang YT, Tien FM, Lin CC, Wang YH, Tsai XC, Lee WH, Liu JH, Hsu YC, Kao CJ, Peng YL, Yi YH, Yang LT, Chen CC, Hou HA, Tien HF, Chou WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250875"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","title02":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017908. Online ahead of print","author":"Schroder J, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2025017165. Online ahead of print","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.","title02":"XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.","journal":"Blood","issue":"2025 October 30; 146(18):2244-2258. doi: 10.1182\/blood.2025028803","author":"Kruer TL, Quintana A, Newman H, Ferrall-Fairbanks M, Zhang L, McLemore A, Neupane S, Yang Q, Ben-Crentsil NA, Balasis ME, Letson C, Komrokji R, Chaudhry S, Totiger TM, Traina J, Figueroa ME, Ryder CB, Cluzeau T, Taylor J, Sallman DA, Padron E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737597"},{"title01":"ReXPOsing a weakness in TP53-mutant MDS and AML.","title02":"ReXPOsing a weakness in TP53-mutant MDS and AML.","journal":"Blood","issue":"2025 October 30; 146(18):2153-2155. doi: 10.1182\/blood.2025030746","author":"D'Andrea R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41165696"},{"title01":"Clinical outcomes of WHO 2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","title02":"Clinical outcomes of WHO 2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","journal":"Haematologica","issue":"2025 October 30. doi: 10.3324\/haematol.2025.288090. Online ahead of print","author":"Kwag D, Bae B, Jung J, Kim HS, Lee JM, Ahn A, Yoon JS, Park SY, Park S, Kim M, Kim YJ, Kim Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163580"},{"title01":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","title02":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","journal":"Haematologica","issue":"2025 October 30. doi: 10.3324\/haematol.2025.287951. Online ahead of print","author":"Zhang L, Li W, Thalla R, Ma R, Mack R, Kini AR, Runde A, Hagen PA, Barton K, Kosti-Schwartz J, Breslin P, Ji HL, Zhang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163575"},{"title01":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","title02":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","journal":"Blood advances","issue":"2025 October 30. doi: 10.1182\/bloodadvances.2025017745. Online ahead of print","author":"Urrutia S, Sasaki K, Bataller A, Kantarjian HM, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Savona MR, Oganesian A, Sano Y, Keer HN, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170912"},{"title01":"High throughput cloning reveals diverse properties of T cell receptors targeting minor histocompatibility antigens.","title02":"High throughput cloning reveals diverse properties of T cell receptors targeting minor histocompatibility antigens.","journal":"Blood advances","issue":"2025 October 30. doi: 10.1182\/bloodadvances.2025017680. Online ahead of print","author":"Ito S, Martin E, Panousis C, Rowe AM, Stras S, Roy J, Brocca Cofano E, Ventura K, Parr KA, Neupane B, Bellesis A, Toki A, Jing R, Jang J, Turqueti Neves A, Shlomchik MJ, Shlomchik WD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170916"},{"title01":"Olutasidenib: an Achilles&#8217; heel for IDH1-mutated MDS?","title02":"Olutasidenib: an Achilles&#8217; heel for IDH1-mutated MDS?","journal":"Blood advances","issue":"2025 October 28; 9(20):5341-5342. doi: 10.1182\/bloodadvances.2025017582","author":"Wiser L, Lachowiez C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41114970"},{"title01":"Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.","title02":"Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.","journal":"Blood advances","issue":"2025 October 28; 9(20):5293-5305. doi: 10.1182\/bloodadvances.2025016718","author":"Cortes JE, Yang J, Roboz GJ, Dinner SN, Wang ES, Wei AH, Tian H, di Trapani F, Baer MR, Donnellan W, Watts JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40668616"},{"title01":"Somatic mutations in STAG2 are associated with separated megakaryocyte nuclear lobes in myelodysplastic syndromes.","title02":"Somatic mutations in STAG2 are associated with separated megakaryocyte nuclear lobes in myelodysplastic syndromes.","journal":"Blood advances","issue":"2025 October 28; 9(20):5283-5288. doi: 10.1182\/bloodadvances.2025016897","author":"Wong WJ, Zon RL, Gibson CJ, Ho C, Pozdnyakova O, Neuberg D, Battinelli EM, Luskin MR, Tothova Z, Morgan EA, Ebert BL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40720765"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","journal":"Leukemia","issue":"2025 October 27. doi: 10.1038\/s41375-025-02781-6. Online ahead of print","author":"Bill M, Eckardt JN, Dohner K, Rohnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Einsele H, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Valka J, Sramek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Recher C, Pigneux A, Herold T, Ganser A, Dohner H, Bornhauser M, Thiede C, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","title02":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","journal":"J Clin Oncol","issue":"2025 October 24; JCO2501369. doi: 10.1200\/JCO-25-01369. Online ahead of print","author":"Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, Green F, Zheng N, Wang Y, Liu J, Blanco JG, Dorff SE, Booth B, Choe M, Gehrke B, Bhatnagar V, Theoret M, Pazdur R, De Claro RA, Norsworthy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135032"},{"title01":"Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.","title02":"Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.","journal":"Blood","issue":"2025 October 23; 146(17):2102-2118. doi: 10.1182\/blood.2025028993","author":"Umeda M, Hiltenbrand R, Michmerhuizen NL, Barajas JM, Thomas Iii ME, Arthur B, Walsh MP, Song G, Ma J, Westover T, Kumar A, Polonen P, Mecucci C, Di Giacomo D, Locatelli F, Masetti R, Bertuccio SN, Pigazzi M, Pruett-Miller SM, Pounds S, Rubnitz J, Inaba H, Papadopoulos KP, Wick MJ, Iacobucci I, Mullighan CG, Klco JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700635"},{"title01":"A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery.","title02":"A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery.","journal":"Blood","issue":"2025 October 16; 146(16):1883-1896. doi: 10.1182\/blood.2025028619","author":"Roncador M, Bernard E, Hasserjian R, Boultwood J, Elena C, Galli A, Gurnari C, Mecucci C, Michaux L, Mittelman M, Sarchi M, Travaglino E, McLornan DP, Ogawa S, Papaemmanuil E, Hellstrom Lindberg E, Malcovati L, Cazzola M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758958"},{"title01":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","title02":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","journal":"Leukemia","issue":"2025 November; 39(11):2820-2824. doi: 10.1038\/s41375-025-02760-x","author":"Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913105"},{"title01":"Base editing platform to investigate pathogenic SAMD9 mutations in paediatric myelodysplastic syndromes.","title02":"Base editing platform to investigate pathogenic SAMD9 mutations in paediatric myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2025 November; 207(5):2158-2160. doi: 10.1111\/bjh.70117","author":"Canciani G, Lecis M, Frati G, D'Agostino V, Gelosi M, Del Bufalo F, Palumbo G, Palma P, Locatelli F, Ceglie G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251388"},{"title01":"UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES.","title02":"UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025017340. Online ahead of print","author":"Maffeo B, Panuzzo C, Savi A, Itri F, Piccioli S, Danzero AC, Maglione A, Marini S, Voso MT, Fava C, Bracco E, Pergolizzi B, Cilloni D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191526"},{"title01":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","title02":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025031006. Online ahead of print","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew GM, Dillon RJ, Gilkes AF, Marquez-Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne JL, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills RK, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2025 November 1. doi: 10.1182\/blood.2025029727. Online ahead of print","author":"Stahl MF, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.","title02":"Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 September; 39(9):2308. doi: 10.1038\/s41375-025-02716-1","author":"Bartalucci N, Tarantino D, Enderti A, Colazzo D, Guglielmelli P, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702149"},{"title01":"Autophagosome-lysosome mediated secretion of the thrombopoietin receptor is modulated by distinct driver mutations of myeloproliferative neoplasm.","title02":"Autophagosome-lysosome mediated secretion of the thrombopoietin receptor is modulated by distinct driver mutations of myeloproliferative neoplasm.","journal":"Leukemia","issue":"2025 September; 39(9):2181-2195. doi: 10.1038\/s41375-025-02676-6","author":"Chowdhury S, Shrivastva S, Singh A, Ansari F, Naseer S, Roy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610764"},{"title01":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.","title02":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 September; 12(9):e705-e716. doi: 10.1016\/S2352-3026(25)00172-3","author":"Robin M, D'Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, Mediavilla C, Carre M, Himberlin C, Sebert M, Ravinet A, Desseaux K, Labussiere H, Alani M, Rubio MT, Huynh A, Ades L, de Latour RP, Paul F, Chermat F, Petit R, Mokeddem C, Charbonnier A, Thepot S, Chevret S, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40784355"},{"title01":"Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases.","title02":"Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases.","journal":"Haematologica","issue":"2025 September 1; 110(9):2091-2101. doi: 10.3324\/haematol.2025.287569","author":"Iftikhar M, Rana M, Jadoon Y, Abdelmagid M, Reichard K, Mendoza CZ, Pardanani A, Tefferi A, Gangat N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40145292"},{"title01":"Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.","title02":"Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.","journal":"Br J Haematol","issue":"2025 September; 207(3):1029-1037. doi: 10.1111\/bjh.20242","author":"Kristiansen MH, Skov V, Larsen MK, Kjaer L, Nielsen CH, Hasselbalch HC, Wienecke T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40701821"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 September 25. doi: 10.3324\/haematol.2025.288166. Online ahead of print","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","title02":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","journal":"Haematologica","issue":"2025 September 25. doi: 10.3324\/haematol.2024.286697. Online ahead of print","author":"Leontyeva Y, Landtblom AR, Hultcrantz M, Lambe M, Bower H, Lambert PC, Andersson TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994348"},{"title01":"Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Philadelphia-Negative Chronic Myeloproliferative Neoplasms.","title02":"Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Philadelphia-Negative Chronic Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2025 September 18. doi: 10.1182\/bloodadvances.2025017016. Online ahead of print","author":"Davidsen ID, Larsen MK, Loffler L, Skov V, Kjaer L, Knudsen TA, Sorensen AL MD, Christensen SF, Cordua S, Eickhardt-Dalboge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966426"},{"title01":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","title02":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","journal":"Blood","issue":"2025 September 30. doi: 10.1182\/blood.2025028489. Online ahead of print","author":"Tapper WJ, Dawoud AAZ, Score J, Chase AJ, Baxter EJ, Ewing J, Wallis L, Guglielmelli P, Colomer D, Bellosillo B, Gomez M, Hernandez-Boluda JC, Besses C, Cervantes F, Koschmieder S, Green AR, Reiter A, Vannucchi AM, Harrison CN, Cross NCP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026930"},{"title01":"Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression.","title02":"Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression.","journal":"Blood","issue":"2025 September 25; 146(13):1612-1624. doi: 10.1182\/blood.2024027363","author":"Varricchio L, Mosoyan G, Elghaity-Beckley S, Mia MB, Handa S, Salib C, Mascarenhas J, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40643151"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2025 September 19. doi: 10.1182\/blood.2025029916. Online ahead of print","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms.","title02":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 October 1; 110(10):2388-2399. doi: 10.3324\/haematol.2025.287497","author":"Leiva O, Soo S, Liu O, Smilowitz NR, Reynolds H, Shah B, Bernard S, How J, Lee MH, Hobbs G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371905"},{"title01":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","title02":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","journal":"Blood advances","issue":"2025 October 7. doi: 10.1182\/bloodadvances.2025017168. Online ahead of print","author":"Lee MH, Wang Y, Cronin AM, Tramontano AC, Weeks LD, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056521"},{"title01":"A Practical Tool for Predicting Outcomes in Essential Thrombocythemia: Triple A Risk Model and Beyond.","title02":"A Practical Tool for Predicting Outcomes in Essential Thrombocythemia: Triple A Risk Model and Beyond.","journal":"Blood advances","issue":"2025 October 15. doi: 10.1182\/bloodadvances.2025017896. Online ahead of print","author":"Sonmez O, Oyur E, Yonal-Hindilerden I, Hindilerden F, Sonmez M, Karismaz A, Atli Z, Soysal T, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092481"},{"title01":"The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.","title02":"The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.","journal":"Leukemia","issue":"2025 October; 39(10):2406-2418. doi: 10.1038\/s41375-025-02719-y","author":"Kapahnke K, Plenge T, Klaus T, Gupta MK, Anand D, Onder TT, Perner B, Schnoder TM, Thol FR, Damm F, Heidel FH, Perner F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781484"},{"title01":"Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-gamma signaling and driver mutations.","title02":"Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-gamma signaling and driver mutations.","journal":"Leukemia","issue":"2025 October; 39(10):2391-2405. doi: 10.1038\/s41375-025-02706-3","author":"Bauer M, Vaxevanis C, Jaekel N, Hackl H, Wilfer A, Zoellig C, Haemmerle M, Muller-Tidow C, Al-Ali HK, Seliger B, Wickenhauser C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40764668"},{"title01":"QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.","title02":"QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 October; 39(10):2384-2390. doi: 10.1038\/s41375-025-02681-9","author":"Duminuco A, Vaghela R, Virdee S, Woodley C, Asirvatham S, Curto-Garcia N, Sriskandarajah P, O'Sullivan J, de Lavallade H, Radia D, Kordasti S, Palumbo GA, Harrison C, Harrington P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40707675"},{"title01":"Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.","title02":"Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.","journal":"Br J Haematol","issue":"2025 October; 207(4):1388-1396. doi: 10.1111\/bjh.70065","author":"Lubke J, Naumann N, Brand T, Steiner L, Repp R, Metzgeroth G, Fabarius A, Hofmann WK, Radia DH, Reiter A, Schwaab J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781766"},{"title01":"The impact of JAK2(V617F) variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.","title02":"The impact of JAK2(V617F) variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.","journal":"Br J Haematol","issue":"2025 October 24. doi: 10.1111\/bjh.70198. Online ahead of print","author":"Brown R, Bennett R, Crean C, Hindley A, McGimpsey J, Cunningham N, Niblock A, McPherson S, Boyd K, Foy A, Graham C, Greenfield G, McMullin MF, Catherwood MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41132056"},{"title01":"Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.","title02":"Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.","journal":"Blood advances","issue":"2025 October 31. doi: 10.1182\/bloodadvances.2025017938. Online ahead of print","author":"Suo S, Fu RF, Qin A Dr, Shao Z, Bai J, Zhou H, Xu N, Chen S, Zuo X, Du X, Duan M, Wang L, Li P, Zhang X, Zhang S, Wu D, Zhang J, Xiao Z, Zhang L, Jin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172233"},{"title01":"Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis.","title02":"Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis.","journal":"Blood","issue":"2025 October 16. doi: 10.1182\/blood.2025028643. Online ahead of print","author":"Kremyanskaya M, Ginzburg YZ, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100735"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","title02":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 November 10. doi: 10.1038\/s41375-025-02798-x. Online ahead of print","author":"Lisle TL, Holmstrom MO, Penco MP, Ruders JH, Riley CH, Grauslund JH, Jensen EB, Sorensen AL, Skov V, Kjaer L, Hasselbalch H, Andersen MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214139"},{"title01":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","title02":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.287585. Online ahead of print","author":"Masubuchi N, Yang Y, Imai M, Kihara Y, Morishita S, Edahiro Y, Komatsu N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195513"},{"title01":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera.","title02":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2<\/i>V617F-induced polycythemia vera.","journal":"Haematologica","issue":"2025 November 1; 110(11):2702-2713. doi: 10.3324\/haematol.2024.287186","author":"Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468940"},{"title01":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","title02":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 November 1; 110(11):2691-701. doi: 10.3324\/haematol.2024.286123","author":"Yu D, Zhang H, Song Y, Tao Y, Zhou F, Wang Z, Fu R, Sun T, Dong H, Gu W, Yang R, Xiao Z, Sun Q, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501395"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Reconsidering &#8216;primary myelofibrosis with increased haemoglobin&#8217; within the myeloproliferative neoplasms biological continuum.","title02":"Reconsidering &#8216;primary myelofibrosis with increased haemoglobin&#8217; within the myeloproliferative neoplasms biological continuum.","journal":"Br J Haematol","issue":"2025 November; 207(5):2226-2227. doi: 10.1111\/bjh.70103","author":"Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856246"},{"title01":"Improved outcomes in primary myelofibrosis patients with increased haemoglobin concentration.","title02":"Improved outcomes in primary myelofibrosis patients with increased haemoglobin concentration.","journal":"Br J Haematol","issue":"2025 November; 207(5):2224-2225. doi: 10.1111\/bjh.70062","author":"Krecak I, Lucijanic M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40741924"},{"title01":"Primary myelofibrosis with increased haemoglobin concentration at presentation.","title02":"Primary myelofibrosis with increased haemoglobin concentration at presentation.","journal":"Br J Haematol","issue":"2025 November; 207(5):1930-1937. doi: 10.1111\/bjh.20233","author":"Barosi G, Campanelli R, Catarsi P, Abba C, Carolei A, Massa M, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40551505"},{"title01":"Hypoxia-inducible Factors Contribute to Venous Thrombosis in a Mouse Model of Myeloproliferative Neoplasms.","title02":"Hypoxia-inducible Factors Contribute to Venous Thrombosis in a Mouse Model of Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025016344. Online ahead of print","author":"Ghosh S, Miklosz J, Trebak F, Tourn J, Grover SP, Pawlinski R, Reeves BN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191539"},{"title01":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","title02":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","journal":"Blood advances","issue":"2025 November 11; 9(21):5598-5609. doi: 10.1182\/bloodadvances.2025016898","author":"Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829105"},{"title01":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","title02":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","journal":"Blood","issue":"2025 November 13; 146(20):2428-2442. doi: 10.1182\/blood.2024027125","author":"Bonal DM, Oakes A, Chorzalska A, Pardo M, Petersen M, Clarke MY, Lee SH, Olszewski AJ, Treaba DO, Reagan JL, Dooner M, Morgan J, Bertone P, Zhao TC, Yang W, Ventetuolo CE, Hobbs GS, Mills J, Dubielecka PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729727"},{"title01":"Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN.","title02":"Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN.","journal":"Blood","issue":"2025 November 13; 146(20):2377-2378. doi: 10.1182\/blood.2025030551","author":"Zenke M, Koschmieder S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231464"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2025 September 4. doi: 10.3324\/haematol.2025.287860. Online ahead of print","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Overall cancer risk in people with deleterious germline DDX41 variants.","title02":"Overall cancer risk in people with deleterious germline DDX41 variants.","journal":"Haematologica","issue":"2025 September 1; 110(9):2076-2090. doi: 10.3324\/haematol.2024.286887","author":"Korotev SC, Cheng JX, Haribabu Y, Strauss J, Dominguez S, Koppayi A, Perpich M, Pies M, Moma L, Kim A, Basdag H, Rodgers C, Kosuri S, Saiki R, Makishima H, Tawde S, Galasinski S, Kandikatla P, Subramanian HP, Ren K, Bi H, Mohammadhosseini M, Ogawa S, Ji P, Agarwal A, Das S, Godley LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39945023"},{"title01":"Enforcement of stem-cell dormancy by nucleophosmin mutation is a critical determinant of unrestricted self-renewal during myeloid leukemogenesis.","title02":"Enforcement of stem-cell dormancy by nucleophosmin mutation is a critical determinant of unrestricted self-renewal during myeloid leukemogenesis.","journal":"Haematologica","issue":"2025 September 1; 110(9):2009-2023. doi: 10.3324\/haematol.2024.286577","author":"Merlo MEB, Mallardo M, Luzi L, De Conti G, Caprioli C, Hillje R, Faretta M, Restelli C, Polazzi A, Tabanelli V, Calleri A, Pileri S, Pelicci PG, Colombo E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40079083"},{"title01":"Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.","title02":"Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.","journal":"Haematologica","issue":"2025 September 1; 110(9):1974-1986. doi: 10.3324\/haematol.2024.285700","author":"Kotmayer L, Kennedy AL, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568716"},{"title01":"Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series.","title02":"Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series.","journal":"Haematologica","issue":"2025 September 1; 110(9):1921-1922. doi: 10.3324\/haematol.2024.286783","author":"Izraeli S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40888337"},{"title01":"A CHIP off the old (MDS) block.","title02":"A CHIP off the old (MDS) block.","journal":"Haematologica","issue":"2025 September 1; 110(9):1898-1899. doi: 10.3324\/haematol.2025.287929","author":"Luger SM, Ciccarelli BT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40888336"},{"title01":"Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies.","journal":"Blood advances","issue":"2025 September 9. doi: 10.1182\/bloodadvances.2025017084. Online ahead of print","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie SP, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'Aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault De Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.","title02":"Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.","journal":"Leukemia","issue":"2025 September; 39(9):2256-2265. doi: 10.1038\/s41375-025-02711-6","author":"Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40691503"},{"title01":"Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1(S34F) mutant myelodysplastic neoplasms.","title02":"Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1(S34F) mutant myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 September; 39(9):2246-2255. doi: 10.1038\/s41375-025-02684-6","author":"Zhang W, Li B, Liu J, Yan Y, Yang L, Qin T, Xu Z, Sun Q, Jia Y, Wang H, Huang G, Wang H, Shi L, Zhou J, Xiao Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40652060"},{"title01":"5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.","title02":"5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.","journal":"Leukemia","issue":"2025 September; 39(9):2112-2124. doi: 10.1038\/s41375-025-02670-y","author":"Bertoli R, Cao D, Tuckey O, Gammell S, Wokasch A, Chung YJ, Foulks JM, Aplan PD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40681875"},{"title01":"Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.","title02":"Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.","journal":"Leukemia","issue":"2025 September; 39(9):2099-2111. doi: 10.1038\/s41375-025-02665-9","author":"Calderon AS, Ghazanfari R, Masoumi Z, Kharazi S, Palo S, Lang S, Zemaitis K, Eldeeb M, Subramaniam A, Soneji S, Stam RW, Bryder D, Boiers C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40646135"},{"title01":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.","title02":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 September; 12(9):e705-e716. doi: 10.1016\/S2352-3026(25)00172-3","author":"Robin M, D'Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, Mediavilla C, Carre M, Himberlin C, Sebert M, Ravinet A, Desseaux K, Labussiere H, Alani M, Rubio MT, Huynh A, Ades L, de Latour RP, Paul F, Chermat F, Petit R, Mokeddem C, Charbonnier A, Thepot S, Chevret S, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40784355"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 September 25. doi: 10.3324\/haematol.2025.288166. Online ahead of print","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Platelet glycosylation in myelodysplastic syndromes correlates with disease severity.","title02":"Platelet glycosylation in myelodysplastic syndromes correlates with disease severity.","journal":"Blood advances","issue":"2025 September 23; 9(18):4656-4660. doi: 10.1182\/bloodadvances.2025016349","author":"Rosenbalm KE, Wong TL, Hoang D, Andersen VL, Steinhardt G, Zheng S, Griffiths EA, Gu T, Hoffmeister KM, Lau JTY, Nemeth MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40644615"},{"title01":"Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes\/Neoplasms: A Systematic Review and Meta-Analysis.","title02":"Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes\/Neoplasms: A Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2025 September 18. doi: 10.1182\/bloodadvances.2025017611. Online ahead of print","author":"Alhajahjeh A, Link Woite N, Rolles B, Stempel JM, Mina A, Mendez LM, Kewan T, Podoltsev NA, Stahl MF, Grimshaw AA, Zeidan AM, Bewersdorf JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966428"},{"title01":"Determining telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","title02":"Determining telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","journal":"Blood","issue":"2025 September 22. doi: 10.1182\/blood.2025028644. Online ahead of print","author":"Guarnera L, Wahida A, Gurnari C, Hutter S, Stainczyk SA, Williams N, Durmaz A, Kubota Y, Bravo-Perez C, Kawashima N, Orland MD, Pagliuca S, Huang Y, LaFramboise T, Visconte V, Walter W, Meggendorfer M, Kern W, Westermann F, Feuerbach L, Haferlach T, Maciejewski JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983034"},{"title01":"Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.","title02":"Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.","journal":"Blood","issue":"2025 September 18; 146(12):1493-1510. doi: 10.1182\/blood.2024026417","author":"Andricovich J, Lap CJ, Tzatsos A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40540751"},{"title01":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.","title02":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.","journal":"Blood","issue":"2025 September 18; 146(12):1450-1461. doi: 10.1182\/blood.2024028133","author":"Jachiet V, Kosmider O, Beydon M, Hadjadj J, Zhao LP, Grobost V, Lacombe V, Le Guenno G, Nguyen Y, Arlet JB, Dion J, Heiblig M, Garnier A, Samson M, Aouba A, Thepot S, Dimicoli-Salazar S, Dutasta F, Faucher B, Lazaro E, Morel V, Neel A, Outh R, Bezanahary H, Rossignol J, Alary AS, Bidet A, Blateau P, Bouvier A, Boursier G, Decamp M, Lebecque B, Le Bris Y, Sujobert P, Marceau-Renaut A, Pastoret C, Rizzo D, Boiret-Dupre N, Boucher L, Dulucq S, Genevieve F, Jadeau C, Lemaire P, Vazquez R, Rieu JB, Fain O, Georgin-Lavialle S, Rigolot L, Larcher L, Hirsch P, Terrier B, Fenaux P, Mekinian A, Comont T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373272"},{"title01":"The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.","title02":"The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.","journal":"Leukemia","issue":"2025 October; 39(10):2329-2339. doi: 10.1038\/s41375-025-02657-9","author":"Yu H, Hong J, Shin DY, Lee CH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40562788"},{"title01":"Infections in lower-risk myelodysplastic syndromes &#8211; prevalence and risk factors: a report from the European MDS Registry.","title02":"Infections in lower-risk myelodysplastic syndromes &#8211; prevalence and risk factors: a report from the European MDS Registry.","journal":"Haematologica","issue":"2025 October 1; 110(10):2367-2375. doi: 10.3324\/haematol.2024.286880","author":"Houtman B, Taylor A, Van Marrewijk C, Smith A, Fenaux P, Cargo C, Symeonidis A, Mittelman M, Stauder R, Cermak J, Sanz G, Hellstrom-Lindberg E, Malcovati L, Ades L, Comont T, Culligan D, Kotsianidis I, De Witte T, Blijlevens N, Langemeijer S, Hoeks M, Consortium E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40207727"},{"title01":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment.","title02":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment.","journal":"Haematologica","issue":"2025 October 1; 110(10):2293-2304. doi: 10.3324\/haematol.2024.287206","author":"Velazquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, Lengerke C, Bethge W, Trepel M, Muller G, Christopeit M, Schmid C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270206"},{"title01":"Understanding infectious complications in patients with lower-risk myelodysplastic syndromes: a step towards improving survival.","title02":"Understanding infectious complications in patients with lower-risk myelodysplastic syndromes: a step towards improving survival.","journal":"Haematologica","issue":"2025 October 1; 110(10):2253-2254. doi: 10.3324\/haematol.2025.287847","author":"Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568717"},{"title01":"Genomic variation in DDX41 identified through clinical sequencing.","title02":"Genomic variation in DDX41 identified through clinical sequencing.","journal":"Br J Haematol","issue":"2025 October; 207(4):1653-1658. doi: 10.1111\/bjh.70086","author":"Wells C, Tiong IS, Hunter S, Den Elzen N, Goode E, Kankanige Y, Man K, Thompson ER, Tan M, Wu S, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070677"},{"title01":"Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk.","title02":"Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk.","journal":"Br J Haematol","issue":"2025 October; 207(4):1565-1577. doi: 10.1111\/bjh.70001","author":"Marin-Quilez A, Sanchez-Fuentes A, Zamora-Canovas A, Gomez-Gonzalez PL, Diaz-Ajenjo L, Benito R, Rodriguez-Alen A, Sevivas T, Murciano T, Murillo L, Butta NV, Revilla N, Campos R, Escribano P, Esteve J, Fernandez-Mosteirin N, Ferrer-Marin F, Hernandez L, Huerta-Aragones J, Leon A, Lopez-Duarte M, Lopez E, Martin-Salces M, Nomdedeu M, Ona R, Pelaez-Pleguezuelos I, Ramos F, Sebastian E, Serrano C, Sierra-Aisa C, Vidal-Laso R, Gonzalez-Porras JR, Lozano ML, Bastida JM, Rivera J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40670159"},{"title01":"Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.","title02":"Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2025 October; 207(4):1397-1407. doi: 10.1111\/bjh.70078","author":"Huang N, Chang C, Wu L, He Q, Zhang Z, Li X, Xu F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40755402"},{"title01":"Primary CD34(+) cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.","title02":"Primary CD34(+) cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.","journal":"Br J Haematol","issue":"2025 October 12. doi: 10.1111\/bjh.70203. Online ahead of print","author":"Nowak D, Demmerle M, Klar A, Streuer A, Riabov V, Altrock E, Rapp F, Belzer AC, Klink T, Hahn M, Hofmann F, Nowak V, Weimer N, Oblander J, Palme I, Gol M, Darwich A, Steiner L, Abba M, Metzgeroth G, Hofmann WK, Schmitt N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41077698"},{"title01":"Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2025 October 8. doi: 10.1182\/bloodadvances.2025017035. Online ahead of print","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault De Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies.","title02":"Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies.","journal":"Blood advances","issue":"2025 October 7. doi: 10.1182\/bloodadvances.2025017601. Online ahead of print","author":"Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda RW, Miyake H, Yamamoto N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056522"},{"title01":"Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.","title02":"Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.","journal":"Blood advances","issue":"2025 October 6. doi: 10.1182\/bloodadvances.2025017194. Online ahead of print","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah F, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.","title02":"IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.","journal":"Blood","issue":"2025 October 2; 146(14):1693-1706. doi: 10.1182\/blood.2024027540","author":"Raddi MG, Park S, Fontenay M, Kosmider O, Campelo MD, Berrocal JC, Sebert M, Ades L, Platzbecker U, Della Porta MG, Mattiuz G, De Pourcq S, Tofani L, Maggioni G, Tofacchi E, Consagra A, Rigodanza L, Andreossi G, Amato C, Meunier M, Orlando C, Clappier E, Chapuis N, Walczak P, Zoldan K, Kubasch AS, Santini V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40561337"},{"title01":"In low-risk myelodysplastic syndrome, don&#8217;t shoot the STAG2.","title02":"In low-risk myelodysplastic syndrome, don&#8217;t shoot the STAG2.","journal":"Blood","issue":"2025 October 2; 146(14):1636-1638. doi: 10.1182\/blood.2025030114","author":"Szuber N, Busque L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037299"},{"title01":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","title02":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","journal":"Leukemia","issue":"2025 November; 39(11):2820-2824. doi: 10.1038\/s41375-025-02760-x","author":"Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913105"},{"title01":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","title02":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2801-2811. doi: 10.1038\/s41375-025-02740-1","author":"Thier J, Hofmann S, Kirchhof KM, Todisco G, Mortera-Blanco T, Lilienthal I, Kanellis DC, Barbosa I, Bjorklund AC, Deslauriers AG, Bartek J, Herold N, Papaemmanuil E, Papapetrou EP, Hellstrom-Lindberg E, Moura PL, Lundin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858805"},{"title01":"Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms.","title02":"Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2789-2800. doi: 10.1038\/s41375-025-02729-w","author":"Kobayashi H, Komizo Y, Watanabe N, Miyata Y, Ohnuma Y, Kamimura-Aoyagi Y, Yuki K, Hayashi Y, Yoshida M, Harada Y, Harada H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40813622"},{"title01":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","title02":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","journal":"Leukemia","issue":"2025 November; 39(11):2767-2778. doi: 10.1038\/s41375-025-02727-y","author":"Ford BL, Jokinen E, Huuhtanen J, Forsten S, Klievink J, Antignani G, Bruck O, Cerullo V, Peltonen K, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847198"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"New hope, old challenges in myelodysplastic syndromes.","title02":"New hope, old challenges in myelodysplastic syndromes.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e851. doi: 10.1016\/S2352-3026(25)00292-3","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201525"},{"title01":"New hope, old challenges in myelodysplastic syndromes.","title02":"New hope, old challenges in myelodysplastic syndromes.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e851. doi: 10.1016\/S2352-3026(25)00292-3","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201525"},{"title01":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","title02":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","journal":"Leukemia","issue":"2025 November 12. doi: 10.1038\/s41375-025-02812-2. Online ahead of print","author":"Zheng H, Zhang L, Li L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225181"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Response to Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","title02":"Response to Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2866-2867. doi: 10.3324\/haematol.2025.288284","author":"Lia K, Jorgensen RRK, Wikman P, Wold BL, Overgaard N, Fluge O, Fagerli UM, Bersvendsen H, Bo IB, Bhargava S, Molin D, Fossa A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501391"},{"title01":"When &#8216;simplified&#8217; may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","title02":"When &#8216;simplified&#8217; may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2864-2865. doi: 10.3324\/haematol.2025.288186","author":"Huang K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468946"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","title02":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","journal":"Br J Haematol","issue":"2025 November; 207(5):1815-1831. doi: 10.1111\/bjh.70074","author":"Tsai XC, Yao ZH, Chou SW, Hu HC, Liu YC, Chen CH, Yeh SP, Huang WC, Lin TL, Yang TM, Lai CH, Ko HK, Kuo YW, Hsu HH, Cheng SL, Li CC, Ko BS, Wang HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926299"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2187-2191. doi: 10.1111\/bjh.70142","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","title02":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","journal":"Br J Haematol","issue":"2025 November; 207(5):1874-1882. doi: 10.1111\/bjh.70146","author":"Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947302"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2017-2025. doi: 10.1111\/bjh.70105","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.","title02":"Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.","journal":"Blood advances","issue":"2025 November 11; 9(21):5626-5637. doi: 10.1182\/bloodadvances.2025016714","author":"Elzoheiry MA, Dangelmaier CA, Vajipayajula DN, Wright MN, Tsygankov AY, Kunapuli SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779559"},{"title01":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","title02":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","journal":"N Engl J Med","issue":"2025 November 13; 393(19):1912-1925. doi: 10.1056\/NEJMoa2511734","author":"Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124233"},{"title01":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","title02":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","journal":"Lancet Oncol","issue":"2025 November 4. doi: 10.1016\/S1470-2045(25)00605-9. Online ahead of print","author":"Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouche O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202834"},{"title01":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","title02":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2025 November; 26(11):1489-1500. doi: 10.1016\/S1470-2045(25)00475-9","author":"Smith M, Piulats J, Todenhofer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Flechon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167216"},{"title01":"Lutetium-177 [(177)Lu]Lu-PSMA-I&#038;T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial.","title02":"Lutetium-177 [(177)Lu]Lu-PSMA-I&#038;T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial.","journal":"Lancet Oncol","issue":"2025 November; 26(11):1479-1488. doi: 10.1016\/S1470-2045(25)00559-5","author":"Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41119954"},{"title01":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.","title02":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.","journal":"Lancet","issue":"2025 November 8; 406(10516):2235-2243. doi: 10.1016\/S0140-6736(25)01954-3","author":"Yang Y, Zhou H, Tang L, Qiu S, Han Y, Ji D, Chen X, Lei F, Qu S, Deng B, Chen L, Huang J, Guo Y, Liu Z, Chen D, Li J, Shu X, Qin Y, Fu Z, Li B, Zhang P, Chen S, Hong J, Wei Y, Qin X, Qu S, Yang K, Lin D, Wang J, Yang L, Xiao S, Zhu H, Zhu Y, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41125110"},{"title01":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","title02":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","journal":"Lancet","issue":"2025 November 8. doi: 10.1016\/S0140-6736(25)02097-5. Online ahead of print","author":"Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41218619"},{"title01":"Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.","title02":"Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.","journal":"J Clin Oncol","issue":"2025 November 10; 43(32):3505-3515. doi: 10.1200\/JCO-25-00109","author":"Bian X, Yang T, Yin H, Hu B, Yao K, Jiang S, Chen Y, Lin J, Cao M, Liu N, Fu B, Hu C, Sun Z, Qin Y, Wang X, Yu Z, Zhang Q, Zhang X, Zhu Y, Zhu H, Xiao S, Ye D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061200"},{"title01":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","title02":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","journal":"J Clin Oncol","issue":"2025 November 4; JCO2500872. doi: 10.1200\/JCO-25-00872. Online ahead of print","author":"Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouche O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187298"},{"title01":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1): clinical hallmarks in a large pedigree with a novel PUS1 R144Q mutation, remarkable response to somatropin, and review of the literature.","title02":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1): clinical hallmarks in a large pedigree with a novel PUS1 R144Q mutation, remarkable response to somatropin, and review of the literature.","journal":"Haematologica","issue":"2025 November 1; 110(11):2819-2822. doi: 10.3324\/haematol.2025.287393","author":"Parisi L, Escher R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438980"},{"title01":"Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model.","title02":"Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model.","journal":"Haematologica","issue":"2025 November 1; 110(11):2806-2811. doi: 10.3324\/haematol.2024.287221","author":"Daniels DE, Hawksworth J, El Hoss S, Oyawoye FO, Ferrer-Vicens I, Wilson MC, Frayne J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40207730"},{"title01":"Systematic point-of-care newborn screening for sickle cell disease in rural Mali, West Africa.","title02":"Systematic point-of-care newborn screening for sickle cell disease in rural Mali, West Africa.","journal":"Br J Haematol","issue":"2025 November; 207(5):2118-2122. doi: 10.1111\/bjh.70158","author":"Guindo A, Cablay K, Kamate J, MacLean B, Saye D, Dembele P, Anderson AR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41017254"},{"title01":"A structural deletion in the 3&#8217;UTR of SLC11A2 is associated with altered iron status: Evidence from two large Danish cohorts.","title02":"A structural deletion in the 3&#8217;UTR of SLC11A2 is associated with altered iron status: Evidence from two large Danish cohorts.","journal":"Br J Haematol","issue":"2025 November; 207(5):2123-2134. doi: 10.1111\/bjh.70210","author":"Brons N, Rigas AS, Kaspersen KA, Pedersen OB, Erikstrup C, Hansen TF, Sorensen E, Dowsett J, Mikkelsen C, Christoffersen LAN, Dinh KM, Bruun MT, Aagaard B, Frikke-Schmidt R, Bundgaard H, Ullum H, Glenthoj A, Ostrowski SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41103144"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"&#8216;Raise the Bar&#8217;, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation.","title02":"&#8216;Raise the Bar&#8217;, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2219-2223. doi: 10.1111\/bjh.70150","author":"Tang GH, Phillips Z, Poutanen S, Yip P, Brinc D, Goh E, Cheung M, Pai M, Oleschuk C, Beriault D, Stefan C, Matukas L, Good D, Weyand A, Baker J, Crowther M, Cogan J, White-AlHabeeb N, Mohammed-Ali Z, Wozniak M, Nyholt D, Nagarajah S, Bekdache C, Li H, Ghaffar H, Veljkovic K, Uddayasankar U, Sepiashvili L, Catomeris P, Selby R, Sholzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936490"},{"title01":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","title02":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","journal":"Br J Haematol","issue":"2025 November; 207(5):2192-2195. doi: 10.1111\/bjh.70138","author":"Jiang D, Fogerty AE, Kuter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40922594"},{"title01":"Short-term risks and benefits of hydroxyurea (hydroxycarbamide)-induced transfusion independence in patients with beta-thalassaemia syndromes.","title02":"Short-term risks and benefits of hydroxyurea (hydroxycarbamide)-induced transfusion independence in patients with beta-thalassaemia syndromes.","journal":"Br J Haematol","issue":"2025 November; 207(5):2196-2199. doi: 10.1111\/bjh.70109","author":"Sevanthini BR, Hegde S, Sridhar T, Trivedi D, Reddy M, Shah V, Panchamia VM, Geetha T, Vora D, Pushpa H, Agarwal RK, Faulkner L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884002"},{"title01":"Inflammatory cytokine profile in patients with sickle cell anaemia and leg ulcers.","title02":"Inflammatory cytokine profile in patients with sickle cell anaemia and leg ulcers.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70236. Online ahead of print","author":"Diniz MV, Silva AP, Arcanjo GS, Batista THC, Rodrigues JVS, Rego MJBM, Leao HI, Silva RC, Souto FO, Melo CML, Barros BRS, Anjos ACM, Araujo AS, Domingos IF, Saad STO, Costa FF, Lucena-Araujo AR, Bezerra MAC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178469"},{"title01":"Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.","title02":"Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.","journal":"Blood","issue":"2025 November 13; 146(20):2385-2391. doi: 10.1182\/blood.2025029964","author":"Wilks A, Steinberg MH, Frangoul H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834880"},{"title01":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.","title02":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.","journal":"Haematologica","issue":"2025 November 1; 110(11):2764-2773. doi: 10.3324\/haematol.2025.287330","author":"Mannering N, Zadro Y, Hansen DL, Maquet J, Lafaurie M, Pottegard A, Moulis G, Frederiksen H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400464"},{"title01":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia.","title02":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2091-2098. doi: 10.1111\/bjh.70064","author":"O'Farrell C, Luckie TM, Willis MJ, Kirk SE, Lucari BR, Scheurer ME, Gao X, Grimes AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40762147"},{"title01":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","title02":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","journal":"Br J Haematol","issue":"2025 November; 207(5):2192-2195. doi: 10.1111\/bjh.70138","author":"Jiang D, Fogerty AE, Kuter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40922594"},{"title01":"T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.","title02":"T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.","journal":"Br J Haematol","issue":"2025 November 4. doi: 10.1111\/bjh.70242. Online ahead of print","author":"Audia S, Cooper N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187769"},{"title01":"Dysfunctional T cells due to the abnormal glucose metabolism in patients with primary immune thrombocytopenia.","title02":"Dysfunctional T cells due to the abnormal glucose metabolism in patients with primary immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 November 7. doi: 10.1111\/bjh.70229. Online ahead of print","author":"Tang M, Li B, Zhuang J, Zhan Y, Xie F, Ye H, Li Z, Pang W, Cheng Y, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201304"},{"title01":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.","title02":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025029769. Online ahead of print","author":"Mei H, Xu M, Shu JJ, Tang L, Xie Q, Luo L, Wei Q, Jiang H, Ming Z, Hu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237341"},{"title01":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","title02":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","journal":"Lancet Oncol","issue":"2025 November; 26(11):e586-e596. doi: 10.1016\/S1470-2045(25)00426-7","author":"Sanz J, Bug G, Ciceri F, Craddock C, Dillon R, Esteve J, Porta MGD, Heuser M, de Leeuw DC, Nagler A, Onida F, Roboz GJ, Ruggeri A, Sanchez-Ortega I, Srour M, Yakoub-Agha I, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167226"},{"title01":"Perspectives of potential haematopoietic stem-cell donors on education TikToks.","title02":"Perspectives of potential haematopoietic stem-cell donors on education TikToks.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e859-e861. doi: 10.1016\/S2352-3026(25)00287-X","author":"Jian YC, Park B, Vijenthira S, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193115"},{"title01":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","title02":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3369-3380. doi: 10.1200\/JCO-25-00206","author":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966481"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"Role of donor regulatory T cell adoptive immunotherapy in B cell immunity after hematopoietic cell transplantation.","title02":"Role of donor regulatory T cell adoptive immunotherapy in B cell immunity after hematopoietic cell transplantation.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2024.286905. Online ahead of print","author":"Piccinelli S, Limongello R, Viglione V, Hohxa E, Zei T, Ostini RI, Bigerna B, Tabarrini A, Sembenico R, Tricarico S, Zorutti F, Martelli MP, Carotti A, Martelli MF, Velardi A, Ruggeri L, Mancusi A, Pierini A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195519"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.289076. Online ahead of print","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera.","title02":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2<\/i>V617F-induced polycythemia vera.","journal":"Haematologica","issue":"2025 November 1; 110(11):2702-2713. doi: 10.3324\/haematol.2024.287186","author":"Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468940"},{"title01":"Novel and emerging therapeutic strategies for clonal haematopoiesis.","title02":"Novel and emerging therapeutic strategies for clonal haematopoiesis.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.287443. Online ahead of print","author":"Hosseini M, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230698"},{"title01":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","title02":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","journal":"Haematologica","issue":"2025 November 1; 110(11):2683-2690. doi: 10.3324\/haematol.2025.287637","author":"Stenzinger M, Beck S, Ourailidis I, Volckmar AL, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, Budczies J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468967"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2183-2186. doi: 10.1111\/bjh.70119","author":"Iversen PO, Gedde-Dahl T, Tjonnfjord GE, Ali MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","title02":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2049-2058. doi: 10.1111\/bjh.70124","author":"Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859738"},{"title01":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP).","title02":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP).","journal":"Br J Haematol","issue":"2025 November; 207(5):1982-1993. doi: 10.1111\/bjh.70036","author":"Baccelli F, Compagno F, Tridello G, Delle Cave F, Zama D, Masetti R, Petris MG, Chiusaroli L, Spadea M, Trevisan F, Colombini A, Conci S, Meazza C, Muggeo P, Micheletti MV, Pancaldi A, Mura R, Onofrillo D, De Santis R, La Spina M, Castagnola E, Perruccio K, Barone A, Giurici N, Petrone A, Mercolini F, Rinieri S, Cesaro S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976850"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","journal":"Br J Haematol","issue":"2025 November; 207(5):1802-1814. doi: 10.1111\/bjh.70061","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","title02":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025017705. Online ahead of print","author":"Tanaka-Yano M, Sugden W, Wang D, Falchetti M, Badalamenti B, Cote P, Chin DH, Goldstein J, George S, Rodrigues-Luiz GF, Lummertz da Rocha E, Li H, North T, Gryder BE, Rowe RG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191516"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","title02":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","journal":"Blood advances","issue":"2025 November 11; 9(21):5528-5538. doi: 10.1182\/bloodadvances.2025016284","author":"Caballero-Velazquez T, Delgado Serrano J, Lopez-Corral L, Ferra-Coll C, Garcia-Calderon CB, Valcarcel D, Garcia-Cadenas I, Perez Lopez E, Jimenez Lorenzo MJ, Martin-Dominguez FM, Jimenez-Leon MLR, Orti G, Escamilla Gomez V, Blazquez-Goni C, Cabero Martinez A, Andrade Ruiz H, Menendez-Pedregal E, Sanchez-Guijo F, Perez Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737543"},{"title01":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","title02":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5489-5500. doi: 10.1182\/bloodadvances.2025016149","author":"Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737539"},{"title01":"Connexin the dots in hematopoietic stem cell potential.","title02":"Connexin the dots in hematopoietic stem cell potential.","journal":"Blood","issue":"2025 November 6; 146(19):2276-2277. doi: 10.1182\/blood.2025030225","author":"Luchsinger LL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196622"},{"title01":"Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness.","title02":"Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2024028300. Online ahead of print","author":"Rabany O, Ben Dror S, Arafat M, Aharoni Levitanus H, Halperin Y, Marchand V, Romanovski N, Ussishkin N, Livneh Golany M, Reches A, Wexler J, Mayorek N, Monderer-Rothkoff G, Shifman S, Mammer Bouhou W, VanInsberghe M, Pauli C, Muller-Tidow C, Karmi O, Livneh Y, van Oudenaarden A, Motorin Y, Nachmani D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191530"},{"title01":"Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.","title02":"Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2024027948. Online ahead of print","author":"Turkalj S, Radtke FA, Stoilova B, Mecklenbrauck R, Groom AJ, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa GC, Kadia TM, Symeonidou V, de Groot AP, Kantarjian HM, Takahashi K, Konopleva M, DiNardo CD, Vyas P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191518"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","journal":"Blood","issue":"2025 November 6; 146(19):2293-2305. doi: 10.1182\/blood.2025028730","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Muller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Niederland J, Kaufmann M, Schafer-Eckart K, Baldauf H, Stolzel F, Trost S, Rollig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhauser M, Schetelig J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"Metabolic adaptation of regenerative hematopoiesis depends on docking-independent mitochondrial connexin 43.","title02":"Metabolic adaptation of regenerative hematopoiesis depends on docking-independent mitochondrial connexin 43.","journal":"Blood","issue":"2025 November 6; 146(19):2306-2321. doi: 10.1182\/blood.2024028079","author":"Singh AK, D'Alessandro A, Wellendorf AM, Gonzalez-Nieto D, Kofron M, Dzieciatkowska M, Mejia L, Barrio LC, Filippi MD, Cancelas JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749168"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","title02":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3331-3333. doi: 10.1200\/JCO-25-01884","author":"Rambaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026968"},{"title01":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","title02":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3369-3380. doi: 10.1200\/JCO-25-00206","author":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966481"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.289076. Online ahead of print","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","title02":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","journal":"Haematologica","issue":"2025 November 1; 110(11):2752-2763. doi: 10.3324\/haematol.2025.287848","author":"Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Warsame R, Kapoor P, Grogan M, Cook J, Binder M, Leung N, Kourelis T, Gonsalves W, Rajkumar VS, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400470"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","journal":"Haematologica","issue":"2025 November 1; 110(11):2827-2833. doi: 10.3324\/haematol.2025.287485","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, Bohringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","title02":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","journal":"Haematologica","issue":"2025 November 1; 110(11):2683-2690. doi: 10.3324\/haematol.2025.287637","author":"Stenzinger M, Beck S, Ourailidis I, Volckmar AL, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, Budczies J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468967"},{"title01":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","title02":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 November 1; 110(11):2691-701. doi: 10.3324\/haematol.2024.286123","author":"Yu D, Zhang H, Song Y, Tao Y, Zhou F, Wang Z, Fu R, Sun T, Dong H, Gu W, Yang R, Xiao Z, Sun Q, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501395"},{"title01":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","title02":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2041-2048. doi: 10.1111\/bjh.70101","author":"Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gulbas Z, Socie G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40810334"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","title02":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","journal":"Br J Haematol","issue":"2025 November; 207(5):1874-1882. doi: 10.1111\/bjh.70146","author":"Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947302"},{"title01":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation.","title02":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2072-2079. doi: 10.1111\/bjh.70136","author":"Sun G, Tu J, Tang B, Lu Z, Fang X, Liu H, Han Y, Sun Z, Zheng C, Zhu X, Tong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931393"},{"title01":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","title02":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","journal":"Br J Haematol","issue":"2025 November; 207(5):2026-2040. doi: 10.1111\/bjh.70099","author":"Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, Uehara Y, Tokunaga M, Toyosaki M, Miyakoshi S, Doki N, Ishiwata K, Kobayashi H, Onishi Y, Kozai Y, Kato K, Ishimaru F, Fukuda T, Atsuta Y, Takahashi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817823"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","journal":"Br J Haematol","issue":"2025 November; 207(5):1802-1814. doi: 10.1111\/bjh.70061","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2187-2191. doi: 10.1111\/bjh.70142","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2017-2025. doi: 10.1111\/bjh.70105","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","title02":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","journal":"Br J Haematol","issue":"2025 November; 207(5):2178-2182. doi: 10.1111\/bjh.70132","author":"Montes L, Choquet S, Uzunov M, Morel V, Baron M, Roos-Weil D, Joris M, Delette C, Lebon D, Azar N, Metz C, Nichelli L, Le Garff-Tavernier M, Boccon-Gibod C, Lacan C, Souchet L, Hoang-Xuan K, Soussain C, Boussen I, Houillier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887743"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2183-2186. doi: 10.1111\/bjh.70119","author":"Iversen PO, Gedde-Dahl T, Tjonnfjord GE, Ali MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","title02":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2049-2058. doi: 10.1111\/bjh.70124","author":"Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859738"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","title02":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","journal":"Blood advances","issue":"2025 November 11; 9(21):5528-5538. doi: 10.1182\/bloodadvances.2025016284","author":"Caballero-Velazquez T, Delgado Serrano J, Lopez-Corral L, Ferra-Coll C, Garcia-Calderon CB, Valcarcel D, Garcia-Cadenas I, Perez Lopez E, Jimenez Lorenzo MJ, Martin-Dominguez FM, Jimenez-Leon MLR, Orti G, Escamilla Gomez V, Blazquez-Goni C, Cabero Martinez A, Andrade Ruiz H, Menendez-Pedregal E, Sanchez-Guijo F, Perez Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737543"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","title02":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","journal":"Blood","issue":"2025 November 13; 146(20):2428-2442. doi: 10.1182\/blood.2024027125","author":"Bonal DM, Oakes A, Chorzalska A, Pardo M, Petersen M, Clarke MY, Lee SH, Olszewski AJ, Treaba DO, Reagan JL, Dooner M, Morgan J, Bertone P, Zhao TC, Yang W, Ventetuolo CE, Hobbs GS, Mills J, Dubielecka PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729727"},{"title01":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","title02":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2801-2811. doi: 10.1038\/s41375-025-02740-1","author":"Thier J, Hofmann S, Kirchhof KM, Todisco G, Mortera-Blanco T, Lilienthal I, Kanellis DC, Barbosa I, Bjorklund AC, Deslauriers AG, Bartek J, Herold N, Papaemmanuil E, Papapetrou EP, Hellstrom-Lindberg E, Moura PL, Lundin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858805"},{"title01":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","title02":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","journal":"Leukemia","issue":"2025 November; 39(11):2833. doi: 10.1038\/s41375-025-02786-1","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083681"},{"title01":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","title02":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","journal":"Leukemia","issue":"2025 November; 39(11):2825-2829. doi: 10.1038\/s41375-025-02770-9","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958034"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","title02":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","journal":"Br J Haematol","issue":"2025 November; 207(5):2026-2040. doi: 10.1111\/bjh.70099","author":"Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, Uehara Y, Tokunaga M, Toyosaki M, Miyakoshi S, Doki N, Ishiwata K, Kobayashi H, Onishi Y, Kozai Y, Kato K, Ishimaru F, Fukuda T, Atsuta Y, Takahashi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817823"},{"title01":"Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.","title02":"Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025017752. Online ahead of print","author":"Luo Z, Li M, Primeaux B, Shah R, Lin R, Iyer SP, Nastoupil LJ, Green MR, Westin JR, Flowers CR, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201381"},{"title01":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.","title02":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5654-5662. doi: 10.1182\/bloodadvances.2025016315","author":"Epstein-Peterson ZD, Lionel AC, Joseph A, Drill E, Atallah-Yunes SA, Brooks TR, Chong EA, Chong ER, Dela Cruz J, Frank MJ, Ip A, Iqbal M, Jacobson CA, Kamdar MK, Karmali R, Beyar-Katz O, Maddocks KJ, Matasar MJ, McLoughlin D, Merryman RW, Munoz JL, Navalekar R, Rhodes J, Riedell PA, Ryan CE, Salles G, Sauter CS, Sawalha Y, Sharma S, Shouval R, Shukla N, Therwhanger D, van Besien H, Varon B, Wang Y, Yamshon S, Zelenetz AD, Palomba ML, Jain P, Kumar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763269"},{"title01":"Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.","title02":"Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5501-5509. doi: 10.1182\/bloodadvances.2025017378","author":"Galli E, Di Blasi R, Di Rocco A, Cristinelli C, Pansini I, Bommier C, Corrente A, De Bernardis I, Viscovo M, Hohaus S, Modoni A, Sora F, Chiusolo P, Martelli M, Sica S, Thieblemont C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779573"},{"title01":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","title02":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","journal":"Blood advances","issue":"2025 November 11; 9(21):5473-5488. doi: 10.1182\/bloodadvances.2025015806","author":"Zhang J, Zhang Z, Liu J, Luan S, Qu J, Wu Z, Kuang Y, Gong P, Bao Y, Wang Y, Yan X, Waxman S, Zhao L, Jing Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40795245"},{"title01":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.","title02":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5571-5584. doi: 10.1182\/bloodadvances.2025016778","author":"Deschenes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, Marcus R, Avigdor A, Ballweg A, Rabinovich E, Alhomoud M, Rivas Delgado A, Corona De Lapuerta M, Luna De Abia A, Palomba ML, Shah GL, Lin R, Boardman AP, Falchi L, Lue J, Salles G, Perales MA, Shouval R, Dahi PB, Scordo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815804"},{"title01":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","title02":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288692. Online ahead of print","author":"Cheng SS, Jiang JG, Lin SC, Yu YH, Chang TW, Lim C, Yu YB, Chu HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195521"},{"title01":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies.","title02":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies.","journal":"Haematologica","issue":"2025 November 1; 110(11):2774-2778. doi: 10.3324\/haematol.2024.286264","author":"Susca N, Borrelli P, Botta C, Solimando AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371907"},{"title01":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.","title02":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.","journal":"Haematologica","issue":"2025 November 1; 110(11):2779-2785. doi: 10.3324\/haematol.2024.286835","author":"Zuo L, Li Z, Cai L, Li Q, Fan F, Zhang B, Zhao F, Luo S, Zheng Y, Hu Y, Sun C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336322"},{"title01":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","title02":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","journal":"Haematologica","issue":"2025 November 1; 110(11):2752-2763. doi: 10.3324\/haematol.2025.287848","author":"Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Warsame R, Kapoor P, Grogan M, Cook J, Binder M, Leung N, Kourelis T, Gonsalves W, Rajkumar VS, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400470"},{"title01":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study.","title02":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2839-2843. doi: 10.3324\/haematol.2025.287506","author":"Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438975"},{"title01":"Outcomes for unselected, newly diagnosed multiple myeloma patients.","title02":"Outcomes for unselected, newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2025 November 1; 110(11):2823-2826. doi: 10.3324\/haematol.2025.287458","author":"Moore JT, Mettias SM, Cheung J, Swift R, Eades B, Eshaghian S, Schwartz G, Berenson JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468965"},{"title01":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.","title02":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.","journal":"Haematologica","issue":"2025 November 1; 110(11):2740-2751. doi: 10.3324\/haematol.2025.287717","author":"Ling W, Zangari M, Van Rhee F, Barlogie B, Yaccoby S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501401"},{"title01":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.","title02":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.","journal":"Haematologica","issue":"2025 November 1; 110(11):2726-2739. doi: 10.3324\/haematol.2025.287586","author":"Liu L, Sun H, Feng F, Sun X, Ma J, Lv R, Yu T, Ye L, Li X, Yu Z, Zhang X, Jing H, Yao Y, Ma F, Qiu L, Hao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438979"},{"title01":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort.","title02":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort.","journal":"Br J Haematol","issue":"2025 November; 207(5):2161-2166. doi: 10.1111\/bjh.70108","author":"Noveihed A, Al Hadidi S, Mohan M, Shah MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251392"},{"title01":"Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.","title02":"Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70239. Online ahead of print","author":"Seefat MR, Cucchi DGJ, van Boven L, Durdu-Rayman N, Groen K, Levin MD, de Heer K, de Valk B, Wester R, van der Spek E, Rentenaar R, Korst CLBM, Quik M, O'Neill CA, Tzortzi P, Smits F, Mathot R, Heerma van Voss MR, van de Donk NWCJ, Mutis T, Bartelink IH, Zweegman S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178491"},{"title01":"No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.","title02":"No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.","journal":"Br J Haematol","issue":"2025 November 8. doi: 10.1111\/bjh.70238. Online ahead of print","author":"Lim SL, Wellard C, Rajagopal R, Harrison SJ, Khot A, Quach H, Ho PJ, Moore E, Wood E, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204910"},{"title01":"Myeloma bone disease: A constant problem in the changing landscape of myeloma management.","title02":"Myeloma bone disease: A constant problem in the changing landscape of myeloma management.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70240. Online ahead of print","author":"Swan D, Yong A, Vandyke K, Hocking J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178408"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.","title02":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.","journal":"Br J Haematol","issue":"2025 November; 207(5):1789-1801. doi: 10.1111\/bjh.70041","author":"Moore S, Miller H, Parrish C, Seymour F, Miller L, Chandler T, Land J, Karpha I, Brearton G, Thompson S, Clayton L, Jones J, McMillan A, McCourt O, Pawlyn C, Mian H, Cook G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903837"},{"title01":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.","title02":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.","journal":"Br J Haematol","issue":"2025 November; 207(5):1765-1778. doi: 10.1111\/bjh.70116","author":"Wang X, Cui Y, Wang Y, Fang B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40879107"},{"title01":"NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.","title02":"NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.","journal":"Br J Haematol","issue":"2025 November; 207(5):2167-2172. doi: 10.1111\/bjh.70111","author":"Agarwal G, Kazeroun M, Salazar M, McBean K, Kannan A, Larham J, Varghese S, Balik B, Browning J, Caulier A, Chan YLT, Giles H, Jenner M, Kishore B, Pratt G, Rabin N, Robinson R, Talbot A, van de Wyngaert Z, Xu K, Moore S, Boyle E, Ansari-Pour N, Ramasamy K, Hamblin A, Thakurta A, Gooding S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251385"},{"title01":"Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression.","title02":"Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025018078. Online ahead of print","author":"Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko VV, Kim-Schulze S, Rahman AH, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez LJ, Rossi AC, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Lagana A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191534"},{"title01":"HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.","title02":"HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5436-5448. doi: 10.1182\/bloodadvances.2025016276","author":"Ahmad MA, Radinsky O, Kaufman B, Waidha K, Gharra E, Dim S, Manikandan DB, Ofir N, Jager D, Meyer M, Elkabets M, Campbell KS, Zektser M, Gazit R, Rouvio O, Momburg F, Porgador A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706037"},{"title01":"Smoldering multiple myeloma in the United States: A population-based analysis.","title02":"Smoldering multiple myeloma in the United States: A population-based analysis.","journal":"Blood advances","issue":"2025 November 10. doi: 10.1182\/bloodadvances.2025017817. Online ahead of print","author":"Wang SY, Wang R, Schoen M, Huber JH, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff AJ, Chang SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213002"},{"title01":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.","title02":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.","journal":"Blood","issue":"2025 November 6; 146(19):2322-2335. doi: 10.1182\/blood.2025028597","author":"Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700574"},{"title01":"Breaking T-cell tolerance to fight multiple myeloma.","title02":"Breaking T-cell tolerance to fight multiple myeloma.","journal":"Blood","issue":"2025 November 6; 146(19):2277-2278. doi: 10.1182\/blood.2025030552","author":"Luu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196620"},{"title01":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.","title02":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.","journal":"Blood","issue":"2025 November 13; 146(20):2392-2405. doi: 10.1182\/blood.2025028963","author":"Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi J, Singh P, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur M, McCarthy PL, Hillengass J, Mohammadpour H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758944"},{"title01":"PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2025030061. Online ahead of print","author":"Bonolo De Campos C, He R, Pelino TJ, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybenga-Groot L, Moran MF, Tiedemann RE, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","journal":"Leukemia","issue":"2025 November; 39(11):2686-2696. doi: 10.1038\/s41375-025-02744-x","author":"Alfonso-Pierola A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, Martinez-Sanchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garcia-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Perez-Simon JA, Rodriguez-Medina C, Bass-Maturana MF, Lopez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Perez-Encinas M, Barrios-Garcia M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Duran A, Valero-Nunez M, Casado-Calderon S, Balerdi A, Torres V, Fernandez R, Noriega V, Stevenazzi M, Labrador J, Leon-Maldonado P, de Rueda-Ciller B, Arce-Fernandez O, Amigo ML, Raposo-Puglia JA, Sole M, Boluda B, Ayala R, Barragan E, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","title02":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","journal":"Br J Haematol","issue":"2025 November; 207(5):1815-1831. doi: 10.1111\/bjh.70074","author":"Tsai XC, Yao ZH, Chou SW, Hu HC, Liu YC, Chen CH, Yeh SP, Huang WC, Lin TL, Yang TM, Lai CH, Ko HK, Kuo YW, Hsu HH, Cheng SL, Li CC, Ko BS, Wang HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926299"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.","title02":"Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.","journal":"Br J Haematol","issue":"2025 November; 207(5):1863-1873. doi: 10.1111\/bjh.70139","author":"Nakamura N, Liao J, Soda Y, Takahashi M, Kodera H, Kobari Y, Hirai Y, Takaori-Kondo A, Okada T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41030086"},{"title01":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.","title02":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2714-2725. doi: 10.3324\/haematol.2025.287513","author":"Zhong H, Cheng S, Xiong J, Chen J, Mu R, Yang H, Yi H, Song Q, Zhang H, Hu Y, Cui G, Wei J, Zhang X, Xu B, Qian W, Huang X, Hou M, Yan F, Wang X, Song Y, Liu Y, Ma X, Hu J, Li F, Wu C, Chen J, Yu L, Bai O, Xu J, Zhu Z, Liu L, Zhou X, Huang L, Tong Y, Niu T, Wu D, Jiang X, Wang C, Ouyang B, Cai G, Li B, Liu J, Li Z, Xiao R, Wang L, Jiang Y, Liu Y, Zheng X, Xu P, Wang L, Chen S, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40207715"},{"title01":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","title02":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","journal":"Haematologica","issue":"2025 November 1; 110(11):2562-2565. doi: 10.3324\/haematol.2025.287922","author":"Xavier AC, Liao Y, Cairo MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468963"},{"title01":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.","title02":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2661-2672. doi: 10.3324\/haematol.2025.287528","author":"Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Dodero A, Corradini P, Carniti C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438977"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","journal":"Haematologica","issue":"2025 November 1; 110(11):2827-2833. doi: 10.3324\/haematol.2025.287485","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, Bohringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.289153. Online ahead of print","author":"Ringelstein-Harlev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230691"},{"title01":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.","title02":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.","journal":"Br J Haematol","issue":"2025 November; 207(5):2173-2177. doi: 10.1111\/bjh.70137","author":"Kuhnl A, Bouziana S, Barrington SF, Galani S, Menne T, Northend M, Stevens L, Kamat S, Osborne W, Johnson R, Kumar E, Sanderson R, Patten PEM, Benjamin R, Frew J, Prestwich R, Brady JL, Mikhaeel NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936317"},{"title01":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","title02":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","journal":"Br J Haematol","issue":"2025 November; 207(5):2178-2182. doi: 10.1111\/bjh.70132","author":"Montes L, Choquet S, Uzunov M, Morel V, Baron M, Roos-Weil D, Joris M, Delette C, Lebon D, Azar N, Metz C, Nichelli L, Le Garff-Tavernier M, Boccon-Gibod C, Lacan C, Souchet L, Hoang-Xuan K, Soussain C, Boussen I, Houillier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887743"},{"title01":"Towards a chemo-free approach for follicular lymphoma.","title02":"Towards a chemo-free approach for follicular lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1755-1764. doi: 10.1111\/bjh.70126","author":"Luminari S, Barbieri E, Nizzoli ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884311"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.","title02":"Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.","journal":"Br J Haematol","issue":"2025 November; 207(5):1744-1754. doi: 10.1111\/bjh.70115","author":"Koca O, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40843643"},{"title01":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.","title02":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.","journal":"Br J Haematol","issue":"2025 November; 207(5):1832-1841. doi: 10.1111\/bjh.70125","author":"Kleinstern G, Robinson DP, Abu Seir R, Perlman R, Liu J, Jebrini N, Elyan H, Ben Yehuda D, Slager SL, Paltiel O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887045"},{"title01":"A multicenter phase 1\/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.","title02":"A multicenter phase 1\/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.","journal":"Blood advances","issue":"2025 November 11; 9(21):5665-5675. doi: 10.1182\/bloodadvances.2025017092","author":"Cahill K, Godfrey J, Nabhan C, Kline J, Riedell PA, Cohen KS, Narula S, Karrison TG, Robertson J, Karmali R, Venugopal P, Kim SH, Rapoport AP, Lee ST, Law J, Fishkin PAS, Isufi I, Velasco M, Kaminer L, Smith SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40720747"},{"title01":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.","title02":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.","journal":"Blood advances","issue":"2025 November 11; 9(21):5460-5472. doi: 10.1182\/bloodadvances.2025016141","author":"Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435511"},{"title01":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL.","title02":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL.","journal":"Blood advances","issue":"2025 November 11; 9(21):5641-5650. doi: 10.1182\/bloodadvances.2025016689","author":"de Boer JW, Keijzer K, van Dorp S, Mutsaers PGNJ, Niezink AGH, van Doesum JA, Serroukh YIM, Muntendam LW, Pulles AE, Kret EJ, Sijs-Szabo A, Oomen J, Demandt AMP, Stevens WBC, Kuipers MT, Pennings ERA, Spanjaart AM, Kersten MJ, Jak M, van Dijk LV, van der Poel MWM, Vermaat JSP, van Meerten T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40668622"},{"title01":"High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.","title02":"High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5409-5422. doi: 10.1182\/bloodadvances.2025016651","author":"Collinge B, Hilton LK, Wong J, Alduaij W, Ben-Neriah S, Slack GW, Farinha P, Boyle M, Meissner B, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Ondrejka SL, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Feldman AL, Morin RD, Rimsza LM, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674706"},{"title01":"Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.","title02":"Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.","journal":"Blood advances","issue":"2025 November 11; 9(21):5556-5563. doi: 10.1182\/bloodadvances.2025016168","author":"Steiner R, Nikolaenko L, Nair R, Seshan V, Thiruvengadam SK, Khan N, Abramson JS, Horwitz S, Matasar M, Owens C, Rodriguez Rivera II, Straus DJ, Pardee TS, Luther S, Saboukoulou S, Thet WS, Vemuri S, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674734"},{"title01":"Beyond the CAR-T horizon in mantle cell lymphoma.","title02":"Beyond the CAR-T horizon in mantle cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5651-5653. doi: 10.1182\/bloodadvances.2025017583","author":"Lew TE, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41217750"},{"title01":"Double-Hit Lymphoma: Is Lenalidomide Just Right.","title02":"Double-Hit Lymphoma: Is Lenalidomide Just Right.","journal":"Blood advances","issue":"2025 November 11; 9(21):5663-5664. doi: 10.1182\/bloodadvances.2025017787","author":"Driml JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41217749"},{"title01":"Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.","title02":"Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5539-5545. doi: 10.1182\/bloodadvances.2024015788","author":"Krasnow N, Maurer K, Song C, Rhoades J, Xiong K, Crnjac A, Blewett T, Gao L, Jacene H, Merryman R, Gohil SH, Duffy C, Guerrero LI, Dela Cruz J, McDonough M, Wolff JO, Redd R, Mattie M, Miles B, Makrigiorgos GM, Neuberg DS, Rodig SJ, Armand P, Jacobson C, Adalsteinsson VA, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706054"},{"title01":"A Phase I Study of Blinatumomab\/Lenalidomide in Relapsed\/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.","title02":"A Phase I Study of Blinatumomab\/Lenalidomide in Relapsed\/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.","journal":"Blood advances","issue":"2025 November 10. doi: 10.1182\/bloodadvances.2025016845. Online ahead of print","author":"Tuscano JM, Othman T, Frankel P PhD, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde LEE, Mei M, Rosenberg AS, Hoeg RT, Costello CL, Foss FM, William B, Holland HK, Sharon E, Streicher H, Danilov AV, Newman EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213001"},{"title01":"Nivolumab in combination with R-CHOP for treatment-naive diffuse large B-cell lymphoma: an evaluation of safety and efficacy.","title02":"Nivolumab in combination with R-CHOP for treatment-naive diffuse large B-cell lymphoma: an evaluation of safety and efficacy.","journal":"Blood advances","issue":"2025 November 11; 9(21):5616-5625. doi: 10.1182\/bloodadvances.2025016298","author":"Odetola O, Ma S, Winter J, Pro B, Roy I, Xie P, Zhang B, Chen Q, Koulogeorgas GP, Mi X, Chen R, Ma Y, Tang X, Bayer R, Eisner R, Nelson V, Shaikh H, Tsarwhas D, Saghir F, Venugopal P, Gordon LI, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706069"},{"title01":"Racial and Clinical Determinants of Response in 2,304 r\/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials.","title02":"Racial and Clinical Determinants of Response in 2,304 r\/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025016361. Online ahead of print","author":"Kho SJ, Diamond SS, Lafeuille P, Schatz JH, Maura F, Aptekar J, Locke FL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201393"},{"title01":"Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.","title02":"Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025017120. Online ahead of print","author":"Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens DM, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila TA, Hess BT, Fitzgerald LA, Shouse G, Matasar MJ, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover NS, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201962"},{"title01":"Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.","title02":"Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.","journal":"Blood","issue":"2025 November 6; 146(19):2336-2349. doi: 10.1182\/blood.2024026805","author":"Akazawa R, Mikami T, Yamada M, Kato I, Kubota H, Saida S, Uchihara Y, Ishikawa Y, Kamitori T, Tasaka K, Isobe K, Isobe T, Izawa K, Umeda K, Hiramatsu H, Jinnouchi K, Hirata M, Fujimoto M, Daifu T, Ueno H, Nodomi S, Sawada M, Fujino H, Koh K, Hiwatari M, Kato M, Goto H, Katano I, Ito R, Ito M, Kakiuchi N, Nakagawa MM, Shiraishi Y, Honda Y, Yoshitomi H, Ueno H, Sato M, Miyano S, Haga H, Sawada A, Imadome KI, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737598"},{"title01":"Methylation profiling: unmasking CAEBV&#8217;s lymphoma connection.","title02":"Methylation profiling: unmasking CAEBV&#8217;s lymphoma connection.","journal":"Blood","issue":"2025 November 6; 146(19):2279-2280. doi: 10.1182\/blood.2025030040","author":"Fournier B, Latour S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196625"},{"title01":"Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.","title02":"Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.","journal":"Blood","issue":"2025 November 6; 146(19):2370. doi: 10.1182\/blood.2025029949","author":"Elsharawi I, Selegean S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196619"},{"title01":"Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?","title02":"Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?","journal":"Blood","issue":"2025 November 1. doi: 10.1182\/blood.2025029935. Online ahead of print","author":"Jaworek CP, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175363"},{"title01":"Mantle cell lymphoma with KMT2A rearrangement.","title02":"Mantle cell lymphoma with KMT2A rearrangement.","journal":"Blood","issue":"2025 November 13; 146(20):2491. doi: 10.1182\/blood.2025030135","author":"Hu S, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231456"},{"title01":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.","title02":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.","journal":"Leukemia","issue":"2025 November; 39(11):2610-2617. doi: 10.1038\/s41375-025-02654-y","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702148"},{"title01":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma.","title02":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma.","journal":"Leukemia","issue":"2025 November; 39(11):2779-2788. doi: 10.1038\/s41375-025-02736-x","author":"Zocchi S, Trichet P, Guernalec P, Agdada M, Alonso Bartolome A, Ogor V, Choisy C, Vias C, Sabate-Cadenas X, Bories JC, Goodhardt M, Shkumatava A, Garrick D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858807"},{"title01":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.","title02":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e876-e886. doi: 10.1016\/S2352-3026(25)00256-X","author":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193117"},{"title01":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","title02":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5489-5500. doi: 10.1182\/bloodadvances.2025016149","author":"Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737539"},{"title01":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","title02":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","journal":"Blood advances","issue":"2025 November 11; 9(21):5598-5609. doi: 10.1182\/bloodadvances.2025016898","author":"Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829105"},{"title01":"Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.","title02":"Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.","journal":"Blood advances","issue":"2025 November 11; 9(21):5585-5597. doi: 10.1182\/bloodadvances.2024015449","author":"Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy J, Abirached J, Bisharat L, Fraenkel P, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan D, Rosenblatt J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811786"},{"title01":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","title02":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","journal":"Blood advances","issue":"2025 November 11; 9(21):5473-5488. doi: 10.1182\/bloodadvances.2025015806","author":"Zhang J, Zhang Z, Liu J, Luan S, Qu J, Wu Z, Kuang Y, Gong P, Bao Y, Wang Y, Yan X, Waxman S, Zhao L, Jing Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40795245"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study.","title02":"Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025016509. Online ahead of print","author":"Pastoret C, Yang J, Feith DJ, Roussel M, Moignet A, Dighe S, Solga MD, Marchand T, Visser G, Gasparini VR, Teramo A, Zambello R, Loughran TP, Lamy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191533"},{"title01":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","title02":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025028933. Online ahead of print","author":"Ling T, O'Brien C, St-Germain J, Rondeau V, Shi M, Berman JM, Cepa AK, Saez Raez P, Wunderlich M, Carter K, Stillwell C, Sexton CR, Culp-Hill R, Reisz JA, Adeel SA, Zeng AGX, Bansal S, Tsao E, Chen HTT, Dick JE, Minden MD, Arruda A, Amaya ML, Tikhonova AN, Hope K, D'Alessandro A, Raught B, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237364"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","journal":"Blood","issue":"2025 November 6; 146(19):2293-2305. doi: 10.1182\/blood.2025028730","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Muller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Niederland J, Kaufmann M, Schafer-Eckart K, Baldauf H, Stolzel F, Trost S, Rollig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhauser M, Schetelig J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","title02":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2025030209. Online ahead of print","author":"Kawano G, Ikeda R, Ishihara D, Shima T, Sakoda T, Yamamoto S, Kochi Y, Semba Y, Ashitani S, Mori Y, Kato K, Maeda T, Miyamoto T, Soga T, Akashi K, Kikushige Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191529"},{"title01":"AML biology matters, so should we transplant ASAP?","title02":"AML biology matters, so should we transplant ASAP?","journal":"Blood","issue":"2025 November 6; 146(19):2275-2276. doi: 10.1182\/blood.2025030527","author":"Levine JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196624"},{"title01":"Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.","title02":"Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.","journal":"Blood","issue":"2025 November 13; 146(20):2417-2427. doi: 10.1182\/blood.2025029785","author":"Chen C, Cai J, Wu X, Hu Q, Wu X, Guo X, Hu S, Zhai X, Qi B, Zhang W, Wang N, Xu F, Fang Y, Li CK, Liang C, Wang L, Zhu J, Deng W, Tian X, Ju X, Zhang G, Tang J, Cheng C, Yang J, Shen S, Pui CH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40789043"},{"title01":"Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.","title02":"Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.","journal":"Blood","issue":"2025 November 6; 146(19):2350-2356. doi: 10.1182\/blood.2025028985","author":"Montefiori LE, Iacobucci I, Gao Q, Moore J, Wright WC, Wei H, Baviskar P, Sona S, Jin H, Budhraja A, Lott J, Tatarata QZ, Cheng Z, Khan T, Backhaus Wagner EA, Johnson M, Mehr CM, Freeman B, Janke L, Haferlach T, Geeleher P, Mead PE, Konopleva M, Opferman JT, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811853"},{"title01":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.","title02":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.","journal":"Blood","issue":"2025 November 13; 146(20):2443-2456. doi: 10.1182\/blood.2024027822","author":"Pauli C, Kienhofer M, Blank MF, Begik O, Rohde C, Zimmermann SMN, Werner L, Heid D, Xu F, Weidenauer K, Delaunay S, Krall N, Trunk K, Zhao D, Zhou F, Llovera L, Ollivier A, Heit-Mondrzyk A, Platzbecker U, Baldus C, Serve H, Bornhauser M, Vagbo CB, Benitah SA, Krijgsveld J, Novoa EM, Muller-Tidow C, Frye M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749163"},{"title01":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.","title02":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.","journal":"Blood","issue":"2025 November 13; 146(20):2406-2416. doi: 10.1182\/blood.2025028899","author":"Al-Sawaf O, Furstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindstrom V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864973"},{"title01":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","title02":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","journal":"Leukemia","issue":"2025 November 7. doi: 10.1038\/s41375-025-02795-0. Online ahead of print","author":"Moia R, Ragaini S, Cascione L, Rinaldi A, Genuardi E, Talotta D, Almasri M, Bruscaggin A, Zaccaria GM, Evangelista A, Civita AM, Di Rocco A, Petrucci L, Cavallo F, Celli M, Luppi M, Stelitano C, Stefani PM, Visco C, Billio A, Casaroli I, Castellino C, Pavone E, Galimberti S, Plenteda C, Merli F, Mahmoud AM, Rossi D, Gaidano G, Ladetto M, Bertoni F, Ferrero S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204002"},{"title01":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","title02":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","journal":"Leukemia","issue":"2025 November 3. doi: 10.1038\/s41375-025-02787-0. Online ahead of print","author":"Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Gine E, Visco C, Bruggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184633"},{"title01":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","title02":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","journal":"Leukemia","issue":"2025 November 12. doi: 10.1038\/s41375-025-02809-x. Online ahead of print","author":"Wei W, Song Z, Wang Y, Li S, Tan L, Lee J, Cai KQ, Nejati R, Kadin ME, Campbell KS, Nakagawa M, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225182"},{"title01":"Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial.","title02":"Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3426-3427. doi: 10.1200\/JCO-25-02137","author":"Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mule A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41004689"},{"title01":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","title02":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","journal":"J Clin Oncol","issue":"2025 November 7; JCO2502200. doi: 10.1200\/JCO-25-02200. Online ahead of print","author":"Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202195"},{"title01":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma.","title02":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288838. Online ahead of print","author":"Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195517"},{"title01":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","title02":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288185. Online ahead of print","author":"Loh Z, Yeh P, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195522"},{"title01":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","title02":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70244. Online ahead of print","author":"Smith A, Frobisher C, Varghese A, Rawstron A, Crouch S, Howell D, Fielding A, Eastick K, Cargo C, Burton C, Cook G, Easom N, Tooze R, Lillie P, Roman E, Patmore R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41220109"},{"title01":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","title02":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","journal":"Br J Haematol","issue":"2025 November 10. doi: 10.1111\/bjh.70243. Online ahead of print","author":"Fakhri B, Lattupally R, Sint K, Stehr H, Menke JR, Conte M, Shanafelt T, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215498"},{"title01":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.","title02":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.","journal":"Br J Haematol","issue":"2025 November; 207(5):2135-2139. doi: 10.1111\/bjh.70128","author":"Vodicka P, Hamova I, Velasova A, Kupcova K, Zemankova P, Nehasil P, Tkachenko A, Lochovska K, Muzikova S, Hrabetova S, Dlouha J, Blahovcova P, Frouz T, Senavova J, Dlouha L, Polgarova K, Klanova M, Salkova J, Benesova K, Klener P, Trneny M, Havranek O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916568"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Bispecific antibody combination therapies in diffuse large B-cell lymphoma.","title02":"Bispecific antibody combination therapies in diffuse large B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November 7. doi: 10.1111\/bjh.70228. Online ahead of print","author":"Harrop S, Minson A, Steiner TM, Neeson PJ, Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201275"},{"title01":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.","title02":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1742-1743. doi: 10.1111\/bjh.70174","author":"Chiriac R, Baseggio L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41039717"},{"title01":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.","title02":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.","journal":"Br J Haematol","issue":"2025 November; 207(5):1855-1862. doi: 10.1111\/bjh.70143","author":"Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AHV, Dahle J, Bertoni F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40967736"},{"title01":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.","title02":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1994-2005. doi: 10.1111\/bjh.70097","author":"Li Y, Jin L, Liu W, Liu Y, Yang K, Jia Y, Yang X, Dai Y, Yang L, Liu R, Jiang L, Zheng M, Xu J, Liu A, Sun L, Gao H, Jin R, Zheng Q, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958529"},{"title01":"Chronic lymphocytic leukemia and associated chronic lung diseases.","title02":"Chronic lymphocytic leukemia and associated chronic lung diseases.","journal":"Haematologica","issue":"2025 November 1; 110(11):2673-2682. doi: 10.3324\/haematol.2025.287533","author":"Tadmor T, Hardak E, Melamed G, Alapi H, Rokach L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438985"},{"title01":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.","title02":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2647-2660. doi: 10.3324\/haematol.2024.287265","author":"Ikeda J, Kunimoto H, Saito Y, Tsujimoto SI, Takeuchi M, Miura A, Kurosawa T, Murakami K, Kato I, Funakoshi-Tago M, Yokoyama A, Shiba N, Adachi S, Tomizawa D, Tamura T, Ito S, Nakajima H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501394"},{"title01":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia.","title02":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2557-2559. doi: 10.3324\/haematol.2025.287881","author":"Heckl D, Rettinger E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501411"},{"title01":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.","title02":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1782-1788. doi: 10.1111\/bjh.70134","author":"Metzler M, Branford S, Hijiya N, Sakamoto K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921705"},{"title01":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","title02":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2041-2048. doi: 10.1111\/bjh.70101","author":"Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gulbas Z, Socie G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40810334"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.","title02":"Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.","journal":"Br J Haematol","issue":"2025 November; 207(5):2147-2152. doi: 10.1111\/bjh.70118","author":"Lahera A, Vela-Martin L, Fernandez-Navarro P, Lopez-Lorenzo JL, Cornago J, Llamas P, Fresno M, Santos J, Villa-Morales M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859815"},{"title01":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.","title02":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2143-2146. doi: 10.1111\/bjh.70113","author":"Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931545"},{"title01":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.","title02":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.","journal":"Br J Haematol","issue":"2025 November; 207(5):1920-1929. doi: 10.1111\/bjh.70145","author":"Dam M, Centanni M, Centanni D, Friberg LE, Karlsson MO, Lynggaard LS, Johannsdottir IM, Lepik K, Vaitkeviciene GE, Griskevicius L, Poyhonen T, Pyorala M, Jonsson OG, Quist-Paulsen P, Schmiegelow K, Christoforaki T, Overgaard U, Hansen SN, Albertsen BK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916350"},{"title01":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.","title02":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1953-1961. doi: 10.1111\/bjh.70135","author":"Boudry A, Goursaud L, Lebon D, Dumezy F, Harrivel V, Boue-Raguet A, Joudinaud R, Marceau-Renaut A, Geffroy S, Hauspie C, Brijs J, Fenwarth L, Berthon C, Marolleau JP, Figeac M, Preudhomme C, Duployez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903763"},{"title01":"The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.","title02":"The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.","journal":"Br J Haematol","issue":"2025 November; 207(5):1944-1952. doi: 10.1111\/bjh.70129","author":"Ying S, Yang L, Zhang L, Hong R, Luo W, Shao Y, Sun J, Guo Q, Luo Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887822"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.","title02":"A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.","journal":"Br J Haematol","issue":"2025 November; 207(5):1842-1854. doi: 10.1111\/bjh.70130","author":"Tamai M, Komatsu C, Kagami K, Kasai S, Watanabe A, Akahane K, Goi K, Tomoyasu C, Imamura T, Oguri S, Iwasaki S, Teshima T, Yatabe Y, Inukai T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884014"},{"title01":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.","title02":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1893-1901. doi: 10.1111\/bjh.70131","author":"Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40878718"},{"title01":"ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.","title02":"ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2153-2157. doi: 10.1111\/bjh.70076","author":"Bertoli D, Giupponi C, Rossi G, D'Adda M, Cancelli V, Cattaneo C, Masina L, De Marco B, Peli A, Biasiotto G, Tucci A, Borlenghi E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251387"},{"title01":"Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.","title02":"Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5399-5408. doi: 10.1182\/bloodadvances.2025016546","author":"Fresa A, Innocenti I, Tomasso A, Vitale C, Sanna A, Frustaci AM, Visentin A, Romeo A, Sportoletti P, Giordano A, Perutelli F, Murru R, Mauro FR, Mosca A, Morelli F, Laureana R, Galitzia A, Angeletti I, Conte E, Moia R, D'Arena G, Pasquale R, Autore F, Olivieri J, Stirparo L, Benintende G, Angotzi F, Vuono F, Corbingi A, Del Principe MI, Giannarelli D, Tedeschi A, Coscia M, Sangiorgi E, Efremov DG, Laurenti L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40505061"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","title02":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025031006. Online ahead of print","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew GM, Dillon RJ, Gilkes AF, Marquez-Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne JL, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills RK, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"Decoding RNA modifications to unlock new treatments for AML.","title02":"Decoding RNA modifications to unlock new treatments for AML.","journal":"Blood","issue":"2025 November 13; 146(20):2378-2379. doi: 10.1182\/blood.2025030290","author":"Lane SW, Bywater M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231460"},{"title01":"Refitting fitness in CLL.","title02":"Refitting fitness in CLL.","journal":"Blood","issue":"2025 November 13; 146(20):2374-2375. doi: 10.1182\/blood.2025030837","author":"Brander DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231458"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","journal":"Leukemia","issue":"2025 November; 39(11):2686-2696. doi: 10.1038\/s41375-025-02744-x","author":"Alfonso-Pierola A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, Martinez-Sanchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garcia-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Perez-Simon JA, Rodriguez-Medina C, Bass-Maturana MF, Lopez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Perez-Encinas M, Barrios-Garcia M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Duran A, Valero-Nunez M, Casado-Calderon S, Balerdi A, Torres V, Fernandez R, Noriega V, Stevenazzi M, Labrador J, Leon-Maldonado P, de Rueda-Ciller B, Arce-Fernandez O, Amigo ML, Raposo-Puglia JA, Sole M, Boluda B, Ayala R, Barragan E, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.","title02":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.","journal":"Leukemia","issue":"2025 November; 39(11):2640-2651. doi: 10.1038\/s41375-025-02749-6","author":"Xu G, Wang F, Chen M, Gao W, Liu Y, Zhu J, Wang C, Jiang H, Li Y, Zhang P, Yuan J, Zhang T, Zhao C, Wang L, Wang L, Jiang J, Cao W, Zhang Z, Fu H, Dong T, Hu J, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40897850"},{"title01":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","title02":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","journal":"Lancet Oncol","issue":"2025 November; 26(11):e586-e596. doi: 10.1016\/S1470-2045(25)00426-7","author":"Sanz J, Bug G, Ciceri F, Craddock C, Dillon R, Esteve J, Porta MGD, Heuser M, de Leeuw DC, Nagler A, Onida F, Roboz GJ, Ruggeri A, Sanchez-Ortega I, Srour M, Yakoub-Agha I, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167226"},{"title01":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia.","title02":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e853-e855. doi: 10.1016\/S2352-3026(25)00263-7","author":"Faramand RG, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110449"},{"title01":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.","title02":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e898-e907. doi: 10.1016\/S2352-3026(25)00253-4","author":"Xu Q, Guo Y, Gao M, Xue L, Xu H, Li H, Zhang X, Liu C, Li Y, Chen Q, Ren J, Sathiyanadan K, Hu Y, Tang L, Huang H, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110448"},{"title01":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.","title02":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e862-e875. doi: 10.1016\/S2352-3026(25)00264-9","author":"Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193116"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","title02":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","journal":"J Clin Oncol","issue":"2025 November 10; JCO2501357. doi: 10.1200\/JCO-25-01357. Online ahead of print","author":"Gottschalk H, Moricke A, Conter V, Schrappe M, Stary J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213101"},{"title01":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.","title02":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3381-3390. doi: 10.1200\/JCO-25-01694","author":"Wang ES, Montesinos P, Foran J, Erba H, Rodriguez-Arboli E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40997296"},{"title01":"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.","title02":"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.","journal":"J Clin Oncol","issue":"2025 November 10; 43(32):3526-3535. doi: 10.1200\/JCO-25-00307","author":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, Yang J, Li Z, Byrd K, Doucette K, Mangan J, Hall S, Mims AS, Jamieson K, Dinner SN, Bseiso AW, Giordano G, Saygin C, Uy GL, Litzow MR, Stone RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026957"},{"title01":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","title02":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288743. Online ahead of print","author":"Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195510"},{"title01":"Curing acute promyelocytic leukemia: no boost from immunity needed.","title02":"Curing acute promyelocytic leukemia: no boost from immunity needed.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.300055. Online ahead of print","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195516"},{"title01":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","title02":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2024.286833. Online ahead of print","author":"Ciaurro V, Sharlandjieva V, Skwarska A, Chahrour C, Baran N, Zeng Z, Ramage C, Daver N, Carter BZ, Chaundhry S, Thandapani P, Martelli MP, Milne TA, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195508"},{"title01":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","title02":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.289066. Online ahead of print","author":"Boussi L, Goldberg AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230690"},{"title01":"Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.","title02":"Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288256. Online ahead of print","author":"Shao X, Xia Z, Cai M, Shao C, Bing S, Wang T, Du W, Liu J, Shen D, Cao J, Yang B, He Q, Xu X, Zhang J, Ying M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230692"},{"title01":"The comprehensive landscape of TTMV::RARA fusion-driven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusion-driven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288721. Online ahead of print","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","title02":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288112. Online ahead of print","author":"Rodriguez-Veiga R, Gil C, Sobas M, Torres-Minana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Perez-Encinas M, Algarra L, Gonzalez-Campos J, Gomez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, Garcia R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela A, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodriguez-Macias G, Oleksiuk J, Lloret-Madrid P, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230704"},{"title01":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A-rearranged acute lymphoblastic leukemia.","title02":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A-rearranged acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2620-2634. doi: 10.3324\/haematol.2023.284869","author":"Tee T, Ruiter TJJ, Wu S, Zhang W, Schenau DVI, Rodionova M, Wajon D, Vervoort BMT, Grunewald KJT, Bosma M, Hagelaar R, Baker-Hernandez J, Dahaoui A, Schneider P, Verhoeven-Duif NM, Van der Meer LT, Van Leeuwen FN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270205"},{"title01":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy.","title02":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2834-2838. doi: 10.3324\/haematol.2025.287487","author":"Wahba A, Catueno S, Na K, Dickson S, Stevens A, Cuglievan B, Redell MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400478"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.","title02":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70253. Online ahead of print","author":"Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Chumnumsiriwath P, Ciurea SO, Ramos-Perez J, Bellman P, Jeyakumar D, Kongtim P, Naqvi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224356"},{"title01":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","title02":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70244. Online ahead of print","author":"Smith A, Frobisher C, Varghese A, Rawstron A, Crouch S, Howell D, Fielding A, Eastick K, Cargo C, Burton C, Cook G, Easom N, Tooze R, Lillie P, Roman E, Patmore R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41220109"},{"title01":"Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naive chronic lymphocytic leukaemia.","title02":"Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naive chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70241. Online ahead of print","author":"Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, Vezan R, Calle NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215737"},{"title01":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","title02":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","journal":"Br J Haematol","issue":"2025 November 10. doi: 10.1111\/bjh.70243. Online ahead of print","author":"Fakhri B, Lattupally R, Sint K, Stehr H, Menke JR, Conte M, Shanafelt T, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215498"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","title02":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","journal":"Leukemia","issue":"2025 November; 39(11):2832. doi: 10.1038\/s41375-025-02773-6","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973769"},{"title01":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 November; 39(11):2618-2621. doi: 10.1038\/s41375-025-02778-1","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038988"},{"title01":"Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.","title02":"Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2652-2662. doi: 10.1038\/s41375-025-02743-y","author":"Zheng J, Jin L, Chen Y, Duan Y, Zong S, Wu P, Zhu X, Yang W, Hu T, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841767"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","title02":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","journal":"Leukemia","issue":"2025 November; 39(11):2767-2778. doi: 10.1038\/s41375-025-02727-y","author":"Ford BL, Jokinen E, Huuhtanen J, Forsten S, Klievink J, Antignani G, Bruck O, Cerullo V, Peltonen K, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847198"},{"title01":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.","title02":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.","journal":"Leukemia","issue":"2025 November; 39(11):2816-2819. doi: 10.1038\/s41375-025-02780-7","author":"Hund I, Hess ME, Andrieux G, Stomper J, Greve G, Niemoller C, Ma T, Uhl D, Grishina O, Thol F, Heuser M, Bug G, Crysandt M, Neubauer A, Duyster J, Dohner H, Boerries M, Lubbert M, Becker H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057684"},{"title01":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.","title02":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2812-2815. doi: 10.1038\/s41375-025-02782-5","author":"Tamai H, Miyake K, Miyake N, Asano J, Ohashi A, Arai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41053511"},{"title01":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia.","title02":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2673-2685. doi: 10.1038\/s41375-025-02731-2","author":"Hleihel R, Skayneh H, Wu HC, Hamie M, Kurdi A, Dakour J, Machaalani C, El-Sabban M, de The H, Bazarbachi A, El Hajj H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858804"},{"title01":"Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.","title02":"Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2575-2589. doi: 10.1038\/s41375-025-02723-2","author":"Amaral P, Christie R, Gresham DOF, Lucas EJM, Xu LK, Behrmann L, Bond J, Degerman S, van Delft FW, Goossens S, Hagleitner M, Halsey C, Jones N, Lammens T, van Leeuwen FN, Mansour MR, Ntziachristos P, O'Connor D, Barata JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40813621"},{"title01":"The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.","title02":"The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.","journal":"Leukemia","issue":"2025 November; 39(11):2603-2609. doi: 10.1038\/s41375-025-02746-9","author":"Patel SA, Bennett JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858808"},{"title01":"How do ionizing radiations from inter-planetary travel cause leukaemia?","title02":"How do ionizing radiations from inter-planetary travel cause leukaemia?","journal":"Leukemia","issue":"2025 November; 39(11):2830-2831. doi: 10.1038\/s41375-025-02761-w","author":"Badie C, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41023183"},{"title01":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.","title02":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.","journal":"Leukemia","issue":"2025 November; 39(11):2697-2707. doi: 10.1038\/s41375-025-02730-3","author":"Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913104"},{"title01":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.","title02":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2735-2744. doi: 10.1038\/s41375-025-02763-8","author":"Miranda-Galvis M, Tjioe KC, Sharara M, Maloney M, Keruakous AR, Jillella A, Kota V, Guha A, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935825"},{"title01":"PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias.","title02":"PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias.","journal":"Leukemia","issue":"2025 November; 39(11):2708-2720. doi: 10.1038\/s41375-025-02738-9","author":"Zaza A, Zardo G, Banella C, Tucci S, de Marinis E, Gentile M, Travaglini S, Divona M, Ottone T, Castelli G, Cerio AM, Angelini DF, Faraoni I, Palmieri R, Niscola P, Ammatuna E, Venditti A, Nervi C, Voso MT, Catalano G, Noguera NI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931045"},{"title01":"Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.","title02":"Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.","journal":"Leukemia","issue":"2025 November; 39(11):2622-2639. doi: 10.1038\/s41375-025-02734-z","author":"Ferrao Blanco MN, Kazybay B, Belderbos M, Heidenreich O, Vormoor HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817406"},{"title01":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","title02":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","journal":"Leukemia","issue":"2025 November; 39(11):2721-2734. doi: 10.1038\/s41375-025-02748-7","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931047"},{"title01":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","title02":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","journal":"Leukemia","issue":"2025 November 13. doi: 10.1038\/s41375-025-02800-6. Online ahead of print","author":"Locatelli F, Rizzari C, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, Desai R, Henry M, Zugmaier G, von Stackelberg A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41233549"},{"title01":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","title02":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","journal":"Leukemia","issue":"2025 November 10. doi: 10.1038\/s41375-025-02799-w. Online ahead of print","author":"Dhir A, Ethell A, Watkins R, Lam C, Tur-Rodriguez K, Persinger J, Dobish KK, Panda S, Buckley SM, Swenson SA, Brahma S, Rowley MJ, Hyde RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214140"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial","title02":"Enasidenib plus venetoclax in patients with <i>IDH2<\/i>-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial","journal":"Lancet Haematol","issue":"2025 Oct 8:S2352-3026(25)00254-6. doi: 10.1016\/S2352-3026(25)00254-6. Online ahead of print.","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study","title02":"Quizartinib for Newly Diagnosed <i>FLT3<\/i>-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study","journal":"J Clin Oncol","issue":"2025 Oct 13:101200JCO2501841. doi: 10.1200\/JCO-25-01841. Online ahead of print.","author":"Montesinos P, Rodr\u00edguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodr\u00edguez-Arbol\u00ed E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, L\u00f3pez-L\u00f3pez JA, Vives S, L\u00f3pez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, G\u00f3mez-Roncero MI, Barrag\u00e1n E, Ayala R, Chill\u00f3n C, Calasanz MJ, Paiva B, Boluda B, Casas-Avil\u00e9s I, Lloret P, S\u00e1nchez MJ, Rodr\u00edguez-Medina C, Cuevas L, Raposo-Puglia J\u00c1, Mateos MC, Olivares M, Mart\u00ednez-Chamorro C, Alonso N, Su\u00e1rez S, S\u00e1nchez-Vadillo I, Rodr\u00edguez MS, Gonz\u00e1lez BJ, Mart\u00ednez-Franc\u00e9s A, Cuello R, Fern\u00e1ndez A, Mart\u00ednez-Cuadr\u00f3n D, Labrador J; PETHEMA group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41082703"},{"title01":"Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia","title02":"Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A<\/i>-rearranged acute myeloid leukemia","journal":"Haematologica","issue":"2025 Oct 23. doi: 10.3324\/haematol.2025.288481. Online ahead of print.","author":"Shoji K, Yoshida K, Iyoda S, Ishikawa M, Tanaka M, Nobe M, Saito N, Shino Y, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Moritake H, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126738"},{"title01":"Leukemic fusion: partners and mutations shape NUP98r leukemia","title02":"Leukemic fusion: partners and mutations shape <i>NUP98r<\/i> leukemia","journal":"Blood","issue":"2025 Oct 23;146(17):2017-2018.","author":"Duncavage E, Spencer D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41129181"},{"title01":"Donor Hearts for Transplantation after Circulatory Death","title02":"Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1756-1757.","author":"Ross LF, Ladin K, Flescher A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160835"},{"title01":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure","title02":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure","journal":"Leukemia","issue":"2025 Oct 15. doi: 10.1038\/s41375-025-02783-4. Online ahead of print.","author":"Saul D, Lischer C, Bruns H, Ziegler N, Kannt A, Michel M, Mougiakakos D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41094011"},{"title01":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","title02":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","journal":"Leukemia","issue":"2025 Oct 13. doi: 10.1038\/s41375-025-02784-3. Online ahead of print.","author":"Rodr\u00edguez-Arbol\u00ed E, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083680"},{"title01":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","title02":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","journal":"Leukemia","issue":"2025 Oct 13. doi: 10.1038\/s41375-025-02754-9. Online ahead of print.","author":"Salit RB, Hexner EO, Gagelmann N, Kr\u00f6ger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083679"},{"title01":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial","title02":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial","journal":"J Clin Oncol","issue":"2025 Oct 15:JCO2500809. doi: 10.1200\/JCO-25-00809. Online ahead of print.","author":"Mohty M, Soci\u00e9 G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kr\u00f6ger N, St\u00f6lzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092247"},{"title01":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers","title02":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288320. Online ahead of print.","author":"May P, Rassner M, Hoegner M, Shahbaz W, W\u00e4sch R, Martinez AMG, Schmidt B, Theurich S, Engelhardt M, Bassermann F, Jung J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098101"},{"title01":"Time for iMDSCs: off-the-shelf MDSCs to control GVHD","title02":"Time for iMDSCs: off-the-shelf MDSCs to control GVHD","journal":"Blood","issue":"2025 Oct 23;146(17):2011-2012.","author":"Apostolova P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41129180"},{"title01":"The iNKT-Treg axis in GVHD control","title02":"The iNKT-Treg axis in GVHD control","journal":"Blood","issue":"2025 Oct 23;146(17):2009-2010.","author":"Maas-Bauer K, Wehr C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41129184"},{"title01":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage","title02":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage","journal":"Leukemia","issue":"2025 Oct 27. doi: 10.1038\/s41375-025-02791-4. Online ahead of print.","author":"Benz T, Larghero P, Meyer C, Hanewald T, Br\u00fcggmann D, Hentrich AE, Louwen F, Marschalek R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145673"},{"title01":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission","title02":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission","journal":"Leukemia","issue":"2025 Oct 13. doi: 10.1038\/s41375-025-02786-1. Online ahead of print.","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083681"},{"title01":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","title02":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","journal":"Leukemia","issue":"2025 Oct 13. doi: 10.1038\/s41375-025-02754-9. Online ahead of print.","author":"Salit RB, Hexner EO, Gagelmann N, Kr\u00f6ger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083679"},{"title01":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study","title02":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study","journal":"Haematologica","issue":"2025 Oct 23. doi: 10.3324\/haematol.2025.288411. Online ahead of print.","author":"Valentini CG, Pellegrino C, Chiusolo P, Rossi E, Ladiana R, Za T, Sica S, Pagano L, De Stefano V, Teofili L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126731"},{"title01":"Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT","title02":"Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70213. Online ahead of print.","author":"Suzuki T, Jo T, Yoshifuji K, Kondo T, Doki N, Kanda Y, Nishida T, Onishi Y, Asada N, Fukuda T, Sawa M, Hasegawa Y, Serizawa K, Ota S, Tanaka M, Yoshimitsu M, Atsuta Y, Kanda J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111282"},{"title01":"Granulocyte colony-stimulating factor may improve engraftment in adults with sickle cell disease undergoing non-myeloablative haematopoietic stem cell transplantation","title02":"Granulocyte colony-stimulating factor may improve engraftment in adults with sickle cell disease undergoing non-myeloablative haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Oct;207(4):1690-1693.","author":"Zhu S, Maahs L, Sweiss K, Campbell-Lee SA, Mahmud N, Gordeuk VR, Rondelli D, Saraf SL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070679"},{"title01":"CD99 tunes translation to sustain stem cells","title02":"CD99 tunes translation to sustain stem cells","journal":"Blood","issue":"2025 Oct 16;146(16):1872-1873.","author":"Lv K, Tong W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100141"},{"title01":"Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia","title02":"Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1731-1740.0.","author":"Sands BE, Shenoy-Bhangle AS, Lemieux JE, Johnson PC, Nkosi D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160824"},{"title01":"Thirty Years of Hydroxyurea for Sickle Cell Anemia &#8211; Scientific Progress, Global Health Gaps","title02":"Thirty Years of Hydroxyurea for Sickle Cell Anemia &#8211; Scientific Progress, Global Health Gaps","journal":"N Engl J Med","issue":"2025 Oct 23;393(16):1556-1559.","author":"Costa E, Ware R, Tshilolo L, Luzzatto L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115252"},{"title01":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia","title02":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia","journal":"J Clin Oncol","issue":"2025 Oct 24:JCO2501369. doi: 10.1200\/JCO-25-01369. Online ahead of print.","author":"Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, Green F, Zheng N, Wang Y, Liu J, Blanco JG, Dorff SE, Booth B, Choe M, Gehrke B, Bhatnagar V, Theoret M, Pazdur R, De Claro RA, Norsworthy KJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135032"},{"title01":"Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations","title02":"Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations","journal":"Br J Haematol","issue":"2025 Oct 28. doi: 10.1111\/bjh.70224. Online ahead of print.","author":"Stinnett PZ, Ogg RJ, Helton K, Wang W, Heitzer AM, Abramson Z, Li Y, Patni T, VanGilder P, Sharma A, Sitaram R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41152026"},{"title01":"Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia","title02":"Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia","journal":"Br J Haematol","issue":"2025 Oct 22. doi: 10.1111\/bjh.70215. Online ahead of print.","author":"Mulder FVM, Becking AL, Bernelot Moens SJ, Jalink M, Evers D, Te Boome L, Breedijk A, Droogendijk J, van der Griend R, de Heer K, M\u00e4kelburg ABU, Mandigers CMPW, Nieuwenhuizen L, Oostvogels R, Pruijt JFMH, Regelink J, Rozenberg J, Strobbe L, van der Valk FM, Lissenberg-Witte BI, Vos JMI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41122858"},{"title01":"Aligning patient-reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib","title02":"Aligning patient-reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib","journal":"Br J Haematol","issue":"2025 Oct 22. doi: 10.1111\/bjh.70222. Online ahead of print.","author":"Hasan MA, Abid M, Khan HM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41122882"},{"title01":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation","title02":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation","journal":"Blood","issue":"2025 Oct 17:blood.2025029771. doi: 10.1182\/blood.2025029771. Online ahead of print.","author":"Stewart J, Damania B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105850"},{"title01":"T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma","title02":"T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma","journal":"Blood","issue":"2025 Oct 9;146(15):1868.","author":"Shi M, Rech KL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066133"},{"title01":"Smarter combos, stronger T cells in lymphoma","title02":"Smarter combos, stronger T cells in lymphoma","journal":"Blood","issue":"2025 Oct 9;146(15):1742-1744.","author":"Vardhana SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066136"},{"title01":"Comparative efficacy of anti-CD38 monoclonal antibodies in multiple myeloma using a network meta-analysis","title02":"Comparative efficacy of anti-CD38 monoclonal antibodies in multiple myeloma using a network meta-analysis","journal":"Br J Haematol","issue":"2025 Oct 9. doi: 10.1111\/bjh.70199. Online ahead of print.","author":"Doshi A, Souto Filho JT, Grimshaw A, Giri S, Costa LJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41069184"},{"title01":"Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline","title02":"Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline","journal":"Br J Haematol","issue":"2025 Oct 10. doi: 10.1111\/bjh.70149. Online ahead of print.","author":"Jenner M, Boyd K, Choudhuri S, Parrish C, Garg M, Stern S; British Society of Haematology and UK Myeloma Society.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41069303"},{"title01":"Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed\/Refractory Multiple Myeloma","title02":"Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed\/Refractory Multiple Myeloma","journal":"Blood","issue":"2025 Oct 21:blood.2025030559. doi: 10.1182\/blood.2025030559. Online ahead of print.","author":"Pan M, Wang D, Xu J, Jin S, Wang Y, Tao Y, Liu Y, Ouyang W, Weng X, Yi H, Huang Y, Cao X, Li S, Zhang F, Zhang W, Li C, Mi JQ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118600"},{"title01":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models","title02":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models","journal":"Blood","issue":"2025 Oct 16:blood.2025030027. doi: 10.1182\/blood.2025030027. Online ahead of print.","author":"Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, Testa J Jr, Ponticiello R, Brodeur SR, Heidrich B, Packman K, Singh S, Attar RM, Elsayed YA, Philippar U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100731"},{"title01":"Unlocking myeloma&#8217;s spatial world at the micrometer scale","title02":"Unlocking myeloma&#8217;s spatial world at the micrometer scale","journal":"Blood","issue":"2025 Oct 9;146(15):1744-1746.","author":"Rasche L, Weinhold N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066135"},{"title01":"Mel200 or BuMel conditioning in myeloma: is there a winner?","title02":"Mel200 or BuMel conditioning in myeloma: is there a winner?","journal":"Blood","issue":"2025 Oct 9;146(15):1741-1742.","author":"Reece DE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066137"},{"title01":"Donor Hearts for Transplantation after Circulatory Death. Reply","title02":"Donor Hearts for Transplantation after Circulatory Death. Reply","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1760..","author":"Kucera JA, Overbey DM, Turek JW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160841"},{"title01":"Donor Hearts for Transplantation after Circulatory Death. Reply","title02":"Donor Hearts for Transplantation after Circulatory Death. Reply","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1759.","author":"Williams AM, Shah AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160840"},{"title01":"Donor Hearts for Transplantation after Circulatory Death","title02":"Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1758-1759.","author":"Bernat JL, Delmonico FL, Capron AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160839"},{"title01":"Donor Hearts for Transplantation after Circulatory Death","title02":"Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1758.","author":"de Meijer VE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160838"},{"title01":"Donor Hearts for Transplantation after Circulatory Death","title02":"Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1757-1758.","author":"Pradegan N, Zanatta P, Gerosa G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160837"},{"title01":"Donor Hearts for Transplantation after Circulatory Death","title02":"Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Oct 30;393(17):1757.","author":"Pocar M, Boffini M, Rinaldi M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160836"},{"title01":"Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT","title02":"Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70213. Online ahead of print.","author":"Suzuki T, Jo T, Yoshifuji K, Kondo T, Doki N, Kanda Y, Nishida T, Onishi Y, Asada N, Fukuda T, Sawa M, Hasegawa Y, Serizawa K, Ota S, Tanaka M, Yoshimitsu M, Atsuta Y, Kanda J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111282"},{"title01":"Pretransplant MRD and chemotherapy in AML: A transplant physician&#8217;s perspective","title02":"Pretransplant MRD and chemotherapy in AML: A transplant physician&#8217;s perspective","journal":"Br J Haematol","issue":"2025 Oct;207(4):1694-1697.","author":"Ali A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070669"},{"title01":"Granulocyte colony-stimulating factor may improve engraftment in adults with sickle cell disease undergoing non-myeloablative haematopoietic stem cell transplantation","title02":"Granulocyte colony-stimulating factor may improve engraftment in adults with sickle cell disease undergoing non-myeloablative haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Oct;207(4):1690-1693.","author":"Zhu S, Maahs L, Sweiss K, Campbell-Lee SA, Mahmud N, Gordeuk VR, Rondelli D, Saraf SL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070679"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","journal":"Blood","issue":"2025 Oct 27:blood.2025029712. doi: 10.1182\/blood.2025029712. Online ahead of print.","author":"Fetsch V, Schw\u00f6bel LF, Ozyerli-Goknar E PhD, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, K\u00f6hler N, Kuban M, Metzger E, Rummelt C, Duyster J, B\u00f6rries M, Hofmann M, F\u00e4rber J, Braun LM, Z\u00e4hringer A, L\u00fcbbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, K\u00fchn MWM, Timmers M, Wertheimer T, Perner F, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","journal":"Blood","issue":"2025 Oct 24:blood.2025029611. doi: 10.1182\/blood.2025029611. Online ahead of print.","author":"Boissel N, Chevret S, Rigal-Huguet F, Leguay TT, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Schanz U, Cluzeau T, Turlure P, Rousselot P, De Prijck B, Grardel N, B\u00e9n\u00e9 MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah NH, Lheritier V, Asnafi V, Clappier E, Dombret H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Glofitamab with GemOx for diffuse large B-cell lymphoma","title02":"Glofitamab with GemOx for diffuse large B-cell lymphoma","journal":"Lancet","issue":"2025 Oct 18;406(10513):1726.","author":"Borchmann P, Jachimowicz RD, von Tresckow B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41109714"},{"title01":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial","title02":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial","journal":"J Clin Oncol","issue":"2025 Oct 20:JCO2500992. doi: 10.1200\/JCO-25-00992. Online ahead of print.","author":"Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, J\u00f8rgensen JM, Zinzani PL, Leung W, Bottos A, Li D, Relf J, Tandon M, Sellam G, Gritti G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115257"},{"title01":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","title02":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","journal":"J Clin Oncol","issue":"2025 Oct 16:JCO2500668. doi: 10.1200\/JCO-25-00668. Online ahead of print.","author":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100801"},{"title01":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma","title02":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288856. Online ahead of print.","author":"Hardy NM, Yared JA, Luetkens T, Ahmad H, Mulatu R, Yamoah D, Fan X, Weeks S, Bredar SA, Gelin A, Baker JM, Dietze KA, Matsangos A, Fromowitz A, Theruvath J, Wirthlin L, Kaleta R, Wijatyk A, Koka R, Kallen ME, Hankey KG, Rapoport AP, Atanackovic D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098100"},{"title01":"Outcome of T-cell\/histiocyte-rich large B-cell lymphoma-A Danish nationwide matched cohort study","title02":"Outcome of T-cell\/histiocyte-rich large B-cell lymphoma-A Danish nationwide matched cohort study","journal":"Br J Haematol","issue":"2025 Oct 28. doi: 10.1111\/bjh.70217. Online ahead of print.","author":"Br\u00e6ndstrup P, Mortensen TB, El-Galaly TC, M\u00f8ller MB, J\u00f8rgensen JM, Poulsen CB, Roost-Clausen M, de Nully Brown P, Hansen DL, Larsen TS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41152131"},{"title01":"Prognostic impact of valemetostat in relapsed\/refractory adult T-cell leukaemia-lymphoma","title02":"Prognostic impact of valemetostat in relapsed\/refractory adult T-cell leukaemia-lymphoma","journal":"Br J Haematol","issue":"2025 Oct 23. doi: 10.1111\/bjh.70219. Online ahead of print.","author":"Shichijo T, Tatetsu H, Higuchi Y, Miyakawa T, Nosaka K, Nakamura T, Endo S, Yamada A, Wada A, Okamoto Y, Kawakita T, Suzushima H, Matsuoka M, Yasunaga JI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126770"},{"title01":"Paradoxical role and therapeutic potential of autophagy in lymphomas","title02":"Paradoxical role and therapeutic potential of autophagy in lymphomas","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70214. Online ahead of print.","author":"Yu QQ, Quan C, Li Y, Sun R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111341"},{"title01":"BCL-2 inhibition in Waldenstr\u00f6m macroglobulinaemia and marginal zone lymphoma","title02":"BCL-2 inhibition in Waldenstr\u00f6m macroglobulinaemia and marginal zone lymphoma","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70208. Online ahead of print.","author":"Sarosiek S, Suarez U, Fernandez-Turizo M, Sarosiek KA, Castillo JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111358"},{"title01":"A phase I\/II study of brentuximab vedotin\u2009+\u2009AVD in paediatric patients with advanced Hodgkin lymphoma","title02":"A phase I\/II study of brentuximab vedotin\u2009+\u2009AVD in paediatric patients with advanced Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 Oct 14. doi: 10.1111\/bjh.70207. Online ahead of print.","author":"Salvino MA, Luisi FAV, Pianovski MA, Fagioli F, Epelman S, Lima LBA, Filho VO, Zecca M, Favre C, Kobayashi R, Koga Y, Bush R, Sidi Y, Zhou X, Bai X, Campana F, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41084939"},{"title01":"Transient imaging changes accompany &#8216;spinal ICANS&#8217; following CAR T-cell therapy for large B-cell lymphoma in adults","title02":"Transient imaging changes accompany &#8216;spinal ICANS&#8217; following CAR T-cell therapy for large B-cell lymphoma in adults","journal":"Br J Haematol","issue":"2025 Oct 13. doi: 10.1111\/bjh.70206. Online ahead of print.","author":"Vonberg FW, Rice-Wilson D, Malik I, Keddie S, Gorgoraptis N, Araf S, Khanal S, Montoto S, Kasivisvanathan S, Uttenthal B, Panopoulou K, Hyare H, O'Reilly M, Carr AS, Roddie C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41084112"},{"title01":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition","title02":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition","journal":"Blood","issue":"2025 Oct 29:blood.2025031086. doi: 10.1182\/blood.2025031086. Online ahead of print.","author":"Ronceray L, Huibers MHW, Reutter K, Abla O, Andres M, Balagu\u00e9 O, Csoka M, Gilad G, Hagleitner MM, Hori D, Lyngsie Hjalgrim L, Jazbec J, Klapper W, Nakazawa A, Verdu-Amor\u00f3s J, von Mersi H, Woessmann W, Xavier AC, Burkhardt B, Salaverria I, Attarbaschi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160801"},{"title01":"Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3","title02":"Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3","journal":"Blood","issue":"2025 Oct 29:blood.2025029734. doi: 10.1182\/blood.2025029734. Online ahead of print.","author":"van Meerten T, Kersten MJ, Iacoboni G, Hess GR, Mutsaers PGNJ, Martin Garcia-Sancho AM, Goy A, Gine E, Hill BT, Weng WK, Reagan PM, Patel K, Galal A, Herbaux C, Sanderson R, Forcade E, Topp MS, Houot R, Zheng D, Zhang W, Kanska J, Shen RR, Damico Khalid R, Kloos I, Dreyling M, Wang ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160777"},{"title01":"Introduction to a review series on follicular lymphoma: solved or insoluble problem?","title02":"Introduction to a review series on follicular lymphoma: solved or insoluble problem?","journal":"Blood","issue":"2025 Oct 9;146(15):1739-1740..","author":"Armand P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066134"},{"title01":"A Fighter Bigger Than Myeloma","title02":"A Fighter Bigger Than Myeloma","journal":"J Clin Oncol","issue":"2025 Oct 14:JCO2500932. doi: 10.1200\/JCO-25-00932. Online ahead of print.","author":"Khan AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41086373"},{"title01":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile","title02":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile","journal":"Haematologica","issue":"2025 Oct 23. doi: 10.3324\/haematol.2025.288535. Online ahead of print.","author":"Liu J, Fan J, Zhou X, Chen X, Hu X, He H, Jin L, Fu W, Hou J, Du J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126728"},{"title01":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study","title02":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study","journal":"Haematologica","issue":"2025 Oct 23. doi: 10.3324\/haematol.2025.288411. Online ahead of print.","author":"Valentini CG, Pellegrino C, Chiusolo P, Rossi E, Ladiana R, Za T, Sica S, Pagano L, De Stefano V, Teofili L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126731"},{"title01":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers","title02":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288320. Online ahead of print.","author":"May P, Rassner M, Hoegner M, Shahbaz W, W\u00e4sch R, Martinez AMG, Schmidt B, Theurich S, Engelhardt M, Bassermann F, Jung J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098101"},{"title01":"Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy","title02":"Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70216. Online ahead of print.","author":"Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111271"},{"title01":"Reversing the sequence: Efficacy of BCMA-directed therapy following progression on GPRC5D-directed therapies in relapsed multiple myeloma","title02":"Reversing the sequence: Efficacy of BCMA-directed therapy following progression on GPRC5D-directed therapies in relapsed multiple myeloma","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70176. Online ahead of print.","author":"Joiner L, Giri S, Ravi G, Godby K, Hagedorn C, Costa LJ, Bal S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111244"},{"title01":"Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group","title02":"Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group","journal":"Br J Haematol","issue":"2025 Oct;207(4):1638-1642. doi: 10.1111\/bjh.70030. Epub 2025 Jul 23.","author":"Thorsteinsd\u00f3ttir S, Lemonakis K, Sl\u00f8rdahl TS, R\u00f6gnvaldsson S, Richardson AK, Hermansen E, Thorsen J, Schjesvold F, Moore KLF, Szabo AG, Andersen MK, Waage A, Blimark CH, Vangsted A; Nordic Myeloma Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070698"},{"title01":"A newcomer in allosteric therapy for Ph+ leukemias","title02":"A newcomer in allosteric therapy for Ph+ leukemias","journal":"Blood","issue":"2025 Oct 23;146(17):2016-2017.","author":"Rea D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41129182"},{"title01":"Patient-specific enhancers in genetically uniform leukemias","title02":"Patient-specific enhancers in genetically uniform leukemias","journal":"Blood","issue":"2025 Oct 23;146(17):2014-2016.","author":"Kong T, Abdel-Wahab O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41129186"},{"title01":"CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial","title02":"CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial","journal":"Blood","issue":"2025 Oct 21:blood.2025030775. doi: 10.1182\/blood.2025030775. Online ahead of print.","author":"Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, Goncalves-Dias J, Issa H, Miladinovic M, Rettinger E, Wehner S, Kreyenberg H, Bremm M, H\u00fcnecke S, Kerp H, Waack-Buchholz K, Thol FR, Goemans BF, De Moerloose B, Boztug H, Scheidegger NK, Pawinska-Wasikowska K, Reinhardt D, Klusmann JH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118594"},{"title01":"The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia","title02":"The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia","journal":"Blood","issue":"2025 Oct 20:blood.2024026749. doi: 10.1182\/blood.2024026749. Online ahead of print.","author":"Lam K, Kim YJ, Tan EL, Ong CM, Liu AZ, Zhou FJ, Sunshine MJ, Chua B, Vicenzi S, Chen KZ, Yu H, Ford P, Zhou JH, Hong Y, Bennett EJ, Crews LA, Ball ED, Signer R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111393"},{"title01":"Insights from Single-cell Omics: Cellular Heterogeneity as a Foundation of Clinical Outcome in Chronic Myeloid Leukemia","title02":"Insights from Single-cell Omics: Cellular Heterogeneity as a Foundation of Clinical Outcome in Chronic Myeloid Leukemia","journal":"Blood","issue":"2025 Oct 17:blood.2025029011. doi: 10.1182\/blood.2025029011. Online ahead of print.","author":"Thakur RK, Karlsson G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"MRD intervention in AML: A new therapeutic horizon","title02":"MRD intervention in AML: A new therapeutic horizon","journal":"Blood","issue":"2025 Oct 17:blood.2025029010. doi: 10.1182\/blood.2025029010. Online ahead of print.","author":"Wei AH, Iland HJ, DiNardo CD, Reynolds J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105915"},{"title01":"Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel","title02":"Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel","journal":"Blood","issue":"2025 Oct 17:blood.2024027904. doi: 10.1182\/blood.2024027904. Online ahead of print.","author":"Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, De Moerloose B, Dworzak MN, Fogelstrand L, Gibson BE, Goemans BF, Hasle H, Hirsch BA, Kaspers GJ, Klusmann JH, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105890"},{"title01":"Acute myeloid leukemia mimicking mature lymphoid morphology","title02":"Acute myeloid leukemia mimicking mature lymphoid morphology","journal":"Blood","issue":"2025 Oct 16;146(16):2005.","author":"Chiriac R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100138"},{"title01":"How many NOTCHes (activation pathways) are there in CLL?","title02":"How many NOTCHes (activation pathways) are there in CLL?","journal":"Blood","issue":"2025 Oct 16;146(16):1876-1877.","author":"Pozzo F, Gattei V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100142"},{"title01":"Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials","title02":"Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials","journal":"Blood","issue":"2025 Oct 16:blood.2025030741. doi: 10.1182\/blood.2025030741. Online ahead of print.","author":"Hantel A, Wang Y, Cronin A, Khan I, Abraham IE, Eisfeld AK, Patel AA, Stock WA, Monick S, Walsh TP, Gallagher E, Luskin MR, Avila Rodriguez AM, Galvez C, Doukas PG, Altman JK, Burkart M, Erra A, Zia M, Larson ML, Dave A, Tsai SB, Aleem A, Raptis NI, Lathan CS, Uno H, DeAngelo DJ, Abel GA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100728"},{"title01":"T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma","title02":"T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma","journal":"Blood","issue":"2025 Oct 9;146(15):1868.","author":"Shi M, Rech KL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066133"},{"title01":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study","title02":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study","journal":"Leukemia","issue":"2025 Oct 27. doi: 10.1038\/s41375-025-02759-4. Online ahead of print.","author":"Khouja M, Kehden B, Blair D, Kuffer C, Wagner S, Versteegen T, Nakov P, Br\u00fcggemann M, Baldus C, Belada D, Nowakowski GS, Schilhabel A, Darzentas N, Pott C; EuroClonality-NGS Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145670"},{"title01":"Optimising treatment strategies in older patients with mantle cell lymphoma","title02":"Optimising treatment strategies in older patients with mantle cell lymphoma","journal":"Lancet","issue":"2025 Oct 25;406(10514):1924-1925.","author":"Gin\u00e9 E, Perez-Valencia AI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41139085"},{"title01":"Glofitamab with GemOx for diffuse large B-cell lymphoma &#8211; Authors&#8217; reply","title02":"Glofitamab with GemOx for diffuse large B-cell lymphoma &#8211; Authors&#8217; reply","journal":"Lancet","issue":"2025 Oct 18;406(10513):1727-1728.","author":"Abramson JS, Ku M, Gregory GP, Fox CP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41109716"},{"title01":"Glofitamab with GemOx for diffuse large B-cell lymphoma","title02":"Glofitamab with GemOx for diffuse large B-cell lymphoma","journal":"Lancet","issue":"2025 Oct 18;406(10513):1726-1727.","author":"Shimazu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41109715"},{"title01":"Immune reconstitution after CD7 CAR-T cell therapy for refractory\/relapsed acute T-lymphoblastic leukaemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL)","title02":"Immune reconstitution after CD7 CAR-T cell therapy for refractory\/relapsed acute T-lymphoblastic leukaemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL)","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70201. Online ahead of print.","author":"Zhang X, Wang L, Kuang N, Yang J, Wang H, Qiu L, Wang D, Sun J, Long J, Lu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111252"},{"title01":"Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma","title02":"Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma","journal":"Br J Haematol","issue":"2025 Oct;207(4):1668-1672.","author":"Triantafilo N, Chowdhury A, Thiruvengadam S, Herrera AF, Popplewell L, Palmer J, Budde LE, Mei M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070661"},{"title01":"Programmed cell death-1 inhibition activates CD4 T cells in a novel in\u00a0vitro model of Hodgkin lymphoma","title02":"Programmed cell death-1 inhibition activates CD4 T cells in a novel in\u00a0vitro model of Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 Oct;207(4):1643-1647.","author":"Martinez Alcala R, Lei Y, Visser L, Diepstra A, Veldman J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070671"},{"title01":"Population pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma","title02":"Population pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma","journal":"Br J Haematol","issue":"2025 Oct;207(4):1622-1627.","author":"Wu R, Li Y, Zhang D, Liu T, Guo X, Sun X, Liu Y, Fu L, Zhao Z, Mei S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070680"},{"title01":"Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed\/refractory classical Hodgkin lymphoma","title02":"Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed\/refractory classical Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 Oct;207(4):1599-1603.","author":"Lynch RC, Cassaday RD, Smith SD, Cowan AJ, Warren EH, Shadman MS, Till BG, Ujjani CS, Morris K, Rasmussen H, Voutsinas J, Gopal AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070684"},{"title01":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis","title02":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis","journal":"Leukemia","issue":"2025 Oct 10. doi: 10.1038\/s41375-025-02753-w. Online ahead of print.","author":"Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41073560"},{"title01":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia","title02":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia","journal":"Lancet Haematol","issue":"2025 Oct 16:S2352-3026(25)00263-7. doi: 10.1016\/S2352-3026(25)00263-7. Online ahead of print.","author":"Faramand RG, Muffly L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110449"},{"title01":"Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study","title02":"Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study","journal":"Br J Haematol","issue":"2025 Oct 28. doi: 10.1111\/bjh.70202. Online ahead of print.","author":"Tan Y, Zhao X, Suo X, Bai G, Zhao W, Luo Y, Lu X, Yuan L, Zhang C, Li Y, Gao S, Zhang J, Shi Z, Li H, Liu K, Mi Y, Peng H, Guo P, Zhou Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41151983"},{"title01":"Outcomes of patients with relapsed\/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies","title02":"Outcomes of patients with relapsed\/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies","journal":"Br J Haematol","issue":"2025 Oct 26. doi: 10.1111\/bjh.70225. Online ahead of print.","author":"Thomas M, Johnston H, Dworkin E, Wesevich A, Roloff GW, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Madero-Marroquin R, Patel AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41139955"},{"title01":"Prognostic impact of valemetostat in relapsed\/refractory adult T-cell leukaemia-lymphoma","title02":"Prognostic impact of valemetostat in relapsed\/refractory adult T-cell leukaemia-lymphoma","journal":"Br J Haematol","issue":"2025 Oct 23. doi: 10.1111\/bjh.70219. Online ahead of print.","author":"Shichijo T, Tatetsu H, Higuchi Y, Miyakawa T, Nosaka K, Nakamura T, Endo S, Yamada A, Wada A, Okamoto Y, Kawakita T, Suzushima H, Matsuoka M, Yasunaga JI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126770"},{"title01":"CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage","title02":"CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage","journal":"Br J Haematol","issue":"2025 Oct 21. doi: 10.1111\/bjh.70204. Online ahead of print.","author":"Dupont M, Derouault P, Pascal V, Dmytruk N, Roubinet M, Rivi\u00e8re C, Parquet M, Guiyedi K, Boulin M, Peron S, Chauzeix J, Gachard N, Feuillard J, Rizzo D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41117149"},{"title01":"Immune reconstitution after CD7 CAR-T cell therapy for refractory\/relapsed acute T-lymphoblastic leukaemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL)","title02":"Immune reconstitution after CD7 CAR-T cell therapy for refractory\/relapsed acute T-lymphoblastic leukaemia\/lymphoblastic lymphoma (R\/R T-ALL\/LBL)","journal":"Br J Haematol","issue":"2025 Oct 19. doi: 10.1111\/bjh.70201. Online ahead of print.","author":"Zhang X, Wang L, Kuang N, Yang J, Wang H, Qiu L, Wang D, Sun J, Long J, Lu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111252"},{"title01":"Pretransplant MRD and chemotherapy in AML: A transplant physician&#8217;s perspective","title02":"Pretransplant MRD and chemotherapy in AML: A transplant physician&#8217;s perspective","journal":"Br J Haematol","issue":"2025 Oct;207(4):1694-1697.","author":"Ali A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070669"},{"title01":"Quadriparesis after CD19\u2009\u00d7\u2009CD22 bicistronic chimeric antigen receptor T cells for B-cell acute lymphoblastic leukaemia","title02":"Quadriparesis after CD19\u2009\u00d7\u2009CD22 bicistronic chimeric antigen receptor T cells for B-cell acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2025 Oct;207(4):1673-1678.","author":"Rankin AW, Silbert SK, Duncan BB, Yates B, Nath A, Biassou N, Suffredini AF, Danner RL, Natanson C, Ahluwalia AK, Little L, Foley T, Murthy HS, Shalabi H, Nyquist P, Shah NN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070663"},{"title01":"CD123 expression and its correlation with mutation profile in acute myeloid leukaemia","title02":"CD123 expression and its correlation with mutation profile in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Oct;207(4):1648-1652.","author":"Azevedo RS, Wang SA, Swanson DM, Daver NG, Pemmaraju N, Kadia TM, Issa GC, Yilmaz M, Borthakur G, Senapati J, Jen WY, Short NJ, Ravandi F, Wang W, Fang H, Xu J, Patel KP, Tang G, Medeiros LJ, DiNardo CD, Loghavi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41070667"},{"title01":"Peripheral blood profiling of azacitidine&#8217;s hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia","title02":"Peripheral blood profiling of azacitidine&#8217;s hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia","journal":"Br J Haematol","issue":"2025 Oct 9. doi: 10.1111\/bjh.70205. Online ahead of print.","author":"Niscola P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41069135"},{"title01":"2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia","title02":"2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2025 Oct 9. doi: 10.1111\/bjh.70100. Online ahead of print.","author":"Walewska R, Eyre TA, Bloor A, Follows G, Iyengar S, Johnston R, Marr H, Martinez-Calle N, McCaig A, McCarthy H, Munir T, Parry HM, Parry-Jones N, Pettitt A, Riches J, Ringshausen I, Schuh A, Patten PEM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41069109"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia","journal":"Blood","issue":"2025 Oct 29:blood.2025028918. doi: 10.1182\/blood.2025028918. Online ahead of print.","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","title02":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","journal":"Blood","issue":"2025 Oct 27:blood.2025030558. doi: 10.1182\/blood.2025030558. Online ahead of print.","author":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales CE, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144772"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML","journal":"Blood","issue":"2025 Oct 27:blood.2025029712. doi: 10.1182\/blood.2025029712. Online ahead of print.","author":"Fetsch V, Schw\u00f6bel LF, Ozyerli-Goknar E PhD, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, K\u00f6hler N, Kuban M, Metzger E, Rummelt C, Duyster J, B\u00f6rries M, Hofmann M, F\u00e4rber J, Braun LM, Z\u00e4hringer A, L\u00fcbbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, K\u00fchn MWM, Timmers M, Wertheimer T, Perner F, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","journal":"Blood","issue":"2025 Oct 24:blood.2025029611. doi: 10.1182\/blood.2025029611. Online ahead of print.","author":"Boissel N, Chevret S, Rigal-Huguet F, Leguay TT, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Schanz U, Cluzeau T, Turlure P, Rousselot P, De Prijck B, Grardel N, B\u00e9n\u00e9 MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah NH, Lheritier V, Asnafi V, Clappier E, Dombret H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study","title02":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study","journal":"Leukemia","issue":"2025 Oct 27. doi: 10.1038\/s41375-025-02789-y. Online ahead of print.","author":"Nikkil\u00e4 A, Lohi O, Abrahamsson J, Griskevicius L, Hallb\u00f6\u00f6k H, J\u00f3nsson \u00d3G, Lund B, Marquart HV, Overgaard U, Palk K, Pruunsild K, Quist-Paulsen P, Toft N, Vaitkeviciene GE, Wartiovaara-Kautto U, Heyman M, Vettenranta K, Schmiegelow K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145672"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients","journal":"Leukemia","issue":"2025 Oct 27. doi: 10.1038\/s41375-025-02781-6. Online ahead of print.","author":"Bill M, Eckardt JN, D\u00f6hner K, R\u00f6hnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Br\u00fcmmendorf TH, Krug U, W\u00f6rmann B, Einsele H, Hiddemann W, G\u00f6rlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Sch\u00e4fer-Eckart K, Berdel WE, Schliemann C, Krause SW, H\u00e4nel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, M\u00fcller-Tidow C, V\u00e1lka J, \u0160r\u00e1mek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, R\u00e9cher C, Pigneux A, Herold T, Ganser A, D\u00f6hner H, Bornh\u00e4user M, Thiede C, R\u00f6llig C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia","title02":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Oct 27. doi: 10.1038\/s41375-025-02764-7. Online ahead of print.","author":"Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145674"},{"title01":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia","title02":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Oct 17. doi: 10.1038\/s41375-025-02788-z. Online ahead of print.","author":"Vu TT, St\u00f6lzel F, Wang KW, R\u00f6llig C, Tursky ML, Molloy TJ, Ma DD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107617"},{"title01":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits","title02":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits","journal":"Leukemia","issue":"2025 Oct 17. doi: 10.1038\/s41375-025-02779-0. Online ahead of print.","author":"Goodman SJ, Butcher DT, Guger SL, Diehl E, Brzezinski J, Spiegler B, Nieman BJ, Kallurkar P, Boulet Craig A, Krajinovic M, Laniel J, Laverdi\u00e8re C, Sinnett D, Lipp\u00e9 S, Turinsky A, Shago M, Strug LJ, Ito S, Hitzler JK, Schachar R, Weksberg R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107616"},{"title01":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","title02":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","journal":"Leukemia","issue":"2025 Oct 13. doi: 10.1038\/s41375-025-02784-3. Online ahead of print.","author":"Rodr\u00edguez-Arbol\u00ed E, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083680"},{"title01":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study","title02":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study","journal":"Lancet Haematol","issue":"2025 Oct 16:S2352-3026(25)00253-4. doi: 10.1016\/S2352-3026(25)00253-4. Online ahead of print.","author":"Xu Q, Guo Y, Gao M, Xue L, Xu H, Li H, Zhang X, Liu C, Li Y, Chen Q, Ren J, Sathiyanadan K, Hu Y, Tang L, Huang H, Wang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110448"},{"title01":"Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML","title02":"Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML","journal":"Haematologica","issue":"2025 Oct 23. doi: 10.3324\/haematol.2025.288283. Online ahead of print.","author":"Millot F, De Keizer J, Metzler M, Kalwak K, G\u00fcnes AM, De Moerloose B, Luesink M, Honrubia AM, Sedlacek P, Yajima J, Ampatzidou M, Dworzak M, Lausen B, Borisevich M, Li CK, Kolenova A, Jakovljevic G, Farah R, Durocher L, Baruchel A, Suttorp M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126742"},{"title01":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study","title02":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288776. Online ahead of print.","author":"Jung BK, Wei\u00dfmann S, Schock C, Meggendorfer M, Haferlach T, Dicker F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098098"},{"title01":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation","title02":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288249. Online ahead of print.","author":"Yuan M, Zhou L, Li W, Du X, Weng J, Yang L, Ma Y, Liu B, Liu Z, Wen Q, Zhao S, Zhang Y, Bai Q, Feng X, Han Y, Liu C, Meng L, Wang B, Ran X, Wang X, Zhang H, Zeng Y, Leng Q, Yu L, Li Z, Gale RP, Huang X, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098110"},{"title01":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience","title02":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288246. Online ahead of print.","author":"Arcourt A, Ilan U, Murillo L, Arad-Cohen N, Rubio A, Tasian SK, Baruchel A, Zwaan MC, Ducassou S, Goemans BF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098113"},{"title01":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns","title02":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.288006. Online ahead of print.","author":"Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098096"},{"title01":"m6a and NuRD complexes regulate monocytic differentiation and resistance to BCL2\/BCL2L1 inhibitors in acute myeloid leukemia","title02":"m6a and NuRD complexes regulate monocytic differentiation and resistance to BCL2\/BCL2L1 inhibitors in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Oct 16. doi: 10.3324\/haematol.2025.287972. Online ahead of print.","author":"Brim-Edwards J, Morris K, Morrow Q, Kurtz SE, Bottomly D, McWeeney SK, Tognon CE, Nechiporuk T, Watanabe-Smith K, Tyner JW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098095"},{"title01":"Epidemiology and characteristics of validated mixed phenotype acute leukaemia-A comprehensive nationwide Danish cohort study","title02":"Epidemiology and characteristics of validated mixed phenotype acute leukaemia-A comprehensive nationwide Danish cohort study","journal":"Br J Haematol","issue":"2025 Oct 28. doi: 10.1111\/bjh.70235. Online ahead of print.","author":"Christensen LM, Kristensen DT, Dybk\u00e6r K, Gr\u00f8nb\u00e6k K, El-Galaly TC, Ettrup MS, Jensen JF, Ommen HB, S\u00f8rensen ALT, Hansen DL, Br\u00f8ndum RF, Severinsen MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41152030"},{"title01":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia","title02":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in <i>KMT2A::AFF1<\/i>-positive acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 Oct 6. doi: 10.1038\/s41375-025-02782-5. Online ahead of print.","author":"Tamai H, Miyake K, Miyake N, Asano J, Ohashi A, Arai A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41053511"},{"title01":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia","title02":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia","journal":"Leukemia","issue":"2025 Oct 1. doi: 10.1038\/s41375-025-02720-5. Online ahead of print.","author":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, Gough O, Schambach A, Sauer M, Heuser M, Qasim W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034424"},{"title01":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML","title02":"Ziftomenib in Relapsed or Refractory <i>NPM1<\/i>-Mutated AML","journal":"J Clin Oncol","issue":"2025 Sep 25:JCO2501694. doi: 10.1200\/JCO-25-01694. Online ahead of print.","author":"Wang ES, Montesinos P, Foran J, Erba H, Rodr\u00edguez-Arbol\u00ed E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT; KOMET-001.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40997296"},{"title01":"Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes","title02":"Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes","journal":"Br J Haematol","issue":"2025 Sep 29. doi: 10.1111\/bjh.70179. Online ahead of print.","author":"Ali SA, Hicks SM, Coupland LA, Brysland SA, Bhoopalan V, Thong YL, Kaur A, Andrews RK, Gardiner EE, Choi PY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41017483"},{"title01":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma","title02":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Oct 2. doi: 10.1111\/bjh.70174. Online ahead of print.","author":"Chiriac R, Baseggio L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41039717"},{"title01":"Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines","title02":"Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines","journal":"Br J Haematol","issue":"2025 Oct 5. doi: 10.1111\/bjh.70188. Online ahead of print.","author":"Hu X, Li L, Nkwocha J, Vasiyani H, Kazi A, Sebti S, Grant S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41047494"},{"title01":"The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-X(L) in DLBCL","title02":"The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-X(L) in DLBCL","journal":"Br J Haematol","issue":"2025 Oct 5. doi: 10.1111\/bjh.70192. Online ahead of print.","author":"Yildirim N, Anders M, Smith VM, Jayne S, Assmann M, Jukes-Jones R, Dyer MJS, Vogler M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41047548"},{"title01":"Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma","title02":"Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Oct 7. doi: 10.1111\/bjh.70185. Online ahead of print.","author":"Munz N, Arribas AJ, Bordone Pittau R, Simonetta F, Stussi G, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057281"},{"title01":"Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study","title02":"Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study","journal":"Br J Haematol","issue":"2025 Sep 25. doi: 10.1111\/bjh.70181. Online ahead of print.","author":"Kalashnikov I, Reunamo T, Tanskanen T, Viisanen L, Malila N, Jyrkki\u00f6 S, Lepp\u00e4 S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40999643"},{"title01":"Targeting small ubiquitin-related modifier-specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B-cell lymphoma","title02":"Targeting small ubiquitin-related modifier-specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Oct 1. doi: 10.1111\/bjh.70187. Online ahead of print.","author":"Sheng X, Wang D, Li S, Li B, Luan M, Han X, Zhou Q, Zhao Z, Ji C, Lu F, Ye J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41033663"},{"title01":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","title02":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","journal":"Br J Haematol","issue":"2025 Oct 1. doi: 10.1111\/bjh.70186. Online ahead of print.","author":"Suh M, Hyung J, Park CS, Go H, Song IH, Chae EJ, Kim KW, Lee YS, Kwon M, Lee SW, Lee J, Kim S, Lee K, Cho H, Ryu JS, Yoon DH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035136"},{"title01":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis","title02":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis","journal":"Leukemia","issue":"2025 Sep 28. doi: 10.1038\/s41375-025-02776-3. Online ahead of print.","author":"Zanwar S, Belge Bilgin G, Broski SM, Thorpe M, Bilgin C, Gonsalves W, Kapoor P, Kourelis T, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Leung N, Lin Y, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016943"},{"title01":"More is not always more for older patients with multiple myeloma","title02":"More is not always more for older patients with multiple myeloma","journal":"Lancet Oncol","issue":"2025 Oct;26(10):1263-1265.","author":"Shain KH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038179"},{"title01":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","title02":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","journal":"Lancet Oncol","issue":"2025 Oct;26(10):1323-1333.","author":"Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038184"},{"title01":"GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial","title02":"GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial","journal":"Lancet Haematol","issue":"2025 Oct;12(10):e798-e807.","author":"Jin L, Gu S, Ruan Q, Lu J, Qiang W, He H, Fan X, Liu J, Guo P, Meng X, Rajakumaraswamy N, Chen D, Li Z, Du J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41062204"},{"title01":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions","title02":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions","journal":"J Clin Oncol","issue":"2025 Oct 8:JCO2501733. doi: 10.1200\/JCO-25-01733. Online ahead of print.","author":"Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Vi\u00e0 MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061199"},{"title01":"A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma","title02":"A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma","journal":"Br J Haematol","issue":"2025 Oct 6. doi: 10.1111\/bjh.70189. Online ahead of print.","author":"Wang L, Wang J, Wang Y, Niu T, Zhao A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41054252"},{"title01":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone","title02":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone","journal":"Blood","issue":"2025 Oct 8:blood.2025030113. doi: 10.1182\/blood.2025030113. Online ahead of print.","author":"Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060326"},{"title01":"Losing CD38 in myeloma","title02":"Losing CD38 in myeloma","journal":"Blood","issue":"2025 Sep 25;146(13):1529-1530.","author":"Merz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40996753"},{"title01":"Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation","title02":"Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation","journal":"N Engl J Med","issue":"2025 Oct 9;393(14):1447.","author":"Glazier AK, Delmonico FL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061246"},{"title01":"Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation. Reply","title02":"Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation. Reply","journal":"N Engl J Med","issue":"2025 Oct 9;393(14):1447-1448.","author":"Kotton CN, Safa K, Sanders AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061247"},{"title01":"Cyclophosphamide and Cyclosporin for GVHD Prevention","title02":"Cyclophosphamide and Cyclosporin for GVHD Prevention","journal":"N Engl J Med","issue":"2025 Oct 2;393(13):1349-1350.","author":"Desai N, Mattsson J, Law AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032720"},{"title01":"Cyclophosphamide and Cyclosporin for GVHD Prevention","title02":"Cyclophosphamide and Cyclosporin for GVHD Prevention","journal":"N Engl J Med","issue":"2025 Oct 2;393(13):1350.","author":"Akahoshi Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032721"},{"title01":"Cyclophosphamide and Cyclosporin for GVHD Prevention. Reply","title02":"Cyclophosphamide and Cyclosporin for GVHD Prevention. Reply","journal":"N Engl J Med","issue":"2025 Oct 2;393(13):1350-1351.","author":"Curtis DJ, Reynolds J, Hill GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032722"},{"title01":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies","title02":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies","journal":"Leukemia","issue":"2025 Sep 28. doi: 10.1038\/s41375-025-02772-7. Online ahead of print.","author":"Rodriguez L, Delhommeau F, Soussi T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016942"},{"title01":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","title02":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","journal":"J Clin Oncol","issue":"2025 Oct 2:101200JCO2501957. doi: 10.1200\/JCO-25-01957. Online ahead of print.","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Oct 3:JCO2501238. doi: 10.1200\/JCO-25-01238. Online ahead of print.","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere","title02":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere","journal":"J Clin Oncol","issue":"2025 Sep 30:JCO2501884. doi: 10.1200\/JCO-25-01884. Online ahead of print.","author":"Rambaldi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026968"},{"title01":"The KLF4-CD46 axis: a novel therapeutic target in transplant-associated thrombotic microangiopathy and beyond","title02":"The KLF4-CD46 axis: a novel therapeutic target in transplant-associated thrombotic microangiopathy and beyond","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288680. Online ahead of print.","author":"Cugno M, L\u00e4mmle B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063700"},{"title01":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-\u03b21 and LRP6 pathways","title02":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-\u03b21 and LRP6 pathways","journal":"Haematologica","issue":"2025 Sep 25. doi: 10.3324\/haematol.2025.288464. Online ahead of print.","author":"Wu N, Ding W, Wu J, Ling M, Yue K, Cheng C, Jia M, Liu J, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994352"},{"title01":"Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents","title02":"Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents","journal":"Br J Haematol","issue":"2025 Sep 27. doi: 10.1111\/bjh.70184. Online ahead of print.","author":"Ariagno S, Greenmyer J, Kuhn A, Pence L, O'Shea M, Greenmyer L, Cole K, Ferdjallah A, Kohorst M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41014188"},{"title01":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","title02":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","journal":"Br J Haematol","issue":"2025 Sep 30. doi: 10.1111\/bjh.70167. Online ahead of print.","author":"Buchbinder N, Michel V, Dalissier A, Kleinschmidt K, Locatelli F, Maschan A, Wynn R, Fagioli F, Zecca M, Jubert C, Versluys B, Sedlacek P, Zubarovskaya L, Gonzalez Vicent M, Biffi A, Michel G, Mirci-Danicar O, Holter W, Ansari M, Galimard JE, Schneider P, Abouqateb M, Ka\u0142wak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41027844"},{"title01":"Optimizing activation and culture conditions for the production of\u00a0cord blood-derived CAR-T and natural killer cells","title02":"Optimizing activation and culture conditions for the production of\u00a0cord blood-derived CAR-T and natural killer cells","journal":"Br J Haematol","issue":"2025 Sep 30. doi: 10.1111\/bjh.70139. Online ahead of print.","author":"Nakamura N, Liao J, Soda Y, Takahashi M, Kodera H, Kobari Y, Hirai Y, Takaori-Kondo A, Okada T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41030086"},{"title01":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","title02":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","journal":"Br J Haematol","issue":"2025 Oct 1. doi: 10.1111\/bjh.70186. Online ahead of print.","author":"Suh M, Hyung J, Park CS, Go H, Song IH, Chae EJ, Kim KW, Lee YS, Kwon M, Lee SW, Lee J, Kim S, Lee K, Cho H, Ryu JS, Yoon DH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035136"},{"title01":"Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation","title02":"Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation","journal":"Blood","issue":"2025 Oct 8:blood.2025028625. doi: 10.1182\/blood.2025028625. Online ahead of print.","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa RP, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin LM, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Sava\u015fan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation","title02":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation","journal":"Blood","issue":"2025 Oct 1:blood.2025029402. doi: 10.1182\/blood.2025029402. Online ahead of print.","author":"Gurer Kluge EE, Meedt E, Feicht J, Cao K, Hiergeist A, Mamilos A, Hirsch D, Hoepting M Dr med, Kattner AS Dr med, Matos C, B\u00fclow S, Thiele Orberg E, Beckhove P, Kandulski A, Evert M, Hildner K, Kreutz M, Edinger M, Wolff D, Herr W, Poeck H, Gessner A, Weber DA, Kehr B, Holler E Prof Dr med, Ghimire S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032750"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Oct 3:JCO2501238. doi: 10.1200\/JCO-25-01238. Online ahead of print.","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","title02":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288704. Online ahead of print.","author":"Hayal TB, Wu C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063708"},{"title01":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","title02":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","journal":"Br J Haematol","issue":"2025 Sep 30. doi: 10.1111\/bjh.70167. Online ahead of print.","author":"Buchbinder N, Michel V, Dalissier A, Kleinschmidt K, Locatelli F, Maschan A, Wynn R, Fagioli F, Zecca M, Jubert C, Versluys B, Sedlacek P, Zubarovskaya L, Gonzalez Vicent M, Biffi A, Michel G, Mirci-Danicar O, Holter W, Ansari M, Galimard JE, Schneider P, Abouqateb M, Ka\u0142wak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41027844"},{"title01":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","title02":"Prognostic significance of pretransplant (18)F-FDG PET\/CT metrics in relapsed\/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation","journal":"Br J Haematol","issue":"2025 Oct 1. doi: 10.1111\/bjh.70186. Online ahead of print.","author":"Suh M, Hyung J, Park CS, Go H, Song IH, Chae EJ, Kim KW, Lee YS, Kwon M, Lee SW, Lee J, Kim S, Lee K, Cho H, Ryu JS, Yoon DH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035136"},{"title01":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging","title02":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging","journal":"Blood","issue":"2025 Oct 7:blood.2024026505. doi: 10.1182\/blood.2024026505. Online ahead of print.","author":"Matteini F, Thambyrajah R, Montserrat-Vazquez S, Jung S, Ferrer-Perez A, Herrero Molinero P, El Jaramany D, Lozano-Bartolom\u00e9 J, Mejia-Ramirez E, Gonzalez Miranda J, Del Sol A, Bigas A, Florian MC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056036"},{"title01":"Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation","title02":"Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation","journal":"Blood","issue":"2025 Oct 8:blood.2025028625. doi: 10.1182\/blood.2025028625. Online ahead of print.","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa RP, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin LM, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Sava\u015fan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation","title02":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation","journal":"Blood","issue":"2025 Oct 1:blood.2025029402. doi: 10.1182\/blood.2025029402. Online ahead of print.","author":"Gurer Kluge EE, Meedt E, Feicht J, Cao K, Hiergeist A, Mamilos A, Hirsch D, Hoepting M Dr med, Kattner AS Dr med, Matos C, B\u00fclow S, Thiele Orberg E, Beckhove P, Kandulski A, Evert M, Hildner K, Kreutz M, Edinger M, Wolff D, Herr W, Poeck H, Gessner A, Weber DA, Kehr B, Holler E Prof Dr med, Ghimire S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032750"},{"title01":"Hypocellular acute promyelocytic leukaemia mimicking aplastic anaemia: A diagnostic pitfall","title02":"Hypocellular acute promyelocytic leukaemia mimicking aplastic anaemia: A diagnostic pitfall","journal":"Br J Haematol","issue":"2025 Oct 5. doi: 10.1111\/bjh.70175. Online ahead of print.","author":"Chen H, Wang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41047489"},{"title01":"Growth measurements in Ugandan children with sickle cell anaemia from a hydroxyurea (hydroxycarbamide) treatment trial relative to unaffected sibling controls","title02":"Growth measurements in Ugandan children with sickle cell anaemia from a hydroxyurea (hydroxycarbamide) treatment trial relative to unaffected sibling controls","journal":"Br J Haematol","issue":"2025 Oct 6. doi: 10.1111\/bjh.70164. Online ahead of print.","author":"Kalibbala D, Mboizi V, Nambatya G, Murungi S, Ashaba J, Nabaggala C, Turyagyenda L, Munube D, Kasirye P, Wambaka B, Mpungu A, Ssenkusu JM, Namazzi R, Bangirana P, Opoka RO, Mupere E, Idro R, Green NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41053883"},{"title01":"The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia","title02":"The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia","journal":"Blood","issue":"2025 Oct 1:blood.2025028960. doi: 10.1182\/blood.2025028960. Online ahead of print.","author":"Sheng Z, Jiang N, Gao Y, Zhang Y, Zhang X, Li N, Feng Q, Zhang Y, Wang L, Semple JW, Wang S, Li S, Peng J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032749"},{"title01":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis","title02":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis","journal":"Leukemia","issue":"2025 Oct 1. doi: 10.1038\/s41375-025-02768-3. Online ahead of print.","author":"Setiawan T, Muhammad JA, Marcellina N, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034423"},{"title01":"Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study","title02":"Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study","journal":"Lancet Haematol","issue":"2025 Oct;12(10):e808-e822.","author":"Yin W, Yan X, Cai J, Han B, Yin P, Lu G, Cheng W, Zhang J, Wu H, Ren J, Ren P, Zhou Z, Wang H, Shi Y, Gan L, Wu D, Jin J, Song Y, Jiang Z, Yan X, Niu T, Hu Y, Li F, Gao S, Cheng T, Wang J, Zhang X, Huang X, Liu Q, Zhu X, He P, Chen Y, Yang T, Li J, Wei X, Lai Y, Wang J, Yan J, Yu J, Zhu X, Xu W, Liu Y, Gao J, Jiang H, Zheng Y, Wang H, He Y, Fang Y, Shen S, Chen J, Chen B, Zhang S, Shen Y, Wang J, Mi J, Zhao W, Zhang H, Zhou M, Wei W, He J, Chen Z, Chen SJ; China Acute Leukaemia Epidemiology; Clinical and Multi-omics Data Consortium.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41062205"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288780. Online ahead of print.","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Acute leukemia of ambiguous lineage: the known and the uncertain","title02":"Acute leukemia of ambiguous lineage: the known and the uncertain","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.287793. Online ahead of print.","author":"Sherban A, Wolach O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063702"},{"title01":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia","title02":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia","journal":"Haematologica","issue":"2025 Sep 25. doi: 10.3324\/haematol.2025.288787. Online ahead of print.","author":"Haran A, Nachmias B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994341"},{"title01":"Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine\/cytarabine-based salvage regimens against acute myeloid leukaemia","title02":"Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine\/cytarabine-based salvage regimens against acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep 27. doi: 10.1111\/bjh.70180. Online ahead of print.","author":"Lilienthal I, Tao S, Nilsson C, Leonard E, Zhang R, Sorteberg AL, Fredrikson L, Xagoraris I, Fard SS, Tsesmetzis N, Zachariadis V, Cai H, Sandhow L, Langeb\u00e4ck A, Bohlin A, Tamm KP, Bengtz\u00e9n S, Schinazi RF, Lehmann S, Kim B, Rassidakis GZ, Qian H, J\u00e4dersten M, Herold N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41014199"},{"title01":"Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts","title02":"Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts","journal":"Br J Haematol","issue":"2025 Oct 1. doi: 10.1111\/bjh.70166. Online ahead of print.","author":"Barrett N, Gruber TA, Miyamura T, Duguid A, Stutterheim J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41033852"},{"title01":"AML with mutated TP53, therapy-related, with basophilic differentiation, partial CD22, and ring sideroblasts","title02":"AML with mutated TP53, therapy-related, with basophilic differentiation, partial CD22, and ring sideroblasts","journal":"Blood","issue":"2025 Oct 2;146(14):1737.","author":"Xu Z, McGinnis E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037297"},{"title01":"AML halts neutrophil maturation","title02":"AML halts neutrophil maturation","journal":"Blood","issue":"2025 Oct 2;146(14):1638-1639..","author":"Sandhow L, Passaro D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037301"},{"title01":"Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia","title02":"Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia","journal":"Blood","issue":"2025 Oct 7:blood.2024027009. doi: 10.1182\/blood.2024027009. Online ahead of print.","author":"Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Calado Botelho S, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair BC, Abada PB, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41055698"},{"title01":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia","title02":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia","journal":"Blood","issue":"2025 Oct 8:blood.2025031243. doi: 10.1182\/blood.2025031243. Online ahead of print.","author":"Schroeder B, Yuan CM, Wang HW, Mohindroo C, Zhou H, Raffeld M, Xi L, Arons E, Feurtado JC, James-Echenique L, Calvo KR, Maric I, Kreitman RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060318"},{"title01":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia","title02":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia","journal":"Blood","issue":"2025 Oct 8:blood.2025028914. doi: 10.1182\/blood.2025028914. Online ahead of print.","author":"Pastoors D, Havermans M, Mulet-Lazaro R, Smeenk L, Ottema S, Erpelinck-Verschueren CAJ, van Herk S, Anthonissen M, Grob T, Subramanian S, Thoms JAI, Pimanda JE, Wouters BJ, Beverloo BH, Haferlach T, Haferlach C, Zuber J, Bindels E, Delwel R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060369"},{"title01":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis","title02":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis","journal":"Blood","issue":"2025 Sep 30:blood.2025029121. doi: 10.1182\/blood.2025029121. Online ahead of print.","author":"Penter L, Maurer K, Cieri N, Lu W, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026928"},{"title01":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3","title02":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3","journal":"Blood","issue":"2025 Oct 1:blood.2025029686. doi: 10.1182\/blood.2025029686. Online ahead of print.","author":"Mendoza-Castrejon J, Yang W, Denby ED, Wang HC, Casey EB, Muthukumar R, Patel RM, Yoon J, Li Y, White JM, Chen R, Batista LFZ, Magee JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032751"},{"title01":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma","title02":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma","journal":"Leukemia","issue":"2025 Oct 7. doi: 10.1038\/s41375-025-02777-2. Online ahead of print.","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057685"},{"title01":"Primary thyroid diffuse large B-cell lymphoma in a teenager","title02":"Primary thyroid diffuse large B-cell lymphoma in a teenager","journal":"Lancet Haematol","issue":"2025 Oct;12(10):e850.","author":"Le Calvez B, Mathis S, Lemaire P, Meignin V, Leblanc T, Vercellino L, Chevillon F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41062206"},{"title01":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","title02":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","journal":"Lancet","issue":"2025 Oct 3:S0140-6736(25)01432-1. doi: 10.1016\/S0140-6736(25)01432-1. Online ahead of print.","author":"Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerl\u00f6f I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S; ENRICH investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052510"},{"title01":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","title02":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","journal":"J Clin Oncol","issue":"2025 Oct 2:101200JCO2501957. doi: 10.1200\/JCO-25-01957. Online ahead of print.","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","title02":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","journal":"J Clin Oncol","issue":"2025 Oct 7:JCO2501932. doi: 10.1200\/JCO-25-01932. Online ahead of print.","author":"Rossi D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056509"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288780. Online ahead of print.","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience","title02":"Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288058. Online ahead of print.","author":"Marr KC, Tang T, Simkin J, Kim J, Lo AC, Villa D, Gerrie AS, Hapgood G, Scott DW, Sehn LH, Woods RR, Savage KJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063706"},{"title01":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study","title02":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study","journal":"Haematologica","issue":"2025 Sep 25. doi: 10.3324\/haematol.2025.287919. Online ahead of print.","author":"Chung E, Wang L, Wellard C, Barraclough A, Campbell BA, Chong G, Ciaccio PD, Gregory GP, Hapgood G, Johnston AM, Tam CS, Opat S, Wood EM, McQuilten ZK, Hawkes EA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994345"},{"title01":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy","title02":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy","journal":"Haematologica","issue":"2025 Oct 2. doi: 10.3324\/haematol.2025.288699. Online ahead of print.","author":"Yang J, Hayden AR, Villa D, Jiang A, Gerrie AS, Venner CP, Farinha P, Scott DW, Sehn LH, Savage KJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035405"},{"title01":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study","title02":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.287334. Online ahead of print.","author":"An G, Jin J, Cai Z, Jing H, Fu C, He P, Xia Z, Liu R, Li L, Gai X, Zhang H, Zhu D, Luo X, Sun B, Xu H, Zhou L, Campagna M, Masterson TJ, Lau BW, Renaud T, Heuck C, Singh I, Vishwamitra D, Qiu L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063704"},{"title01":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma","title02":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma","journal":"Haematologica","issue":"2025 Oct 9. doi: 10.3324\/haematol.2025.288521. Online ahead of print.","author":"Siegel A, Reci S, Grossman L, Gleason C, Crary J, Song L, Park J, Verina D, Desai S, Kappes K, Stillman I, LaBaer J, Aleman A, Jagannath S, Parekh S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063705"},{"title01":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches","title02":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches","journal":"Haematologica","issue":"2025 Sep 25. doi: 10.3324\/haematol.2025.288381. Online ahead of print.","author":"Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch JSZ, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994343"},{"title01":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib","title02":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib","journal":"Leukemia","issue":"eukemia. 2025 Oct 2. doi: 10.1038\/s41375-025-02778-1. Online ahead of print.","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038988"},{"title01":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial","title02":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial","journal":"Leukemia","issue":"2025 Oct 7. doi: 10.1038\/s41375-025-02780-7. Online ahead of print.","author":"Hund I, Hess ME, Andrieux G, Stomper J, Greve G, Niem\u00f6ller C, Ma T, Uhl D, Grishina O, Thol F, Heuser M, Bug G, Crysandt M, Neubauer A, Duyster J, D\u00f6hner H, Boerries M, L\u00fcbbert M, Becker H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057684"},{"title01":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment","title02":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment","journal":"Leukemia","issue":"2025 Oct 7. doi: 10.1038\/s41375-025-02774-5. Online ahead of print.","author":"Voss RK, Pastor Loyola VB, Cardenas MF, Kumar P, Maciaszek JL, Namwanje M, Ma J, Neary JL, Jin M, Umeda M, Wilkinson MR, Payne-Turner D, Eldomery MK, Ma J, Gu J, Dalton J, Melton S, Liu YC, Foy S, Rusch M, Wheeler DA, Zhang J, Nichols KE, Karol SE, Inaba H, Ribeiro R, Rubnitz JE, Klco JM, Wang L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057686"},{"title01":"How do ionizing radiations from inter-planetary travel cause leukaemia?","title02":"How do ionizing radiations from inter-planetary travel cause leukaemia?","journal":"Leukemia","issue":"2025 Sep 29. doi: 10.1038\/s41375-025-02761-w. Online ahead of print.","author":"Badie C, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41023183"},{"title01":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies","title02":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies","journal":"Leukemia","issue":"2025 Sep 28. doi: 10.1038\/s41375-025-02772-7. Online ahead of print.","author":"Rodriguez L, Delhommeau F, Soussi T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016942"},{"title01":"The sobering reality of fertility preservation in young female patients with acute leukemia","title02":"The sobering reality of fertility preservation in young female patients with acute leukemia","journal":"Haematologica","issue":"2025 Sep 25. doi: 10.3324\/haematol.2025.288538. Online ahead of print.","author":"Frisch A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994349"},{"title01":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor","title02":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor","journal":"Haematologica","issue":"2025 Oct 2. doi: 10.3324\/haematol.2025.288553. Online ahead of print.","author":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035402"},{"title01":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study","title02":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study","journal":"Haematologica","issue":"2025 Oct 2. doi: 10.3324\/haematol.2025.288516. Online ahead of print.","author":"Lokhorst DN, Smit Y, Van den Bemt BJF, Hermens RPMG, Nijziel MR, Jie AK, Daenen LGM, Klein SK, Posthuma EFM, Westerweel PE, Donker M, Hoogendoorn M, Bekker CL, Blijlevens NMA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035410"},{"title01":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/\u03b2-catenin pathway","title02":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/\u03b2-catenin pathway","journal":"Haematologica","issue":"2025 Oct 2. doi: 10.3324\/haematol.2025.287651. Online ahead of print.","author":"Veltri G, Peloso A, Cani A, Mariotto E, Corallo D, Aveic S, Russo L, Cescon M, Santinon G, Frasson C, Simon K, Arrighi A, Iorio E, Minuzzo SA, Indraccolo S, Marmiroli S, Ntziachristos P, Biffi A, Pigazzi M, Buldini B, Bresolin S, Serafin V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035400"},{"title01":"The French-American-British classification system for acute myeloid leukemia","title02":"The French-American-British classification system for acute myeloid leukemia","journal":"Haematologica","issue":"2025 Oct 1;110(10):2246-2247.","author":"Pollyea DA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41031420"},{"title01":"Leucostasis-induced limb ischaemia in acute myeloid leukaemia","title02":"Leucostasis-induced limb ischaemia in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Oct 2. doi: 10.1111\/bjh.70177. Online ahead of print.","author":"Sandberg Y, Mingels L, van Zutven LJCM, Lam KH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41039705"},{"title01":"Hypocellular acute promyelocytic leukaemia mimicking aplastic anaemia: A diagnostic pitfall","title02":"Hypocellular acute promyelocytic leukaemia mimicking aplastic anaemia: A diagnostic pitfall","journal":"Br J Haematol","issue":"2025 Oct 5. doi: 10.1111\/bjh.70175. Online ahead of print.","author":"Chen H, Wang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41047489"},{"title01":"Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study","title02":"Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study","journal":"Br J Haematol","issue":"2025 Oct 7. doi: 10.1111\/bjh.70193. Online ahead of print.","author":"Chen EY, Dickman PW, Di Mari F, Dahl\u00e9n T, Stenke L, Bj\u00f6rkholm M, Clements MS, Hao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057969"},{"title01":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","title02":"Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party","journal":"Br J Haematol","issue":"2025 Sep 30. doi: 10.1111\/bjh.70167. Online ahead of print.","author":"Buchbinder N, Michel V, Dalissier A, Kleinschmidt K, Locatelli F, Maschan A, Wynn R, Fagioli F, Zecca M, Jubert C, Versluys B, Sedlacek P, Zubarovskaya L, Gonzalez Vicent M, Biffi A, Michel G, Mirci-Danicar O, Holter W, Ansari M, Galimard JE, Schneider P, Abouqateb M, Ka\u0142wak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41027844"},{"title01":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution","title02":"Resolving inter- and intra-patient heterogeneity in <i>NPM1<\/i>-mutated AML at single-cell resolution","journal":"Leukemia","issue":"2025 Sep 15. doi: 10.1038\/s41375-025-02745-w. Online ahead of print.","author":"Karakaslar EO, Argiro EM, Struckman NE, Shirali Hz R, Severens JF, Honders MW, Kloet SL, Veelken H, Reinders MJ, Griffioen M, van den Akker EB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954214"},{"title01":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival","title02":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival","journal":"Leukemia","issue":"2025 Sep 11. doi: 10.1038\/s41375-025-02752-x. Online ahead of print.","author":"Miraki-Moud F, Ariza-McNaughton L, KoKo T, Othman J, Stronge R, de Bono J, Russell N, Thomas I, Gilkes A, Burnett A, Santiago LR, Cafferty F, Taussig L, Thornhill A, O'Connor S, Bonnet D, Taussig DC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935826"},{"title01":"Response to Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"Response to Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.289110. Online ahead of print.","author":"Sanz J, Mohty M, Ciceri F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963383"},{"title01":"Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia","title02":"Metallothionein 1: the Achilles heel of <i>Dnmt3a;Npm1<\/i>-mutant acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.288820. Online ahead of print.","author":"Yan B, Guryanova OA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963388"},{"title01":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","title02":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.288178. Online ahead of print.","author":"Verdeyen K, Reuvekamp T, Van der Velden WJFM, Wouters BJ, Von dem Borne PA, Van Rhenen A, Lissenberg-Witte BI, Van Lammeren D, Van Sluis GL, De Jongh E, Fiets RB, Corsten MF, Van der Spek AC, Gerrits AM, Van Bladel ER, Tick LW, De Weerdt O, Van Zaane B, Cruijsen MJ, Posthuma EFM, Van Elssen CHMJ, Klein SK, Van de Loosdrecht AA, De Leeuw DC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963393"},{"title01":"MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia","title02":"<i>MECOM<\/i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM<\/i> rearranged acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep 22. doi: 10.1111\/bjh.70171. Online ahead of print.","author":"Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983567"},{"title01":"Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk KMT2A-rearranged acute myeloid leukaemia","title02":"Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk <i>KMT2A<\/i>-rearranged acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep 21. doi: 10.1111\/bjh.70183. Online ahead of print.","author":"Chavan A, Frett B, Armstrong DT, Acharya B, Lockyer P, Boerma M, Roy Choudhury S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976985"},{"title01":"A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia","title02":"A novel <i>PML<\/i> germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep;207(3):1118-1121.","author":"Soussi T, Kundu S, Gerbaud P, Pandzic T, Baskin B, Ladenvall C, Delhommeau F, Sj\u00f6blom T, Baliakas P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954117"},{"title01":"Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study","title02":"Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study","journal":"Br J Haematol","issue":"2025 Sep 14. doi: 10.1111\/bjh.70159. Online ahead of print.","author":"Quist-Paulsen P, Horvei L, Dalgaard J, Moksnes M, Eilertsen AL, Paulson M, Azrakhsh NA, Majeed W, Wik HS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947499"},{"title01":"Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia","title02":"Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia","journal":"Blood","issue":"2025 Sep 24:blood.2025028988. doi: 10.1182\/blood.2025028988. Online ahead of print.","author":"Derevyanko PK, Swart LE, Mata Casimiro LD, van Oort A, Du Plessis M, van den Brink L, Ashtiani M, Zwaan CM, Krippner-Heidenreich A, Bonifer C, Schiffelers RM, Vormoor JJ, Kellaway S, Heidenreich O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991849"},{"title01":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias","title02":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias","journal":"Blood","issue":"2025 Sep 24:blood.2025028954. doi: 10.1182\/blood.2025028954. Online ahead of print.","author":"Fleming T, Antoszewski M, Lambo S, Gundry M, Piussi R, Wahlster L, Shah SB, Reed F, Dong K, Paulo JA, Gygi S, Mimoso CA, Goldman S, Adelman K, Perry JA, Pikman Y, Stegmaier K, Barrachina MN, Machlus KR, Hovestadt V, Arruda A, Minden MD, Voit RA, Sankaran VG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991835"},{"title01":"INCREASED LEF1 PROTEIN LEVELS AND ISOFORM SWITCHING DRIVE CELL PROLIFERATION IN CHRONIC LYMPHOCYTIC LEUKEMIA","title02":"INCREASED LEF1 PROTEIN LEVELS AND ISOFORM SWITCHING DRIVE CELL PROLIFERATION IN CHRONIC LYMPHOCYTIC LEUKEMIA","journal":"Blood","issue":"2025 Sep 22:blood.2025030129. doi: 10.1182\/blood.2025030129. Online ahead of print.","author":"Mateos-Jaimez J, Vidal Crespo A, Charalampopoulou S, Fernandez Perez R, Chapaprieta V, Jim\u00e9nez-Mart\u00ednez V, Caviedes-C\u00e1rdenas L, Duran-Ferrer M, Espadas G, Sabido E, Largeot A, Herbst SA, Dietrich S, Bastos Boente M, Alcoceba M, Nadeu F, Ringshausen I, Paggetti J, Moussay E, Colomer D, Campo E, Maiques-Diaz A, Martin-Subero JI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983031"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort","journal":"Blood","issue":"2025 Sep 19:blood.2025029916. doi: 10.1182\/blood.2025029916. Online ahead of print.","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cav\u00e9 H, Strullu M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML","title02":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML","journal":"Blood","issue":"2025 Sep 19:blood.2025029391. doi: 10.1182\/blood.2025029391. Online ahead of print.","author":"Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth ME, Sasaki K, Tewari P, Issa GC, Farhat A, Connors JS, Sheikh IN, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla KN, Petropoulos D, Daver NG, Kadia TM, Cuglievan B, DiNardo CD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971491"},{"title01":"BAP1\/TP53 loss defines a BCL-xL-dependent erythroleukemia","title02":"<i>BAP1\/TP53<\/i> loss defines a BCL-xL-dependent erythroleukemia","journal":"Blood","issue":"2025 Sep 18;146(12):1385-1387.","author":"Ho TC, Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40965944"},{"title01":"ELEVATE-ing clinical trial reporting in CLL","title02":"ELEVATE-ing clinical trial reporting in CLL","journal":"Blood","issue":"2025 Sep 11;146(11):1253-1254.","author":"Simon F, Al-Sawaf O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40932743"},{"title01":"Subcutaneous Panniculitis-like T-Cell Lymphoma","title02":"Subcutaneous Panniculitis-like T-Cell Lymphoma","journal":"N Engl J Med","issue":"2025 Sep 18;393(11):1117.","author":"Okada S, Nishikubo M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40948476"},{"title01":"Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study","title02":"Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study","journal":"Lancet Haematol","issue":"2025 Sep 17:S2352-3026(25)00252-2. doi: 10.1016\/S2352-3026(25)00252-2. Online ahead of print.","author":"Visco C, Tabanelli V, Sacchi MV, Evangelista A, Quaglia FM, Fiori S, Bomben R, Tisi MC, Riva M, Merli A, Rotondo F, Fraenza C, Carazzolo ME, Corradini P, Farina L, Castellino C, Castellino A, Zilioli VR, Muzi C, Piazza F, Re A, Hohaus S, Rossi FG, Musuraca G, Di Rocco A, Puccini B, Sciarra R, Ballerini F, Cavallo F, Bruna R, Moia R, Moioli A, Bernardelli A, Drandi D, Arcari A, Merli F, Gini G, Freilone R, Tani M, Pavone V, Ladetto M, Pileri SA, Balzarotti M; Fondazione Italiana Linfomi.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40975105"},{"title01":"Advancing understanding of mature T-cell and natural killer-cell lymphomas","title02":"Advancing understanding of mature T-cell and natural killer-cell lymphomas","journal":"Lancet Haematol","issue":"2025 Sep 14:S2352-3026(25)00237-6. doi: 10.1016\/S2352-3026(25)00237-6. Online ahead of print.","author":"Qi S, Cai Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961950"},{"title01":"Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas","title02":"Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas","journal":"Lancet Haematol","issue":"2025 Sep 14:S2352-3026(25)00228-5. doi: 10.1016\/S2352-3026(25)00228-5. Online ahead of print.","author":"Tse E, Querfeld C, Ishitsuka K, Kwong YL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961949"},{"title01":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","title02":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","journal":"J Clin Oncol","issue":"2025 Sep 24:JCO2500925. doi: 10.1200\/JCO-25-00925. Online ahead of print.","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgu\u00e9s JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991874"},{"title01":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma","title02":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.287672. Online ahead of print.","author":"Santoro A, Improta CM, Sarina B, Mannina D, De Philippis C, Taurino D, Mariotti J, Balzarotti M, Bramanti S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963380"},{"title01":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy","title02":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy","journal":"Br J Haematol","issue":"2025 Sep 11. doi: 10.1111\/bjh.70137. Online ahead of print.","author":"Kuhnl A, Bouziana S, Barrington SF, Galani S, Menne T, Northend M, Stevens L, Kamat S, Osborne W, Johnson R, Kumar E, Sanderson R, Patten PEM, Benjamin R, Frew J, Prestwich R, Brady JL, Mikhaeel NG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936317"},{"title01":"Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma","title02":"Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma","journal":"Br J Haematol","issue":"2025 Jul 15. doi: 10.1111\/bjh.70007. Online ahead of print.","author":"Khavandi MM, Strati P, Habibollahi P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40955110"},{"title01":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial","title02":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial","journal":"Blood","issue":"2025 Sep 12:blood.2025028823. doi: 10.1182\/blood.2025028823. Online ahead of print.","author":"Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M MD, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka AP, Ferreri AJM, Merli F, Zhao WL, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Foss\u00e5 A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens KS, Ielmini N, De Martino I, Walewski J, Trn\u011bn\u00fd M, Cavalli F, Ricardi U, Johnson PWM, Davies AJ, Martelli M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40939190"},{"title01":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma","title02":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma","journal":"Leukemia","issue":"2025 Sep 19. doi: 10.1038\/s41375-025-02766-5. Online ahead of print.","author":"Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr JG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973768"},{"title01":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study","title02":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study","journal":"Leukemia","issue":"2025 Sep 12. doi: 10.1038\/s41375-025-02762-9. Online ahead of print.","author":"Andersen LS, Navarro RB, Ekberg S, R\u00f6gnvaldsson S, Levy MR, Sverrisd\u00f3ttir IS, Vi\u00f0arsson B, \u00d6nundarson PT, Agnarsson BA, Sigur\u00f0ard\u00f3ttir M, \u00deorsteinsd\u00f3ttir I, \u00d3lafsson \u00cd, \u00de\u00f3r\u00f0ard\u00f3ttir \u00c1R, Ey\u00fe\u00f3rsson E, J\u00f3nsson \u00c1, \u00d3lafsson A, Durie BGM, Harding S, Landgren O, L\u00f6ve TJ, Kristinsson SY, Thorsteinsd\u00f3ttir S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40940581"},{"title01":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies","title02":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.288466. Online ahead of print.","author":"Cook J, Dispenzieri A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963394"},{"title01":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial","title02":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial","journal":"Blood","issue":"2025 Sep 24:blood.2025030084. doi: 10.1182\/blood.2025030084. Online ahead of print.","author":"Kraeber-Bodere F, Jamet B, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Moreau P, Carlier T, Touzeau C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991848"},{"title01":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","title02":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","journal":"Blood","issue":"2025 Sep 24:blood.2025029999. doi: 10.1182\/blood.2025029999. Online ahead of print.","author":"Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M Dr, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991836"},{"title01":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","title02":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","journal":"Blood","issue":"2025 Sep 22:blood.2025029360. doi: 10.1182\/blood.2025029360. Online ahead of print.","author":"Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosi\u00f1ol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, W\u00e4sch R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983036"},{"title01":"Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma","title02":"Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma","journal":"Blood","issue":"2025 Sep 19:blood.2024027496. doi: 10.1182\/blood.2024027496. Online ahead of print.","author":"Navarro F, Lozano T, Fuentes-Garc\u00eda A, S\u00e1nchez-Moreno I, Larrayoz M, Justicia P, Perucha B, Martinez-Tabar M, Martinez-Turrillas R, Casares N, Mart\u00edn-Otal C, Gorraiz M, Meermeier EW, Chesi M, Lake D, Bergsagel PL, Santamar\u00eda E, Calleja-Cervantes ME, San Mart\u00edn-\u00dariz P, Jordana-Urriza L, Agirre X, Hervas-Stubbs S, Rodriguez-Madoz JR, Mart\u00ednez-Climent JA, Prosper F, Lasarte JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971494"},{"title01":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma","title02":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma","journal":"Blood","issue":"2025 Sep 12:blood.2025029950. doi: 10.1182\/blood.2025029950. Online ahead of print.","author":"Yan Z, Han Z, Wang Y, Beus M, Zhang Y, Picado A, Wells CI, Wu J, Weidenhammer LB, Pires KM, Leibold EA, Liu L, Gooden DM, Spasojevic I, Soderblom E, Kang Y, Boise LH, Willson TM, Nikiforov MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40953235"},{"title01":"ClpP: a new Achilles&#8217; heel in myeloma","title02":"ClpP: a new Achilles&#8217; heel in myeloma","journal":"Blood","issue":"2025 Sep 11;146(11):1254-1255.","author":"Sacco A, Roccaro AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40932746"},{"title01":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation","title02":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation","journal":"J Clin Oncol","issue":"2025 Sep 18:JCO2500206. doi: 10.1200\/JCO-25-00206. Online ahead of print.","author":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966481"},{"title01":"Response to Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"Response to Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.289110. Online ahead of print.","author":"Sanz J, Mohty M, Ciceri F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963383"},{"title01":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","title02":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 18. doi: 10.3324\/haematol.2025.288178. Online ahead of print.","author":"Verdeyen K, Reuvekamp T, Van der Velden WJFM, Wouters BJ, Von dem Borne PA, Van Rhenen A, Lissenberg-Witte BI, Van Lammeren D, Van Sluis GL, De Jongh E, Fiets RB, Corsten MF, Van der Spek AC, Gerrits AM, Van Bladel ER, Tick LW, De Weerdt O, Van Zaane B, Cruijsen MJ, Posthuma EFM, Van Elssen CHMJ, Klein SK, Van de Loosdrecht AA, De Leeuw DC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963393"},{"title01":"Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study","title02":"Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study","journal":"Br J Haematol","issue":"2025 Sep 22. doi: 10.1111\/bjh.70154. Online ahead of print.","author":"Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo DJ, McGuirk J, Mensah F, Nadiminti KV, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns LJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983528"},{"title01":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP)","title02":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP)","journal":"Br J Haematol","issue":"2025 Sep 21. doi: 10.1111\/bjh.70036. Online ahead of print.","author":"Baccelli F, Compagno F, Tridello G, Delle Cave F, Zama D, Masetti R, Petris MG, Chiusaroli L, Spadea M, Trevisan F, Colombini A, Conci S, Meazza C, Muggeo P, Micheletti MV, Pancaldi A, Mura R, Onofrillo D, De Santis R, La Spina M, Castagnola E, Perruccio K, Barone A, Giurici N, Petrone A, Mercolini F, Rinieri S, Cesaro S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976850"},{"title01":"Can we move beyond myeloablative conditioning (MAC)? A\u00a0comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65\u2009years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis","title02":"Can we move beyond myeloablative conditioning (MAC)? A\u00a0comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65\u2009years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis","journal":"Br J Haematol","issue":"2025 Sep 18. doi: 10.1111\/bjh.70170. Online ahead of print.","author":"Alyamany R, Alnughmush A, Remberger M, Law AD, Lam W, Kim DDH, Michelis FV, Pasic I, Novitzky-Basso I, Gerbitz A, Kumar R, Mattsson J, Viswabandya A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40968076"},{"title01":"Cord blood porphyrin analysis in neonates at risk of inheriting protoporphyria: An observational cohort study","title02":"Cord blood porphyrin analysis in neonates at risk of inheriting protoporphyria: An observational cohort study","journal":"Br J Haematol","issue":"2025 Sep;207(3):1148-1151.","author":"Schulenburg-Brand D, Peek R, Bentley L, Swingler R, Pavlova YT, Dawe RS, McGuire VA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954119"},{"title01":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment","title02":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment","journal":"Br J Haematol","issue":"2025 Sep 14. doi: 10.1111\/bjh.70146. Online ahead of print.","author":"Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Pohier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947302"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia","journal":"Br J Haematol","issue":"2025 Sep 14. doi: 10.1111\/bjh.70133. Online ahead of print.","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study","journal":"Blood","issue":"2025 Sep 22:blood.2025029640. doi: 10.1182\/blood.2025029640. Online ahead of print.","author":"Herrmann US, Felber M, Worth AJ, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll AH, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans CA, Bordon Cueto de Braem MV, Bredius RG, K\u00fchl JS, V\u00f6ller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl MM, Lankester AC, Ikinciogullari A, Guilcher GMT, Hackenberg A, Ye\u015filipek MA, Davies EG, Hershfield M, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, G\u00fcng\u00f6r T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"Sclerotic GVHD and Scleroderma Share Dysregulated Gene Expression that is Ameliorated by EREG Therapeutic Antibody","title02":"Sclerotic GVHD and Scleroderma Share Dysregulated Gene Expression that is Ameliorated by EREG Therapeutic Antibody","journal":"Blood","issue":"2025 Sep 17:blood.2025029836. doi: 10.1182\/blood.2025029836. Online ahead of print.","author":"Newton NM, Agrawal K, Odell AV, Tracy TS, Hackett CS, Eldrup AB, Whitfield M, Martyanov V, Girardi M, Sefik E, Flavell RA, Odell ID.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961242"},{"title01":"Mac-Man clearance of alloreactive T cells in GVHD","title02":"Mac-Man clearance of alloreactive T cells in GVHD","journal":"Blood","issue":"2025 Sep 11;146(11):1262-1263.","author":"Buxbaum NP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40932747"},{"title01":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission","title02":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission","journal":"Leukemia","issue":"2025 Sep 16. doi: 10.1038\/s41375-025-02770-9. Online ahead of print.","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958034"},{"title01":"Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study","title02":"Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study","journal":"Br J Haematol","issue":"2025 Sep 22. doi: 10.1111\/bjh.70154. Online ahead of print.","author":"Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo DJ, McGuirk J, Mensah F, Nadiminti KV, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns LJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983528"},{"title01":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP)","title02":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP)","journal":"Br J Haematol","issue":"2025 Sep 21. doi: 10.1111\/bjh.70036. Online ahead of print.","author":"Baccelli F, Compagno F, Tridello G, Delle Cave F, Zama D, Masetti R, Petris MG, Chiusaroli L, Spadea M, Trevisan F, Colombini A, Conci S, Meazza C, Muggeo P, Micheletti MV, Pancaldi A, Mura R, Onofrillo D, De Santis R, La Spina M, Castagnola E, Perruccio K, Barone A, Giurici N, Petrone A, Mercolini F, Rinieri S, Cesaro S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976850"},{"title01":"Can we move beyond myeloablative conditioning (MAC)? A\u00a0comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65\u2009years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis","title02":"Can we move beyond myeloablative conditioning (MAC)? A\u00a0comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65\u2009years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis","journal":"Br J Haematol","issue":"2025 Sep 18. doi: 10.1111\/bjh.70170. Online ahead of print.","author":"Alyamany R, Alnughmush A, Remberger M, Law AD, Lam W, Kim DDH, Michelis FV, Pasic I, Novitzky-Basso I, Gerbitz A, Kumar R, Mattsson J, Viswabandya A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40968076"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study","journal":"Blood","issue":"2025 Sep 22:blood.2025029640. doi: 10.1182\/blood.2025029640. Online ahead of print.","author":"Herrmann US, Felber M, Worth AJ, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll AH, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans CA, Bordon Cueto de Braem MV, Bredius RG, K\u00fchl JS, V\u00f6ller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl MM, Lankester AC, Ikinciogullari A, Guilcher GMT, Hackenberg A, Ye\u015filipek MA, Davies EG, Hershfield M, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, G\u00fcng\u00f6r T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"Clonal tracing of blood stem cells across mouse and human lifespans","title02":"Clonal tracing of blood stem cells across mouse and human lifespans","journal":"Blood","issue":"2025 Sep 22:blood.2024028195. doi: 10.1182\/blood.2024028195. Online ahead of print.","author":"Rodriguez-Fraticelli AE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983030"},{"title01":"UPS delivers apolarity and senescence to HSCs","title02":"UPS delivers apolarity and senescence to HSCs","journal":"Blood","issue":"2025 Sep 18;146(12):1382-1383.","author":"Geiger H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40965939"},{"title01":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment","title02":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment","journal":"Blood","issue":"2025 Sep 17:blood.2025029115. doi: 10.1182\/blood.2025029115. Online ahead of print.","author":"Meaker GA, Nicholls M, Chahrour C, Hsu I, Smith A, Bozhilov Y, Leung MGH, Vassort H Mr, Olender L, Beaven O, Huang X, Brown EJ, Vanden Bempt M, Khoo HM, Bhadury J, Milne TA, Wilkinson AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961240"},{"title01":"The diagnostic performance of the basic versus the detailed telomere Flow FISH test in young patients with aplastic anaemia","title02":"The diagnostic performance of the basic versus the detailed telomere Flow FISH test in young patients with aplastic anaemia","journal":"Br J Haematol","issue":"2025 Sep 23. doi: 10.1111\/bjh.70155. Online ahead of print.","author":"DeCleene NF, Nguyen DT, Kirk SE, Helber HL, Sasa GS, Bertuch AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40988089"},{"title01":"Germline mosaicism in a family affected by Diamond-Blackfan anaemia","title02":"Germline mosaicism in a family affected by Diamond-Blackfan anaemia","journal":"Br J Haematol","issue":"2025 Sep 21. doi: 10.1111\/bjh.70173. Online ahead of print.","author":"Dunlea E, Lynch SA, Angelov D, Cotter M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976991"},{"title01":"A new unstable haemoglobin, Hb Alger, causes a transfusion-dependent anaemia in early childhood","title02":"A new unstable haemoglobin, Hb Alger, causes a transfusion-dependent anaemia in early childhood","journal":"Br J Haematol","issue":"2025 Jul 31. doi: 10.1111\/bjh.70040. Online ahead of print.","author":"Bouazizi S, Cerino M, Lim S, Desgrouas C, Badens C, Szepetowski S, Bonello-Palot N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963508"},{"title01":"A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia","title02":"A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia","journal":"Br J Haematol","issue":"2025 Sep 12. doi: 10.1111\/bjh.70152. Online ahead of print.","author":"Brenac G, Dautriche A, Freppel R, Facile A, Revol B, Beurrier M, Bonnotte B, Audia S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936476"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia","journal":"Br J Haematol","issue":"2025 Sep 14. doi: 10.1111\/bjh.70133. Online ahead of print.","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"VEXAS anemia is a mosaic erythroblastopenia","title02":"VEXAS anemia is a mosaic erythroblastopenia","journal":"Blood","issue":"2025 Sep 19:blood.2025029081. doi: 10.1182\/blood.2025029081. Online ahead of print.","author":"Rodrigues F, Hardouin G, El Hoss S, Ghoul A, Gautier EF, Dussiot M, A Lizarralde-Iragorri M, Santini A, Peltier S, Amireault P, Soldan V, Miccio A, Debili M, Jachiet V, Trovati Maciel T, Rossignol J, Allemand E, M\u00e9kinian AM, Georgin-Lavialle SA Pr, Salma M, Soler E, Gleizes PE, O'Donohue MF, Kosmider O, Rodriguez MS, Hermine O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971475"},{"title01":"Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A\u00a0prospective, multicentre, phase 2 clinical trial","title02":"Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A\u00a0prospective, multicentre, phase 2 clinical trial","journal":"Br J Haematol","issue":"2025 Sep 15. doi: 10.1111\/bjh.70168. Online ahead of print.","author":"Liu Q, Dong X, Rong C, Shen Y, Xu L, Zhou M, Xu X, Cai J, Wu L, Chen S, Qiu D, Zhao J, Zhou P, Liu S, Liu W, Hu H, Zhao Y, Zhang Y, Zhou Y, Shen Y, Ye B, Xia Y, Shou L, Wu D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954566"},{"title01":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML","title02":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML","journal":"Leukemia","issue":"2025 Sep 19. doi: 10.1038\/s41375-025-02773-6. Online ahead of print.","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973769"},{"title01":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling","title02":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling","journal":"Leukemia","issue":"2025 Sep 19. doi: 10.1038\/s41375-025-02756-7. Online ahead of print.","author":"Mazzeo P, Penir SM, Shumilov E, Wolf S, H\u00e4upl B, Markus K, Shirneshan K, Rittscher K, Brzuszkiewicz E, Aydilek E, Treiber H, Oellerich T, Ganster C, Haase D, Koch R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973765"},{"title01":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study","title02":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study","journal":"Leukemia","issue":"2025 Sep 19. doi: 10.1038\/s41375-025-02755-8. Online ahead of print.","author":"Visentin A, Gaffo E, F\u00fcrstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarf\u00f2 L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973766"},{"title01":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &#038; Alliance for Clinical Trials in Oncology)","title02":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &#038; Alliance for Clinical Trials in Oncology)","journal":"Leukemia","issue":"2025 Sep 19. doi: 10.1038\/s41375-025-02644-0. Online ahead of print.","author":"Cusan M, Larkin K, Nicolet D, Jurinovic V, Mr\u00f3zek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, G\u00f6rlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973764"},{"title01":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML","title02":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML","journal":"Leukemia","issue":"2025 Sep 16. doi: 10.1038\/s41375-025-02769-2. Online ahead of print.","author":"Purhonen M, Tatun M, Luukkainen K, Hung K, Sundquist H, Tafjord O, S\u00f6derlund S, Adnan-Awad S, Dohlen A, Heikkinen J, Koskenvesa P, Siitonen S, Mustjoki S, Shanmuganathan N, Bryce C, Danielsson S, Hjorth-Hansen H, Olsson-Str\u00f6mberg U, Kumagai T, Kimura S, Ross DM, Br\u00fcck O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958033"},{"title01":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","title02":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","journal":"Leukemia","issue":"2025 Sep 15. doi: 10.1038\/s41375-025-02767-4. Online ahead of print.","author":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954213"},{"title01":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia","title02":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia","journal":"Leukemia","issue":"2025 Sep 11. doi: 10.1038\/s41375-025-02763-8. Online ahead of print.","author":"Miranda-Galvis M, Tjioe KC, Sharara M, Maloney M, Keruakous AR, Jillella A, Kota V, Guha A, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935825"},{"title01":"Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma","title02":"Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma","journal":"Br J Haematol","issue":"2025 Sep 21. doi: 10.1111\/bjh.70178. Online ahead of print.","author":"Olszewski AJ, Treaba DO, Winter A, Donnelly S, Ollila TA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976986"},{"title01":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes","title02":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes","journal":"Br J Haematol","issue":"2025 Sep 18. doi: 10.1111\/bjh.70143. Online ahead of print.","author":"Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AHV, Dahle J, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40967736"},{"title01":"Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm","title02":"Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm","journal":"Br J Haematol","issue":"2025 Sep;207(3):1104-1107. doi: 10.1111\/bjh.20261. Epub 2025 Jul 7.","author":"Nordkin M, Fadaos N, Leiba R, Sharon-Horesh N, Varon B, Beyar-Katz O, Levi T, Horowitz NA, Tzoran I, Lavi N, Zuckerman T, Dann EJ, Ringelstein-Harlev S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954124"},{"title01":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma","title02":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma","journal":"Br J Haematol","issue":"2025 Sep 16. doi: 10.1111\/bjh.70097. Online ahead of print.","author":"Li Y, Jin L, Liu W, Liu Y, Yang K, Jia Y, Yang X, Dai Y, Yang L, Liu R, Jiang L, Zheng M, Xu J, Liu A, Sun L, Gao H, Jin R, Zheng Q, Zhang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958529"},{"title01":"Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study","title02":"Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study","journal":"Br J Haematol","issue":"2025 Sep 15. doi: 10.1111\/bjh.70157. Online ahead of print.","author":"Bahabri AS, Lau C, Kim VHD, Alexander S, Gupta S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40953918"},{"title01":"Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes","title02":"Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes","journal":"Br J Haematol","issue":"2025 Sep 14. doi: 10.1111\/bjh.70161. Online ahead of print.","author":"Broccoli A, Argnani L, Pileri A, Mazzoni C, Sordi B, Pimpinelli N, Fava P, Quaglino P, Pennese E, Perrone T, Bernardelli A, Visco C, Teoli M, Flenghi L, Ibatici A, Massone C, Zinzani PL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947509"},{"title01":"CCRL2 and who? An important driver in TP53-mutant myeloid leukemias","title02":"CCRL2 and who? An important driver in <i>TP53<\/i>-mutant myeloid leukemias","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288631. Online ahead of print.","author":"Arnold O, Saygin C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931868"},{"title01":"Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response","title02":"Wild-type p53 overexpression in <i>NPM1<\/i>-mutated acute myeloid leukemia: potential implications for disease biology and therapy response","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288054. Online ahead of print.","author":"Barone PD, Dzedzik S, Kleinman AS, Chin CR, Meydan C, Valencia I, Sugita M, Guzman ML, Fein JA, Kaner JD, Desai P, Roboz GJ, Melnick AM, Mason CE, Patel SS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931876"},{"title01":"Gene expression signature of IKZF1 deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4","title02":"Gene expression signature of <i>IKZF1<\/i> deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of <i>MUC4<\/i>","journal":"Br J Haematol","issue":"2025 Aug 28. doi: 10.1111\/bjh.70014. Online ahead of print.","author":"Sharma P, Leons GK, Singh V, Naseer S, Ribeyron L, Bakhshi S, Gupta R, Gajendra S, Thoudam DS, Sarawat SK, Khan MA, Pushpam D, Sahoo RK, Roy A, Gupta SK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40878232"},{"title01":"Lineage switch from KMT2A-rearranged congenital B-ALL to AML in an infant: a genomic perspective","title02":"Lineage switch from <i>KMT2A<\/i>-rearranged congenital B-ALL to AML in an infant: a genomic perspective","journal":"Blood","issue":"2025 Aug 28;146(9):1142.","author":"Kodgule R, Vij KR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875548"},{"title01":"Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era","title02":"Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288306. Online ahead of print.","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288279. Online ahead of print.","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287860. Online ahead of print.","author":"Villalba M, Montoro J, Balaguer-Rosell\u00f3 A, Chor\u00e3o P, Cant\u00f3 PA, Granados P, G\u00f3mez-Segu\u00ed I, Solves P, Such E, Cervera J, Barrrag\u00e1n E, Santiago M, Gil-Ort\u00ed JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz M\u00c1, Sanz J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287344. Online ahead of print.","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitek\u0117nait\u0117 V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"HLA matching in the PTCy era: the locus still matters. Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"HLA matching in the PTCy era: the locus still matters. Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.289055. Online ahead of print.","author":"Desai N, Mattsson J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931871"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288957. Online ahead of print.","author":"Bethge W, Dreger P; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT), German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation","title02":"Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288004. Online ahead of print.","author":"Kawamura K, Kanda J, Seo S, Kimura F, Hirayama M, Uchida N, Doki N, Takeda W, Nishida T, Katayama Y, Tanaka M, Sawa M, Yoshihara S, Eto T, Kawakita T, Nakamae H, Ota S, Ishimaru F, Fukuda T, Atsuta Y, Kanda Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931859"},{"title01":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations","title02":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to <i>SLC29A3<\/i> mutations","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288098. Online ahead of print.","author":"Quigg TC, Kurt BA, Seaver LH, Holsworth AR, Duffner UA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874332"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2024.287157. Online ahead of print.","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM)","title02":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM)","journal":"Br J Haematol","issue":"2025 Sep 9. doi: 10.1111\/bjh.70074. Online ahead of print.","author":"Tsai XC, Yao ZH, Chou SW, Hu HC, Liu YC, Chen CH, Yeh SP, Huang WC, Lin TL, Yang TM, Lai CH, Ko HK, Kuo YW, Hsu HH, Cheng SL, Li CC, Ko BS, Wang HC; Taiwan Society of Blood and Marrow Transplantation and Taiwan Society of Pulmonary and Critical Care Medicine.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926299"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)","journal":"Br J Haematol","issue":"2025 Sep 9. doi: 10.1111\/bjh.70061. Online ahead of print.","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Sep 7. doi: 10.1111\/bjh.70142. Online ahead of print.","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation","title02":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation","journal":"Br J Haematol","issue":"2025 Sep 10. doi: 10.1111\/bjh.70136. Online ahead of print.","author":"Sun G, Tu J, Tang B, Lu Z, Fang X, Liu H, Han Y, Sun Z, Zheng C, Zhu X, Tong J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931393"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation","journal":"Br J Haematol","issue":"2025 Sep 3. doi: 10.1111\/bjh.70105. Online ahead of print.","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288279. Online ahead of print.","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287860. Online ahead of print.","author":"Villalba M, Montoro J, Balaguer-Rosell\u00f3 A, Chor\u00e3o P, Cant\u00f3 PA, Granados P, G\u00f3mez-Segu\u00ed I, Solves P, Such E, Cervera J, Barrrag\u00e1n E, Santiago M, Gil-Ort\u00ed JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz M\u00c1, Sanz J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287344. Online ahead of print.","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitek\u0117nait\u0117 V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288957. Online ahead of print.","author":"Bethge W, Dreger P; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT), German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations","title02":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to <i>SLC29A3<\/i> mutations","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288098. Online ahead of print.","author":"Quigg TC, Kurt BA, Seaver LH, Holsworth AR, Duffner UA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874332"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2024.287157. Online ahead of print.","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)","journal":"Br J Haematol","issue":"2025 Sep 9. doi: 10.1111\/bjh.70061. Online ahead of print.","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Sep 7. doi: 10.1111\/bjh.70142. Online ahead of print.","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation","journal":"Br J Haematol","issue":"2025 Sep 3. doi: 10.1111\/bjh.70105. Online ahead of print.","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as\u00a0outpatient versus inpatient","title02":"Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as\u00a0outpatient versus inpatient","journal":"Br J Haematol","issue":"2025 Sep 2. doi: 10.1111\/bjh.70104. Online ahead of print.","author":"Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898649"},{"title01":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","title02":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70091. Online ahead of print.","author":"Mariotti J, Pinton C, Giordano L, Taurino D, Sarina B, De Philippis C, Mannina D, Tentori C, Santoro A, Bramanti S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887735"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease","journal":"Br J Haematol","issue":"2025 Aug 26. doi: 10.1111\/bjh.70119. Online ahead of print.","author":"Iversen PO, Gedde-Dahl T, Tj\u00f8nnfjord GE, Ali MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging","title02":"Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging","journal":"Blood","issue":"2025 Sep 8:blood.2024027432. doi: 10.1182\/blood.2024027432. Online ahead of print.","author":"Zhang S, Ayemoba CE, Di Staulo AM, Joves K, Patel CM, Leung EHW, Bueno MLP, Du X, Poncz M, Ong SG, Nerlov C, Maryanovich M, Chronis C, Pinho S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920871"},{"title01":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways","title02":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways","journal":"Blood","issue":"2025 Sep 8:blood.2024026815. doi: 10.1182\/blood.2024026815. Online ahead of print.","author":"Martinez TC, Jotte MRM, Khan S, Stoddart A, Blaylock HZ, Malik A, McNerney ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920873"},{"title01":"Getting back on track to meet global anaemia reduction targets: a Lancet Haematology Commission","title02":"Getting back on track to meet global anaemia reduction targets: a <i>Lancet Haematology<\/i> Commission","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e717-e767.","author":"Atkinson SH, Suchdev PS, Bode M, Carducci B, Cerami C, Mwangi MN, Namaste S, Winichagoon P, Leung S, Mutua AM, Abuga KM, Angeles-Agdeppa I, Blythe R, Carvalho N, Cepeda-Lopez A, Cross JH, de Pee S, Di Ruggiero E, Fanzo J, Gentilini U, Gichohi-Wainaina WN, Glover-Wright C, Gomes F, Hess S, Holloway-Brown J, Joof F, Karakochuk C, Kassebaum NJ, Larson L, Mettananda S, Muriuki JM, Mwangome M, Ohuma EO, Oliver V, Perumal N, Phiri K, Samuel F, Sinharoy S, Tizifa T, Valleriani G, van Zutphen-K\u00fcffer KG, Vasta F, Verhoef H, Wang Y, Yadav K, Yang Z, Young M, Zimmermann MB, Pasricha SR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882649"},{"title01":"Estimated unit costs of anaemia interventions for women of reproductive age in 193 UN member states: a costing study","title02":"Estimated unit costs of anaemia interventions for women of reproductive age in 193 UN member states: a costing study","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e684-e693.","author":"Oliver VL, Wang Y, Leung S, Blythe R, Glover-Wright C, Holloway-Brown J, Bode M, Pasricha SR, Carvalho N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882647"},{"title01":"Cost-effective targets for anaemia reduction in 191 countries: a modelling study","title02":"Cost-effective targets for anaemia reduction in 191 countries: a modelling study","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e674-e683.","author":"Blythe R, Carvalho N, Holloway-Brown J, Leung S, Oliver VL, Wang Y, Glover-Wright C, Pasricha SR, Bode M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882648"},{"title01":"Two mothers&#8217; perspectives on childhood anaemia in Kilifi, Kenya","title02":"Two mothers&#8217; perspectives on childhood anaemia in Kilifi, Kenya","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e672-e673.","author":"Mutua AM, Atkinson SH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882651"},{"title01":"Experience of the Anaemia Mukt Bharat anaemia control programme in India","title02":"Experience of the <i>Anaemia Mukt<\/i> Bharat anaemia control programme in India","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e671-e672.","author":"Yadav K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882650"},{"title01":"Anaemia in a time of climate crisis","title02":"Anaemia in a time of climate crisis","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e668-e669.","author":"Fanzo J, Carducci B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882652"},{"title01":"USAID&#8217;s enduring impact on anaemia management must be preserved","title02":"USAID&#8217;s enduring impact on anaemia management must be preserved","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e666-e668.","author":"Dary O, Peniston AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882654"},{"title01":"Global initiatives to accelerate anaemia reduction","title02":"Global initiatives to accelerate anaemia reduction","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e664-e665.","author":"Rogers LM, Nieves Garcia-Casal M, Flores-Urrutia MC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882653"},{"title01":"Towards achievable targets for anaemia reduction","title02":"Towards achievable targets for anaemia reduction","journal":"Lancet Haematol","issue":"2025 Sep;12(9):e663.","author":"The Lancet Haematology.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40882646"},{"title01":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative","title02":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288632. Online ahead of print.","author":"Nakao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905092"},{"title01":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study","title02":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study","journal":"Br J Haematol","issue":"2025 Sep 8. doi: 10.1111\/bjh.70144. Online ahead of print.","author":"Ishiyama K, Yamazaki M, Maruyama H, Hosono N, Yamaguchi H, Asada N, Tanimoto K, Sugiura H, Usuki K, Yoshimura K, Ogawa S, Kanakura Y, Matsumura I, Akashi K, Nakao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921497"},{"title01":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation","title02":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation","journal":"Blood","issue":"2025 Sep 9:blood.2025028370. doi: 10.1182\/blood.2025028370. Online ahead of print.","author":"Falabr\u00e8gue M, Aurrand C, Cazaulon L, Boussetta N, Zumerle S, Karim Z, Djebrani-Oussedik N, Poupon J, Guilmeau S, Dupe E, Aucouturier A, Langella P, Bermudez-Humaran LG, Vaulont S, Peyssonnaux C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40925095"},{"title01":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study","title02":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study","journal":"Br J Haematol","issue":"2025 Sep 7. doi: 10.1111\/bjh.70145. Online ahead of print.","author":"Dam M, Centanni M, Centanni D, Friberg LE, Karlsson MO, Lynggaard LS, Johannsdottir IM, Lepik K, Vaitkeviciene GE, Griskevicius L, P\u00f6yh\u00f6nen T, Py\u00f6r\u00e4l\u00e4 M, J\u00f3nsson \u00d3G, Quist-Paulsen P, Schmiegelow K, Christoforaki T, Overgaard U, Hansen SN, Albertsen BK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916350"},{"title01":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia","title02":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia","journal":"Br J Haematol","issue":"2025 Sep 10. doi: 10.1111\/bjh.70113. Online ahead of print.","author":"Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931545"},{"title01":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia","title02":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep 3. doi: 10.1111\/bjh.70135. Online ahead of print.","author":"Boudry A, Goursaud L, Lebon D, Dumezy F, Harrivel V, Boue-Raguet A, Joudinaud R, Marceau-Renaut A, Geffroy S, Hauspie C, Brijs J, Fenwarth L, Berthon C, Marolleau JP, Figeac M, Preudhomme C, Duployez N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903763"},{"title01":"The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia","title02":"The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2025 Sep 1. doi: 10.1111\/bjh.20260. Online ahead of print.","author":"Pourhassan H, Tinajero J, Ma H, Jackson R, Pillai R, Ngo D, Agrawal V, Koller P, Ball B, Blackmon A, Salhotra A, Al Malki M, Aribi A, Otoukesh S, Artz A, Becker P, Nakamura R, Stein A, Forman S, Marcucci G, Pullarkat V, Aldoss I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890465"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70106. Online ahead of print.","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights","title02":"Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70038. Online ahead of print.","author":"Nachmias B, Haran A, Yisraeli Salman M, Stein EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887043"},{"title01":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia","title02":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2025 Aug 29. doi: 10.1111\/bjh.70131. Online ahead of print.","author":"Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40878718"},{"title01":"Breaking ribosomes to fight leukemia","title02":"Breaking ribosomes to fight leukemia","journal":"Blood","issue":"2025 Sep 4;146(10):1155-1156.95.","author":"Papapetrou EP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906502"},{"title01":"Acalabrutinib treatment for older (\u226580 years old) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial","title02":"Acalabrutinib treatment for older (\u226580 years old) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial","journal":"Blood","issue":"2025 Sep 4:blood.2025028550. doi: 10.1182\/blood.2025028550. Online ahead of print.","author":"Simon F, Ligtvoet R, Bohn JP, N\u00f6sslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ulrich K, G\u00e4rtner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart MJ, Decker T, Chakupurakal G, Sch\u00f6ttker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink A, F\u00fcrstenau M, Fischer K, Goede V, Hallek MJ, Eichhorst BF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906922"},{"title01":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells","title02":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells","journal":"Blood","issue":"2025 Sep 4:blood.2024028194. doi: 10.1182\/blood.2024028194. Online ahead of print.","author":"Venkatesh H, Granados Centeno E, Luo Q, Arroyo M, Heltemes Harris LM, Knutson TP, Qiu Y, Haaning A, Webber BR, Bachanova V, Farrar MA, Tracy SI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906918"},{"title01":"Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper","title02":"Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper","journal":"Br J Haematol","issue":"2025 Sep 5. doi: 10.1111\/bjh.70018. Online ahead of print.","author":"Chaganti S, Dulobdas V, Wilson MR, Tucker D, Townsend W, Parry-Jones N, Lewis D, Fox CP, Osborne W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40910188"},{"title01":"Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study","title02":"Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study","journal":"Br J Haematol","issue":"2025 Sep 1. doi: 10.1111\/bjh.20122. Online ahead of print.","author":"Song Y, Zou D, Yang H, Wu J, Guo Y, Li W, Liu H, Xia Z, Zhang Y, Zhou Z, Zhu J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40888120"},{"title01":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas","title02":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70132. Online ahead of print.","author":"Montes L, Choquet S, Uzunov M, Morel V, Baron M, Roos-Weil D, Joris M, Delette C, Lebon D, Azar N, Metz C, Nichelli L, Le Garff-Tavernier M, Boccon-Gibod C, Lacan C, Souchet L, Hoang-Xuan K, Soussain C, Boussen I, Houillier C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887743"},{"title01":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs","title02":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70125. Online ahead of print.","author":"Kleinstern G, Robinson DP, Abu Seir R, Perlman R, Liu J, Jebrini N, Elyan H, Ben Yehuda D, Slager SL, Paltiel O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887045"},{"title01":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","title02":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70091. Online ahead of print.","author":"Mariotti J, Pinton C, Giordano L, Taurino D, Sarina B, De Philippis C, Mannina D, Tentori C, Santoro A, Bramanti S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887735"},{"title01":"Towards a chemo-free approach for follicular lymphoma","title02":"Towards a chemo-free approach for follicular lymphoma","journal":"Br J Haematol","issue":"2025 Aug 30. doi: 10.1111\/bjh.70126. Online ahead of print.","author":"Luminari S, Barbieri E, Nizzoli ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884311"},{"title01":"Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma","title02":"Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma","journal":"Blood","issue":"2025 Sep 8:blood.2025029909. doi: 10.1182\/blood.2025029909. Online ahead of print.","author":"Falchi L, Sureda A, Lepp\u00e4 S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920572"},{"title01":"Classic Hodgkin lymphoma: the journey over the destination","title02":"Classic Hodgkin lymphoma: the journey over the destination","journal":"Blood","issue":"2025 Sep 4;146(10):1152-1153.","author":"Havranek O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906501"},{"title01":"The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma","title02":"The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma","journal":"Blood","issue":"2025 Sep 2:blood.2025029163. doi: 10.1182\/blood.2025029163. Online ahead of print.","author":"Tatterton DJ, Newby ML, Allen JD, Sale BJ, Chiodin G, Duriez PJ, Butler J, McCann KJ, Scott DW, Morin RD, Dreval K, Davies AJ, Bryant D, Crispin M, Forconi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896832"},{"title01":"Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma","title02":"Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma","journal":"Blood","issue":"2025 Sep 2:blood.2024027997. doi: 10.1182\/blood.2024027997. Online ahead of print.","author":"Pal I, Illendula A, Joyner AM, Manavalan JS, Deddens TM, Sabzevari A, Damera DP, Zuberi S, Marchi E, Fox TE, Brown MD, Danappa Jayappa K, Khalife J, Craig JW, Loughran TP, Feith DJ, O'Connor OA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896830"},{"title01":"Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma","title02":"Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma","journal":"Leukemia","issue":"2025 Sep 10. doi: 10.1038\/s41375-025-02757-6. Online ahead of print.","author":"Neubert S, Munawar U, Mersi J, Noderer J, Nerreter S, Kurian S, Han S, Verbruggen C, Besant E, Rein N, K\u00f6ppel M, Lehmann J, K\u00f6hler T, Labinsky H, H\u00e4usl S, Tamamushi Y, Zhou X, Pinter J, Herzog AL, Lopau K, Hoxha E, Rummelt C, Gerhard-Hartmann E, Rosenwald A, Steinbrunn T, Nerreter T, Hudecek M, Einsele H, Rasche L, Kort\u00fcm KM, Waldschmidt JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931044"},{"title01":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma","title02":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma","journal":"Leukemia","issue":"2025 Aug 26. doi: 10.1038\/s41375-025-02736-x. Online ahead of print.","author":"Zocchi S, Trichet P, Guernalec P, Agdada M, Alonso Bartolom\u00e9 A, Ogor V, Choisy C, Vias C, Sabat\u00e9-Cadenas X, Bories JC, Goodhardt M, Shkumatava A, Garrick D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858807"},{"title01":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma","title02":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma","journal":"J Clin Oncol","issue":"2025 Sep 10:JCO2501088. doi: 10.1200\/JCO-25-01088. Online ahead of print.","author":"Kaiser MF, Cliff ERS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40929614"},{"title01":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies","title02":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288942. Online ahead of print.","author":"Rago A, Ridola L, Di Toritto TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905098"},{"title01":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","title02":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288187. Online ahead of print.","author":"Cani L, Scott SA, Roberts D, Joseph NS, Hofmeister CC, Gupta VA, Dhodapkar MV, Lonial S, Nooka AK, Kaufman JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905083"},{"title01":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes &#8211; insights from a single-site study","title02":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes &#8211; insights from a single-site study","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287760. Online ahead of print.","author":"Bauer MA, Farmer P, Su JL, Schootman M, Li C, Van Rhee F, Al Hadidi S, Schinke C, Shaughnessy JD, Zhan F, Ashby C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905079"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287344. Online ahead of print.","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitek\u0117nait\u0117 V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies","title02":"Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.289053. Online ahead of print.","author":"Rees MJ, Quach H, Jardine D, Thompson A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931863"},{"title01":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma","title02":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288203. Online ahead of print.","author":"Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Patel S, Suchindran S, Zhou X, Richardson PG, Cohen AD, Lowther DE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874339"},{"title01":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study","title02":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.287954. Online ahead of print.","author":"Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874328"},{"title01":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group","title02":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group","journal":"Br J Haematol","issue":"2025 Sep 3. doi: 10.1111\/bjh.70041. Online ahead of print.","author":"Moore S, Miller H, Parrish C, Seymour F, Miller L, Chandler T, Land J, Karpha I, Brearton G, Thompson S, Clayton L, Jones J, McMillan A, McCourt O, Pawlyn C, Mian H, Cook G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903837"},{"title01":"Differences in adverse events between manuscript and drug labels for myeloma T-cell-redirecting therapies","title02":"Differences in adverse events between manuscript and drug labels for myeloma T-cell-redirecting therapies","journal":"Br J Haematol","issue":"2025 Jul 27. doi: 10.1111\/bjh.70042. Online ahead of print.","author":"Bashy B, Shah D, Steensma D, Van Oekelen O, Chakraborty R, Mohyuddin GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40923801"},{"title01":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies","title02":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies","journal":"Br J Haematol","issue":"2025 Aug 29. doi: 10.1111\/bjh.70116. Online ahead of print.","author":"Wang X, Cui Y, Wang Y, Fang B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40879107"},{"title01":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy","title02":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy","journal":"Blood","issue":"2025 Sep 8:blood.2025028441. doi: 10.1182\/blood.2025028441. Online ahead of print.","author":"Bruno T, Cappelletto MC, Cortile C, Di Giovenale S, Amadio B, De Nicola F, Falcone I, Giuliani S, Palermo B, Catena V, Ciuffreda L, Cerruti F, Cascio P, Merola R, Masi S, De Pascale V, Annibali O, Ferraro S +39, Gumenyuk S, Pisani F, Marchesi F, Mengarelli A, Fanciulli M, Corleone G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920573"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","journal":"Leukemia","issue":"2025 Sep 1. doi: 10.1038\/s41375-025-02744-x. Online ahead of print.","author":"Alfonso-Pierola A, Martinez-Cuadr\u00f3n D, Rodr\u00edguez-Veiga R, Gil C, Mart\u00ednez-S\u00e1nchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garc\u00eda-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, P\u00e9rez-Simon JA, Rodr\u00edguez-Medina C, Bass-Maturana MF, L\u00f3pez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, P\u00e9rez-Encinas M, Barrios-Garc\u00eda M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Dur\u00e1n A, Valero-Nu\u00f1ez M, Casado-Calder\u00f3n S, Balerdi A, Torres V, Fern\u00e1ndez R, Noriega V, Stevenazzi M, Labrador J, Le\u00f3n-Maldonado P, de Rueda-Ciller B, Arce-Fern\u00e1ndez O, Amigo ML, Raposo-Puglia J\u00c1, Sol\u00e9 M, Boluda B, Ayala R, Barrag\u00e1n E, Montesinos P; PETHEMA Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as\u00a0outpatient versus inpatient","title02":"Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as\u00a0outpatient versus inpatient","journal":"Br J Haematol","issue":"2025 Sep 2. doi: 10.1111\/bjh.70104. Online ahead of print.","author":"Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898649"},{"title01":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","title02":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","journal":"Br J Haematol","issue":"2025 Aug 31. doi: 10.1111\/bjh.70091. Online ahead of print.","author":"Mariotti J, Pinton C, Giordano L, Taurino D, Sarina B, De Philippis C, Mannina D, Tentori C, Santoro A, Bramanti S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887735"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease","journal":"Br J Haematol","issue":"2025 Aug 26. doi: 10.1111\/bjh.70119. Online ahead of print.","author":"Iversen PO, Gedde-Dahl T, Tj\u00f8nnfjord GE, Ali MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence","title02":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence","journal":"Blood","issue":"2025 Sep 4:blood.2025028504. doi: 10.1182\/blood.2025028504. Online ahead of print.","author":"Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones DC, Hall SC, Cruz Cruz J, Vernaris M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906917"},{"title01":"Hole in one: CD137-ADC eliminates GVHD","title02":"Hole in one: CD137-ADC eliminates GVHD","journal":"Blood","issue":"2025 Aug 28;146(9):1038-1040.","author":"Nierkens S, Lindemans CA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875553"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","journal":"Leukemia","issue":"2025 Sep 1. doi: 10.1038\/s41375-025-02744-x. Online ahead of print.","author":"Alfonso-Pierola A, Martinez-Cuadr\u00f3n D, Rodr\u00edguez-Veiga R, Gil C, Mart\u00ednez-S\u00e1nchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garc\u00eda-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, P\u00e9rez-Simon JA, Rodr\u00edguez-Medina C, Bass-Maturana MF, L\u00f3pez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, P\u00e9rez-Encinas M, Barrios-Garc\u00eda M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Dur\u00e1n A, Valero-Nu\u00f1ez M, Casado-Calder\u00f3n S, Balerdi A, Torres V, Fern\u00e1ndez R, Noriega V, Stevenazzi M, Labrador J, Le\u00f3n-Maldonado P, de Rueda-Ciller B, Arce-Fern\u00e1ndez O, Amigo ML, Raposo-Puglia J\u00c1, Sol\u00e9 M, Boluda B, Ayala R, Barrag\u00e1n E, Montesinos P; PETHEMA Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era","title02":"Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288306. Online ahead of print.","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML","title02":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML","journal":"Leukemia","issue":"2025 Sep 10. doi: 10.1038\/s41375-025-02748-7. Online ahead of print.","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931047"},{"title01":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia","title02":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 Sep 10. doi: 10.1038\/s41375-025-02739-8. Online ahead of print.","author":"Kanari M, Jimenez Garcia I, Steffen FD, Krattiger LA, Bataclan C, Liu W, Simona BR, Deplancke B, Naveiras O, Ehrbar M, Bornhauser B, Bourquin JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931046"},{"title01":"PML::RAR\u03b1+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias","title02":"PML::RAR\u03b1+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias","journal":"Leukemia","issue":"2025 Sep 10. doi: 10.1038\/s41375-025-02738-9. Online ahead of print.","author":"Zaza A, Zardo G, Banella C, Tucci S, de Marinis E, Gentile M, Travaglini S, Divona M, Ottone T, Castelli G, Cerio AM, Angelini DF, Faraoni I, Palmieri R, Niscola P, Ammatuna E, Venditti A, Nervi C, Voso MT, Catalano G, Noguera NI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931045"},{"title01":"Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial","title02":"Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial","journal":"Leukemia","issue":"2025 Sep 3. doi: 10.1038\/s41375-025-02747-8. Online ahead of print.","author":"Mocking TR, Haaksma LH, Reuvekamp T, Kelder A, Scholten WJ, Ngai LL, Breems DA, Fischer T, Gjertsen BT, Gri\u0161kevi\u010dius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, L\u00f6wenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, van de Loosdrecht AA, Cloos J, Bachas C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903492"},{"title01":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1\u03b1","title02":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1\u03b1","journal":"Leukemia","issue":"2025 Sep 2. doi: 10.1038\/s41375-025-02749-6. Online ahead of print.","author":"Xu G, Wang F, Chen M, Gao W, Liu Y, Zhu J, Wang C, Jiang H, Li Y, Zhang P, Yuan J, Zhang T, Zhao C, Wang L, Wang L, Jiang J, Cao W, Zhang Z, Fu H, Dong T, Hu J, Li K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40897850"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry","journal":"Leukemia","issue":"2025 Sep 1. doi: 10.1038\/s41375-025-02744-x. Online ahead of print.","author":"Alfonso-Pierola A, Martinez-Cuadr\u00f3n D, Rodr\u00edguez-Veiga R, Gil C, Mart\u00ednez-S\u00e1nchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garc\u00eda-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, P\u00e9rez-Simon JA, Rodr\u00edguez-Medina C, Bass-Maturana MF, L\u00f3pez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, P\u00e9rez-Encinas M, Barrios-Garc\u00eda M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Dur\u00e1n A, Valero-Nu\u00f1ez M, Casado-Calder\u00f3n S, Balerdi A, Torres V, Fern\u00e1ndez R, Noriega V, Stevenazzi M, Labrador J, Le\u00f3n-Maldonado P, de Rueda-Ciller B, Arce-Fern\u00e1ndez O, Amigo ML, Raposo-Puglia J\u00c1, Sol\u00e9 M, Boluda B, Ayala R, Barrag\u00e1n E, Montesinos P; PETHEMA Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"HLA matching in the PTCy era: the locus still matters. Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"HLA matching in the PTCy era: the locus still matters. Comment on: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.289055. Online ahead of print.","author":"Desai N, Mattsson J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931871"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288957. Online ahead of print.","author":"Bethge W, Dreger P; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT), German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Immune intervention is dispensable for retinoic acid\/arsenic therapy of murine acute promyelocytic leukemia","title02":"Immune intervention is dispensable for retinoic acid\/arsenic therapy of murine acute promyelocytic leukemia","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288562. Online ahead of print.","author":"Esnault C, Fortin G, Qiu F, Soilihi H, Souqu\u00e8re S, Niwa-Kawakita M, Lanchais K, Dirami T, Pierron G, De Th\u00e9 H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931862"},{"title01":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia","title02":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288275. Online ahead of print.","author":"Breimer GE, Rozeman EA, Braunius WW, Daenen LGM, Kester LA, Leguit RJ, Mahieu R, Solleveld-Westerink N, Straatman L, Schutgens F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931869"},{"title01":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia","title02":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.288131. Online ahead of print.","author":"Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931864"},{"title01":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells","title02":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.287934. Online ahead of print.","author":"Holl NJ, Fearnow A, Christodoulou I, Vorri SC, Rahnama R, Choe J, Ghosal A, Ng WI, Vyas V, Song HW, Varadhan R, Bonifant CL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931866"},{"title01":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEG-Asparaginase hypersensitivity","title02":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEG-Asparaginase hypersensitivity","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.287910. Online ahead of print.","author":"Tang X, Zhao L, Li W, Liu S, Li X, Zhu L, Wang D, Chen S, Liu Z, Liu S, Wen F, Abla O, Wang Y, Mai H, Fu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931858"},{"title01":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia","title02":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2025.287697. Online ahead of print.","author":"Fischer C, Chen SS, Nimmerfroh J, Eugster A, St\u00fccheli S, Schulthei\u00df C, Widmer C, Heim D, Kasenda B, Passweg J, Kobold S, Egli L, Coianiz N, Chijioke O, Chiorazzi N, Follo M, L\u00e4ubli H, Peipp M, Binder M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931870"},{"title01":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia","title02":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia","journal":"Haematologica","issue":"2025 Sep 11. doi: 10.3324\/haematol.2024.287099. Online ahead of print.","author":"Chan WK, Tan L, Martinez SA, Du D, Horvath TD, Pontikos M, Rusling LA, Chiu Y, Tran BQ, Rempe SB, Sukharev S, Weinstein JN, Lorenzi PL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931860"},{"title01":"Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series","title02":"Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series","journal":"Haematologica","issue":"2025 Sep 1;110(9):1921-1922.","author":"Izraeli S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40888337"},{"title01":"Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia","title02":"Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288448. Online ahead of print.","author":"Loghavi S, Ravandi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874334"},{"title01":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia","title02":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288379. Online ahead of print.","author":"Owen C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874327"},{"title01":"The immunophenotypic and genetic characterization of pediatric T -L ymphoblastic leukemia with a mature immunophenotype","title02":"The immunophenotypic and genetic characterization of pediatric T -L ymphoblastic leukemia with a mature immunophenotype","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.288233. Online ahead of print.","author":"Khanlari M, Wang W, Tizro P, Eldomery MK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874330"},{"title01":"Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology","title02":"Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology","journal":"Haematologica","issue":"2025 Aug 28. doi: 10.3324\/haematol.2025.287931. Online ahead of print.","author":"Van Outersterp I, Boer JM, Sonneveld E, De Jong AX, Nierkens S, Van der Velden VHJ, Buijs A, Luesink M, Den Boer ML, Hoogerbrugge PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874338"},{"title01":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia","title02":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Sep 8. doi: 10.1111\/bjh.70134. Online ahead of print.","author":"Metzler M, Branford S, Hijiya N, Sakamoto K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921705"},{"title01":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia","title02":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia","journal":"Blood","issue":"2025 Sep 3:blood.2025029302. doi: 10.1182\/blood.2025029302. Online ahead of print.","author":"Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field LM, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O Professor, Bond J, Roberts I, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898981"},{"title01":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations","title02":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations","journal":"Blood","issue":"2025 Sep 2:blood.2025030259. doi: 10.1182\/blood.2025030259. Online ahead of print.","author":"Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, Maqsood M, Shahrin N, Saunders VA Ms, Kenyon R, Lin M, Toubia J, McConnell J, Kaczorowski D, Ross DM, Yong AS, Chee L, Shortt J, Viiala N, Braley JA, Kok CH, Hughes TP, Branford S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896831"},{"title01":"Meddling with METTL3 in acute megakaryoblastic leukemia","title02":"Meddling with METTL3 in acute megakaryoblastic leukemia","journal":"Blood","issue":"2025 Aug 28;146(9):1035-1036.","author":"Crispino JD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875550"},{"title01":"NPM1: the ultimate target in AML","title02":"NPM1: the ultimate target in AML","journal":"Blood","issue":"2025 Aug 28;146(9):1031-1032.","author":"R\u00e9cher C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875551"},{"title01":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice","title02":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice","journal":"Br J Haematol","issue":"2025 Sep 7. doi: 10.1111\/bjh.70128. Online ahead of print.","author":"Vodicka P, Hamova I, Velasova A, Kupcova K, Zemankova P, Nehasil P, Tkachenko A, Lochovska K, Muzikova S, Hrabetova S, Dlouha J, Blahovcova P, Frouz T, Senavova J, Dlouha L, Polgarova K, Klanova M, Salkova J, Benesova K, Klener P, Trneny M, Havranek O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916568"},{"title01":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","title02":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","journal":"Leukemia","issue":"2025 Sep 5. doi: 10.1038\/s41375-025-02730-3. Online ahead of print.","author":"Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913104"},{"title01":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia","title02":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Aug 26. doi: 10.1038\/s41375-025-02731-2. Online ahead of print.","author":"Hleihel R, Skayneh H, Wu HC, Hamie M, Kurdi A, Dakour J, Machaalani C, El-Sabban M, de Th\u00e9 H, Bazarbachi A, El Hajj H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858804"},{"title01":"Beating the STATs: targeting the metabolome in acute myeloid leukemia","title02":"Beating the STATs: targeting the metabolome in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288349. Online ahead of print.","author":"Nachmias B, Wolach O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905076"},{"title01":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel","title02":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.288228. Online ahead of print.","author":"Wang SA, Arenillas L, Buccisano F, Bruggemann M, Kern W, Menes M, Plesa A, Stone L, Wellnitz D, Westerman DA, Wood BL, Freeman SD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905082"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2025.287860. Online ahead of print.","author":"Villalba M, Montoro J, Balaguer-Rosell\u00f3 A, Chor\u00e3o P, Cant\u00f3 PA, Granados P, G\u00f3mez-Segu\u00ed I, Solves P, Such E, Cervera J, Barrrag\u00e1n E, Santiago M, Gil-Ort\u00ed JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz M\u00c1, Sanz J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia","title02":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia","journal":"Haematologica","issue":"2025 Sep 4. doi: 10.3324\/haematol.2024.287269. Online ahead of print.","author":"Chen M, Li W, Tao Y, Hu C, Ge R, Kang S, Yue P, Man CH, Wang L, Yan X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905075"}]